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Platelets contribute to disease-relevant inflammatory processes, and research indicates that 
platelet recruitment to inflamed lungs might be important in the platelet-dependence of in-
flammatory responses. Compared to platelet recruitment to lesions in blood vessel walls or to 
thrombi, the mechanisms of platelet recruitment to lungs following inflammatory responses 
in lung airpaces are poorly understood, so methods were sought to enable the characterisation 
of this response in mouse and human models. 
Methods 
Bright field and fluorescence microscopy for quantifying immunostained platelets, non-inva-
sive radiolabelled platelet tracking, radiolabelled platelet biodistribution, lung intravital mul-
tiphoton microscopy with genetic platelet labelling, and blood microsample platelet counts 
were assessed as methods for measuring and describing lung platelet recruitment in a mouse 
model of lung inflammation induced by intranasal challenge with bacterial lipopolysaccharides 
(LPS). Platelets were also immunostained in human lung samples exposed to LPS via in-
trabronchial installation during ex vivo blood-perfused lung experiments. The effects of neu-
trophil depletion, blockade of the adhesion molecules P-selectin or PSGL-1, and treatment 
with the anti-platelet drugs MRS2500, AR-C 66096 or aspirin on LPS-induced lung platelet 
recruitment were  then investigated in mice. 
Results 
Immunostaining and radiolabelled platelet tracking methods showed that LPS inhalation 
caused platelet recruitment to lungs of mice, and intravital microscopy revealed that LPS 
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inhalation increased platelet adhesion without causing thrombosis. Radiolabelled and im-
munostained platelets were also found in airspaces of LPS-challenged mice and human lungs. 
The lung platelet recruitment response was preceded by a decrease in blood platelet counts 
associated with recruitment of platelets to the liver and spleen. Platelet recruitment to mouse 
lungs was not detectably altered by neutrophil depletion, blockade of PSGL-1 or P-selectin, 
or treatment with MRS2500, AR-C 66096, or aspirin. In this model, lung neutrophil recruit-
ment was reduced with neutrophil depletion or PSGL-1 blockade but not with other inter-
ventions tested. Platelet depletion did not significantly alter neutrophil counts in bronchoalve-
olar lavage in the mouse model used but did reduce the quantity of neutrophil extracellular 
traps detected in lung airspaces. 
Conclusions 
Platelet recruitment to mouse lungs following LPS inhalation showed no clear evidence of 
dependence on neutrophils or PSGL-1, suggestive that platelet recruitment occurs through 
mechanisms distinct from those driving lung neutrophil recruitment. Platelet recruitment to 
lungs inflamed by LPS inhalation involved increased platelet adhesion not extending to 
thrombosis, and migration of platelets into lung airspaces in mice and in human lungs, with 
interactions of platelets with the release of neutrophil extracellular traps in lung airspaces 
identified. The immunostaining, radiolabelling and intravital microscopy methods described 
in this thesis allow for further investigation into the molecular mediators and physiological 
consequences of platelet recruitment to inflamed lungs. 
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“it is not inconceivable that platelets, along with many cells of the body, play an 
important part in resisting infection. The difficulty comes when one attempts to analyse and 
define their exact mode and sphere of activity in this respect” 
Leandro M. Tocantins (1938) 
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1.1 The need for research into lung health, disease and platelets 
1.1.1 The global burden of lung diseases 
Diseases affecting the lungs result in around 12% of the world’s total suffering from death 
and disability, with particularly large global disease burdens of lung infections, chronic ob-
structive pulmonary disease (COPD), lung cancers and asthma (Figure 1.1). In pathophysi-
ological terms, the majority of this global lung disease burden comes from a failure of the 
immune system to defend against infection or the growth of cancerous cells, or from excessive 
inflammatory responses against inappropriate stimuli.  
The most urgent and obvious interventions required for improving global lung health are 
reducing the major COPD, cancer and infection risk factors of exposure to tobacco smoke 
and other air pollutants, but tobacco use is projected to continue contributing to the deaths 
at the present rate or higher, and the world continues to become increasingly urbanised with 
cities across the world struggling to control air pollution (Mathers and Loncar, 2006). Adding 
the burden of disease on these sufferers to that on those whose disease is due to chance, 
genetics or other environmental factors, leaves a huge unmet need for drugs for lung diseases.  
 





Figure 1.1. Contribution of lung diseases to global suffering and death.  Expressed as disability 
adjusted life years (DALYs, years of life lost + years of life lived with disability), the global disease 
burden in 2015 was 30% communicable, neonatal, maternal and nutritional diseases, 60% non-
communicable diseases and 10% injuries. Around 6.6% of global loss of DALYs was due to com-
municable diseases affecting the lungs, and 5.4% was due to non-communicable diseases affecting 
the lungs. Data are from Global Burden of Disease, Institute for Health Metrics and Evaluation.1  
                                           
 
1 Institute for Health Metrics and Evaluation, Global Burden of Disease project: 
http://healthdata.org/gbd 
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Lung diseases have been particularly challenging for drug discovery and development 
programmes and make up a large and growing proportion of the global unmet need for new 
treatments (Barnes et al., 2015). There has been a stagnation in discovery of new antimicro-
bial drugs for treating infectious diseases together with an increase in microbial resistance to 
existing drugs, with tuberculosis, for example, escaping eradication and increasing in morbid-
ity due to multi drug resistance, and to immunocompromisation of hosts with concomitant 
human immunodeficiency virus infection (Silver, 2011). 
Despite some advances in cancer treatment, amongst cancer types those affecting the 
lungs have some of the lowest survival rates and highest contributions to the total mortality 
from cancers (Siegel et al., 2015). 
Asthma and Chronic Obstructive Pulmonary Disease (COPD) lack cures, no drugs have 
been successful in preventing the progression of COPD, and a subpopulation of asthmatic 
patients are resistant to current preventative treatment and suffer from a disproportionate 
share of the asthma disease burden (Barnes, 2010; Mushtaq, 2014).  
Prognosis of acute respiratory distress syndrome (ARDS) has been improved with venti-
lation strategies, but drug interventions have been without success and chances of survival 
are still around 50% lower in patients with injured lungs compared to other critically ill 
intensive care patients (Summers et al., 2016).  
Many, or all of the diseases mentioned can have a characteristically large inflammatory 
component, with pulmonary recruitment and activation of inflammatory cells, or cancer cells 
in the case of secondary lung cancers. In inflammatory lung diseases and some lung infections, 
the inflammation component of the disease has been causally associated with progression of 
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symptoms, and has therefore been the subject of many drug discovery programmes (Barnes 
et al., 2015). 
1.1.2 Platelets as targets for therapeutic interventions 
Research has enabled the production of drugs targeting platelets which have proven clin-
ical success in treating patients presenting with unstable angina, and the in the secondary 
prevention of further morbidity and mortality in patients who have survived a myocardial 
infarction or a cerebrovascular ischaemic event (Antithrombotic Trialists’ Collaboration, 2002; 
Jackson and Schoenwaelder, 2003). Platelets have proven to be particularly useful targets for 
drugs, as many functionally important proteins have expression relatively restricted to the 
megakaryocyte-platelet lineage, and platelets are relatively easy to isolate and study in phar-
macological and proteomic studies compared to other cell types. 
There is also a growing body of evidence that platelets contribute to pathological pro-
cesses underlying infectious and inflammatory diseases as well as related functions in the 
growth and metastasis of cancers across the body (reviewed in Pitchford and Page, 2006; 
Pitchford, 2007; Zarbock and Ley, 2009; Semple et al., 2011; Menter et al., 2014; Yeaman, 
2014; Middleton et al., 2016).  
A better understanding of these roles for platelets in processes other than haemostasis 
and thrombosis could lead to development of new antiplatelet drugs for novel indications. In 
particular, these drugs could find use in inflammatory diseases affecting the lungs, as the lung 
diseases with inflammatory compenents such as asthma, COPD, ARDS and cystic fibrosis 
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are all under investigation as diseases in which platelets might have key roles (Pitchford, 
2009; Zarbock and Ley, 2009; Sin, 2014; Toner et al., 2015; Middleton et al., 2016).  
The sections of this thesis introduction that follow review current understanding of plate-
let contributions to inflammatory processes and the phenomenon of platelet recruitment in 
lung inflammation, in order to set the scene for the broad experimental aim of the present 
doctoral research project: to develop methods for imaging, measuring and characterising the 
cellular and molecular basis of lung platelet recruitment in models of lung inflammation, 
which can also be used for investigating lung platelet recruitment in other disease contexts. 
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1.2 Platelets as mediators of haemostasis, thrombosis and inflammation 
1.2.1 Mechanisms of platelet function in haemostasis, thrombosis and repair 
Platelets, are small, anucleate cells2 ~2-3 µm in diameter in humans at their widest point 
(Paulus, 1975), formed by the fragmentation of large, polyploid megakaryocyte cells originat-
ing from hematopoetic precursor cells (Wright, 1906; Schmitt et al., 2001). Platelets circulate 
in the blood as the second most numerous endogenous single cell type after erythrocytes – a 
70 Kg human male has around 1.4 ×1012 platelets and 24.9 ×1012 red blood cells (Sender et 
al., 2016). The human blood platelet pool is maintained by the estimated daily production of 
around 1011 platelets which stay in the circulation for an average of 8-9 days (Leeksma and 
Cohen, 1955), before entering programmed cell death and clearance from the blood by the 
mononuclear phagocyte system in the liver or the spleen (Kile, 2014).  
The classical and best-understood role of platelets comes following traumatic breaching 
of the blood vessel wall, a role particulary important in the high-pressure, high-shear arterial 
system where blood rheology particularly favours platelet adhesion and blood clots are most 
platelet-rich (Watts et al., 2013). The mediators that are employed by platelets to prevent 
bleeding following trauma to blood vessels have been well characterised in experiments in 
vitro, in preclinical animal models, and in many cases have been clinically proven by the 
                                           
 
2 Platelets are referred to here as cells – there is a strong case that has been made that they 
are at least as qualified as anucleate red blood cells for this title – but there is some controversy 
about whether to do so (Garraud and Cognasse, 2015). 
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increased bleeding risk in patients treated with antiplatelet drugs targeting relevant pathways, 
and in patients with relevant hereditary bleeding disorders (Jackson and Schoenwaelder, 
2003). 
In healthy conditions, circulating platelets are actively prevented from sticking to the 
endothelial wall through the release of substances from healthy endothelial cells such as pros-
tacyclin (PGI2), nitric oxide and ectoadenosine 5’-diphosphatase, which act respectively to 
promote platelet quiescence mediated through elevation of platelet cyclic adenodine mono-
phosphate (cAMP), or cyclic guanosine monophosphate (cGMP) signalling;  or to prevent 
platelet activation by metabolising the platelet agonist adenosine diphosphate (ADP) (Davì 
and Patrono, 2007). Platelets may also assist in maintenance of resting endothelial integrity, 
although the mechanisms underlying this function of platelets are relatively poorly under-
stood compared with haemostasis following trauma (Nachman and Rafii, 2008; Ho-Tin-Noé 
et al., 2011).  
When the endothelial lining is damaged, the anti-adhesion effects of endothelial cells are 
absent or overcome, and surface receptors constitutively expressed by platelets engage in 
tethering interactions on exposed subendothelial matrix components including von Wil-
lebrand Factor (vWF), collagen, fibronectin, vitronectin and laminin (Figure 1.2B), or on 
activated endothelial cells which have released vWF through exocytosis of their Weibel Palade 
bodies (Figure 1.2A). Tethering is mediated by  platelets expressing a variety of adhesion 
molecules, for example the glycoprotein (GP) receptors, the GPIb-V-IX complex (which binds 
vWF) and GPVI (a receptor for collagen), and integrins including α2β1 (GPIa-IIa, also a 
collagen receptor), αIIbβ3 (GPIIb-IIIa, a receptor for fibrinogen), α5β1 (receptor for fibronectin) 
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and α6β1 (binding partner of laminins) (Jackson and Schoenwaelder, 2003; Varga-Szabo et 
al., 2008).  
 
 
Figure 1.2: Overview of roles of platelets in haemostasis and thrombosis. Schematic of a blood 
vessel with damaged endothelial lining showing platelet adhesion to (A) activated endothelial cells, 
(B) subendothelial matrix components, (C) development of platelet thrombus covering the site of 
injury, (D) fibrin mesh formation around the platelet thrombus, and (E) tearing away of platelet 
emboli into the bloodstream.  
 
Continued engagement of adhesion molecules triggers signalling that promotes a series of 
changes in platelets referred to as ‘activation’. When platelet activation is initiated by adhe-
sion molecule engagement, it involves PLC-γ-driven increases in cytoplasmic Ca2+ flux leading 
to shape change, increases in avidity of integrin engagement, and exocytosis of platelet gran-
ules (Varga-Szabo et al., 2008). The activated platelets increase the local concentration of 
soluble platelet agonists such as ADP released through exocytosis of dense granules, throm-
boxane A2 (TXA2) generated through increased production from phospholipase A2-mediated 
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arachidonic acid generation from platelet membranes, and thrombin produced in greatly in-
creased amounts from plasma prothrombin by the assembly of the intrinsic factor Xase com-
plex on phospholipid surfaces of activated platelet membranes (Mann et al., 2003). 
ADP, TXA2 and thrombin all act through autocrine or paracrine signalling involving G-
protein coupled receptors and PLC-β induction, leading to a positive feedback loop which 
further promotes platelet activation, and recruitment of more platelets from the blood to the 
already adherent platelets (Varga-Szabo et al., 2008). A critical mechanism for platelet-plate-
let interactions leading is the increased expression and conformational change of integrin 
αIIbβ3, allowing fibrinogen to bivalently bind to adjacent platelets to form a permament plate-
let aggregate, although other mechanisms can also promote platelet aggregation (Jackson and 
Schoenwaelder, 2003). These mechanisms lead the the rapid, local formation of a platelet 
thrombus which can temporarily cover the lesion in the vessel wall and prevent blood leakage 
(Figure 1.2C). Serotonin (5-hydroxytryptamine, 5-HT) is also released from platelet dense 
granules, and causes local vasoconstriction, therefore diverting blood away from the site of a 
potential breach in the circulation (Versteeg et al., 2013). 
Platelet aggregates are continually torn away from the vessel wall by the shear force of 
passing blood, forming emboli (Figure 1.2E). In the healthy state, most of these thromboem-
boli are small, and as pro-thrombotic stimuli are diluted in the bloodstream in the absence 
of endothelial damage, will dissipate. If thromboemboli fail to disaggregate they can occlude 
vessels and cause downstream ischaemia. Depending on the site of generation and size of the 
embolus, this process can cause acute thrombotic diseases such as a myocardial infarction or 
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a thrombotic cerebrovascular incident (Jackson and Schoenwaelder, 2003). Excessive throm-
bosis can also cause vascular disease if the growth of the primary thrombus causes unresolving 
or unwarranted occlusion (Dicuio et al., 2003; Jackson and Schoenwaelder, 2003). 
Platelets in the primary adherent thrombus greatly promote the activation of the coagu-
lation cascade. Platelet phospholipids support the coagulant factor Xase activating complex 
(Factor IXa, platelet bound factor VIIIa, and calcium), and prothrombinase complex for-
mation (factor Xa, platelet bound factor Va, and calcium). As mentioned above, thrombin 
generation, granule release of platelet agonists, and the synthesis of TXA2 are boosted, acti-
vating and recruiting additional platelets,  provides a greater surface for the development of 
a fibrin mesh, the synthesis of which is a product of the coagulation cascade, which strength-
ens the haemostatic plug on the vessel wall (Versteeg et al., 2013). 
The contractile apparatus in platelets will then contribute to clot retraction, further 
strengthening the clot and assisting in wound closure (Bettex-Galland and Luescher, 1959), 
and factors released by platelets contribute to the eventual dissolution of the clot through 
promotion of fibrinolysis (Whyte et al., 2015), and to wound healing and tissue regeneration 
through release of substances including stromal cell-derived factor-1α (SDF-1α: CXCL12), 
vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF) and 
hepatocyte growth factor (HGF), which can promote angiogenesis, and the recruitment, ac-
tivation and proliferation of both stromal and inflammatory cells, leading to resolution of the 
injury (Gawaz and Vogel, 2013). 
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1.2.2 Platelet function in inflammatory responses 
Overlapping platelet roles in haemostasis, thrombosis and inflammation  
In a non-sterile world, haemostasis and host defence against invading pathogens are often 
required simultaneously, and interplay has therefore evolved between the haemostatic pro-
cesses of coagulation, platelet adhesion and activation, and the immune responses of comple-
ment cascade activation and cell-mediated inflammation (Semple et al., 2011; Li et al., 2017).  
In inflammatory responses where thrombosis occurs, thrombosis itself can be viewed as a 
host defence response to block the entry of pathogens to the bloodstream and their dissemi-
nation throughout the body, as in some cases immune cell activation can promote the for-
mation of thrombi which are thought to act as scaffolds for pathogen immobilisation in ‘im-
munothrombosis’ (Engelmann and Massberg, 2013).  
Conversely, thrombi can recruit leukocytes from the blood as the haemostatic plug grows, 
develops and resolves, but this ability of platelets to recruit and activate leukocytes has po-
tential for causing pathological ‘thromboinflammation’, where thrombi promote inflammation 
that may cause tissue damage (Maugeri et al., 2014). 
Alterations in platelet function in inflammatory lung diseases 
There are also mechanisms of platelet function in inflammation, which are discussed fur-
ther below, which have no clear overlap with haemostatic or thrombotic function (Nachman 
and Weksler, 1972; Page, 1988, 1989; Li et al., 2017). In clinical studies, evidence has been 
found of altered platelet function in a variety of inflammatory diseases, but these alterations 
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are often subtle and can occur without any major alterations in haemostatic or thrombotic 
function.  
For example, patients with asthma show no overt changes in haemostasis, with a small 
increase in risk of cardiovascular disease (Iribarren et al., 2012). Platelets from asthmatics 
exhibit either a reduced lifespan (Taytard et al., 1986), or a similar lifespan to healthy control 
platelets, with reduced evidence of clearance in the spleen and liver (Plaza et al., 1992). 
Platelet responsiveness to collagen or platelet activating factor (PAF) was reduced in asth-
matics (Gresele et al., 1993), whilst blood platelet counts are decreased after allergen chal-
lenge (Sullivan et al., 2000; Kowal et al., 2006) and blood platelet-leukocyte conjugates 
(Pitchford et al., 2003), and platelet activation markers such as soluble P-selectin are in-
creased (Kowal et al., 2006). Platelets from patients with asthma may also be metabolically 
altered as they show less reliance on glycolysis than platelets from healthy controls, despite 
evidence of similar mitochondrial mass (Xu et al., 2015). 
 COPD and ARDS patients may have altered haemostatic and thrombotic responses due 
to cardiovascular comorbidities (Barnes, 2008; Yadav and Kor, 2015), but nonetheless COPD 
patients have increased blood platelet-monocyte conjugates which increase further during 
exacerbations (Maclay et al., 2011), ARDS incidence and mortality is associated with de-
creased blood platelet counts (Wang et al., 2014), whilst platelet-derived platelet factor 4 
(PF4, CXCL4)-CCL5 complexes correlate positively with extent of pulmonary leukocyte re-
cruitment (Grommes et al., 2012). In sepsis, a major risk factor for ARDS, blood platelet-
neutrophil conjugates are increased in the context of septicaemia without organ failure, and 
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then decreased if sepsis progresses to multiple organ failure, which may reflect increased 
platelet-neutrophil or platelet recruitment to failing organs (Gawaz et al., 1995, 1997). 
When innate immune inflammatory responses are studied through intravenous admin-
istration of healthy volunteers with bacterial lipopolysaccharides (LPS), LPS exposure has 
been shown to cause small decreases in blood platelet counts with increases in blood platelet-
neutrophil and platelet-monocyte conjugates in the absence of increases in platelet P-selectin 
(Thomas et al., 2015), small decreases in blood platelet count with evidence of platelet acti-
vation through increased surface CD40L expression, elevated plasma CXCL4 and increased 
endothelial cell adhesion ex vivo, all occurring in the absence of increases in the traditional 
thrombotic platelet activation markers, increased surface P-selectin or αIIbβ3 expression 
(Schrottmaier et al., 2016), or no effect on blood platelet counts with increases in platelet-
neutrophil conjugates and decreases in platelet-monocyte conjugates (Schoergenhofer et al., 
2016). 
Platelets are functionally important in lung inflammation  
Interestingly, although the effects of inflammation on haemostatic and thrombotic platelet 
responses can be minor compared to those of classical platelet agonists, experiments where 
platelets are depleted in animal models of inflammatory lung disease mechanisms have shown 
that removal of platelets can have major effects on the inflammatory response. These studies 
provide evidence that alterations in platelet function are causal in, rather than the sequelae 
of, inflammatory disease progression, with a particularly extensive number of studies carried 
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out in lung inflammation models involving lung neutrophil recruitment, especially those in-
volving LPS exposure (overview in Table 1.1), and in allergic airway inflammation models 
(overview in Table 1.2). 
 
Table 1.1: Effects of platelet depletion in lung inflammation models involving pulmonary 
neutrophil recruitment. Summary of studies in which lung inflammation outcomes have been 
measured in control animals and animals depleted of platelets in models where pulmonary neu-
trophil recruitment occurs. Effects or otherwise on primary outcomes of platelet depletion are 
given, and results are shaded according to outcome of platelet depletion with regards to health 
status of experimental animal: orange=positive outcome of platelet depletion, no shading=no 
detected effect of platelet depletion, blue shading=negative outcome of platelet depletion. Results 
are loosely chronologically sorted within categories of inflammation model. *Different results were 
obtained with different routes of depleting antibody administration (Table overleaf). 
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 Model Effect of platelet depletion Reference 
Dog, LPS i.v. ↓lung resistance (Stein and Thomas, 1967) 
Dog, LPS i.v. 
↓Pulmonary arterial pressure 
(Bredenberg et al., 1980) 
↓Pulmonary microvascular slowing 
Sheep, LPS i.v. ─haemodynamics, ─gas exchange (Snapper et al., 1984) 
Guinea pig, LPS inhalation ↓pulmonary inflatory pressure (Vincent et al., 1993) 
Mouse, LPS inhalation ↓BAL neutrophils (Kornerup et al., 2010) 
Mouse, LPS inhalation ↓BAL neutrophils, ↓BAL protein (Grommes et al., 2012) 
Mouse, LPS inhalation ↓lung histological injury score (Kornerup et al., 2010) 
Mouse, LPS inhalation ↓BAL neutrophils (Pan et al., 2015) 
Mouse, LPS inhalation ↑lung haemmorhage (Goerge et al., 2008) 
Mouse, LPS inhalation ↑lung haemmorhage (Boulaftali et al., 2013) 
Mouse, LPS inhalation ↑lung haemmorhage (Deppermann et al., 2017) 
Mouse, LPS i.p. ─/↑ lung haemmorhage*, ↓survival (Xiang et al., 2013) 
Mouse, LPS i.p. ─lung MPO (Andonegui et al., 2005) 
Mouse, anti-MHCI antibody i.v. ↓BAL protein (Hidalgo et al., 2009) 
Mouse, LPS inhalation, anti-MHCI 
antibody i.v. 
↑survival, ↓oedema (Looney et al., 2009) 
Mouse, LPS i.p. ↑lung MPO (Andonegui et al., 2005) 
Mouse, LPS i.p., anti-MHCI antibody i.p. ↑survival (Sreeramkumar et al., 2014) 
Mouse, acid inhalation ↑gas exchange (Zarbock et al., 2006) 
Mouse, LPS i.v. and human UVB-treated 
platelets i.v. 
↓BAL protein, ↓human UVB-treated 
(Chi et al., 2012) 
platelet recruitment 
Mouse, mesenteric ischaemia reperfusion ↓histological lung injury score (Lapchak et al., 2012) 
Mouse, caecal ligation and puncture ↓BAL neutrophils ↓oedema (Asaduzzaman et al., 2009a) 
Mouse, caecal ligation and puncture* ↓BAL neutrophils* (Asaduzzaman et al., 2009b) 
Mouse, caecal ligation and puncture* ─lung Ly-6G or MPO* (Asaduzzaman et al., 2009b) 
Mouse, K. pneumoniae inhalation ↑lung haemmorhage, ↓survival (de Stoppelaar et al., 2014) 
Mouse, colon carcinoma cells i.v. ↓neutrophils in lung metastatic niches (Labelle et al., 2014) 
Sheep, complement i.v. ─haemodynamics, ─gas exchange (McDonald et al., 1983) 
Sheep, phorbol myristate acetate i.v. ↓Pulmonary arterial pressure (Nakano et al., 1995) 
Mouse, NY1DD sickle cell crisis model ↓pulmonary vascular permeability 
(Polanowska-Grabowska et 
al., 2010) 




Table 1.2: Effects of platelet depletion in models of allergic lung inflammation. Summary of 
studies in which lung inflammation outcomes have been measured in control animals and animals 
depleted of platelets in models of allergic airway inflammation. Effects or otherwise on primary 
outcomes of platelet depletion are given, and results are shaded according to outcome of platelet 
depletion with regards to health status of experimental animal: orange=positive outcome of plate-
let depletion, no shading=no detected effect of platelet depletion. Results are loosely chronologi-
cally sorted within categories of inflammation model. 
 
 Model Effect of platelet depletion Reference 
Guinea pig, ovalbumin allergen challnege ↓Bronchial wall eosinophils 
(Lellouch-Tubiana et al., 
1988) 
Rabbit, ragweed allergen challenge ↓BAL eosinophils (Coyle et al., 1990) 
Guinea pig, ovalbumin allergen challnege ↓airway reactivity to histamine 
(Lellouch-Tubiana et al., 
1988) 
Guinea pig, ovalbumin allergen challenge 
─BAL eosinophils 
(Sanjar et al., 1990) 
─airway reactivity to histamine 
Mouse, ovalbumin allergen challenge 
↓BAL eosinophils, lymphocytes 
(Pitchford et al., 2003) 
─airway responsiveness to methacholine 
Mouse, ovalbumin allergen challenge 
(chronic) 
↓airway remodelling (Pitchford et al., 2004) 
Mouse, ovalbumin allergen challenge ↓BAL eosinophils, lymphocytes (Pitchford et al., 2005) 
Mouse, ovalbumin allergen challenge ↓BAL eosinophils, lymphocytes (Tian et al., 2014) 
Mouse, ovalbumin allergen challenge ↓BAL eosinophils, lymphocytes (Amison et al., 2015) 
Mouse, ovalbumin allergen challenge ↓BAL eosinophils, lymphocytes (Pan et al., 2015) 
Mouse, dust mite allergy, ptges-/-,  
lysine-aspirin inhalation 
↓lung resistance (Liu et al., 2013) 
Mouse, papain-induced airway  
inflammation 
↓BAL eosinophils (Takeda et al., 2016) 
 
Moving away from the lung, platelet depletion studies also indicate that platelets are 
important for inflammation occurring elsewhere in the body, in ischaemia and reperfusion 
injuries in the gut (Salter et al., 2001), in synovial inflammation occurring in arthritis models 
(Boilard et al., 2010), in autoimmune encephalitis (Langer et al., 2012), in the eyes when 
inflammation is induced by corneal abrasion (Lam et al., 2011), and in various skin inflam-
mation models (Tamagawa-Mineoka et al., 2007, 2009; Hara et al., 2010).  
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Platelets may also contribute to pathophysiological inflammatory responses in influenza 
virus infections (Lê et al., 2015) and in some phases of infection with the parasite P. berghei 
(van der Heyde et al., 2005; Gramaglia et al., 2017). However platelet depletion experiments 
in infection models have also shown that platelets are integrated into protective host defence 
responses, as platelet-depleted animals respond poorly relative to platelet-replete controls 
following infection with a variety of bacteria including S. sanguis (Dall et al., 1998), E. coli 
(Xiang et al., 2013), S. aureus (Wuescher et al., 2015), K. pneumoniae (de Stoppelaar et al., 
2014) and S. pneumoniae (van den Boogaard et al., 2015), as well the parasites T. cruzi 
(Fernandes et al., 1992) and P. falciparum (Polack et al., 1997). 
Another cautionary observation from some platelet depletion studies is that of inflamma-
tory bleeding in the context of both thrombocytopaenia and inflammation (Table 1.1). Alt-
hough bleeding does not normally accompany leukocyte transendothelial migration and 
plasma extravasation in inflammation, a minority of experimental thrombocytopaenia studies 
have produced data which suggest that pathological bleeding occurs in platelet-depleted mice 
following inflammatory challenge, indicating roles for platelets in maintaining haemostasis in 
some inflammatory contexts (Goerge et al., 2008; Boulaftali et al., 2013; Gros et al., 2015; 
Deppermann et al., 2017). 
Together these clinical and experimental studies indicate that platelets, like other immune 
cells that have been effectively targeted in inflammatory diseases, are effectors in both patho-
logical inflammation and in protective host defence across a variety of tissue and inflammatory 
contexts.  
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Studies in human volunteer LPS challenge models using drugs with anti-platelet activity 
are also suggestive that it may be possible to reduce inflammation in the human context, 
including in lungs, by targeting platelets. Drugs used in these studies include the dual PDE3/4 
inhibitor RPL-544 which possesses anti-platelet, anti-inflammatory and bronchodilatory ac-
tivity and reduces lung leukocyte recruitment following LPS inhalation (Franciosi et al., 
2013), the P2Y12 antagonists ticagrelor and clopidogrel which reduce systemic inflammation 
following intravenous LPS (Thomas et al., 2015), although the P2Y12 antagonist prasugrel 
had no effect in a similar study (Schoergenhofer et al., 2016), and aspirin, which reduced lung 
leukocyte recruitment following inhaled LPS challenge (Hamid et al., 2017).  
However, in the more complex setting of clinical trials, the P2Y12 antagonist prasugrel 
had no detected effect on lung function in asthmatics (Lussana et al., 2015), and aspirin did 
not prevent the development of ARDS in a trial in at-risk intensive care patients (Kor et al., 
2016a). These unsuccessful trials indicate a need for better understanding of platelet contri-
butions to inflammatory responses, and a need for new drugs that can inhibit inflammatory 
platelet responses. 
Recent studies in mouse models have also shown that disruption of the function of the 
signalling pathways in platelets that control lung leukocyte recruitment can be achieved with-
out prevention of haemostatic functions. These reports have identified platelet P2Y1 antago-
nism at doses insufficient to increase bleeding time (Amison et al., 2015, 2017), deletion of 
guanine nucleotide exchange factors (GEFs) P-Rex1 and either Vav1 or Vav3 in platelets 
(Pan et al., 2015) and the treatment of platelets with non-anticoagulant fragments of heparin 
(Riffo-Vasquez et al., 2016) as potential mechanisms through which platelets promote lung 
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leukocyte recruitment in inflammation through pathways that are not integral for haemosta-
sis. These observations open up the possibility of targeting platelets in inflammation without 
causing bleeding-related side effects (Page, 1988; Pitchford, 2007), an aim which mirrors re-
search in the thrombosis field, where processes key to thrombosis, but not haemostasis, are 
sought as targets for anti-thrombotic drugs (Jackson and Schoenwaelder, 2003). The following 
sections provide an overview of mechanisms through which platelets exert their functions in 
inflammation. 
1.2.3 Mechanisms involved in inflammatory platelet responses 
Platelet sensing of the presence of pathogens 
As well as acting as early sensors of damage to the endothelial barrier when conventional 
haemostatic responses are required, platelets also express pathogen-associated molecular pat-
tern (PAMP) recognition receptors, the initial host sensors of invading microbes in innate 
immunity (Janeway and Medzhitov, 2002).  
Receptors for PAMPs are more classically associated with immunity than haemostasis, 
but a wide variety are expressed by platelets. These include the toll-like receptors (TLRs): 
TLR1, a receptor for bacterial peptidoglycan and lipoproteins; TLR2, which recognises a 
variety of bacterial, viral, fungal, parasite and endogenous ligands; TLR4, which is the most-
studied PAMP recognition receptor which binds the LPS which coat Gram-negative bacteria, 
to which the platelet adhesion molecule P-selectin can also bind (Malhotra et al., 1998); and 
TLR9, which detects unmethylated CpG dinucleotides in bacterial DNA, as well as functional 
receptors for detection of bacterial N-formyl peptides (Czapiga et al., 2005).  
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Bacteria use receptors for, or mimicry of, endogenous proteins to operate within hosts. 
This has led to the evolution of the expression of bacterial proteins with similar structural 
motifs to host extracellular matrix or adhesion molecule proteins resulting in the ability of 
platelet receptors including αIIbβ3 and GP1bα to recognise a variety of bacterial surface pro-
teins through, or independently of, their binding by fibrinogen, fibronectin or vWF (Verschoor 
et al., 2011; Wong et al., 2013; Hamzeh-Cognasse et al., 2015). The platelet collagen and 
thrombin receptors GPIV and PAR1 can also mediate activation signals following exposure 
of platelets to bacterial toxins (Cox et al., 2011). This homology of bacterial toxins with 
platelet agonists may promote pathological thrombosis in infection, but may also enable 
platelets to assist in host defence (Hamzeh-Cognasse et al., 2015). 
Platelets also sense the presence of pathogens through detection of inflammation resulting 
from PAMP recognition by other parts of the immune system. Platelets sense activation of 
the complement cascade through expression of gC1q-R, and other unidentified receptors, for 
C1q and C3b (Peerschke et al., 2003; Hamad et al., 2010; Cox et al., 2011), antigen-antibody 
binding through functional expression of the receptor FcγRIIA for immunoglobulin Fc as well 
as other Fc receptors (Joseph et al., 1997). Functional expression on platelets of receptors for 
various inflammatory chemokines and cytokines has been demonstrated, including the CCR4 
receptor for the chemokines CCL17 (TARC) and CCL22 (MDC), the CCR3 receptor which 
binds CCL11 (eotaxin) and CCL5 (RANTES), the CCR1 receptor which has ligands includ-
ing CCL3 (MIP-1α), as well as the IL1R1 and IL1R8 receptors for IL-1 cytokines (Clemetson 
et al., 2000; Abi-Younes et al., 2001; Brown et al., 2013; Anselmo et al., 2016).  
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Direct platelet responses to the presence of pathogens 
Experiments in vitro with isolated platelets have shown that platelets are capable of 
independently mounting responses against pathogens. Platelet expression of PAMP recogni-
tion receptors and adhesion molecules means that platelets can bind pathogens directly, as 
first observed over a century ago with the observation of platelet adhesion on V. cholerae 
(Levaditi, 1901), and platelet adhesion to wide variety of other bacteria, as well as other 
pathogens including viruses, plasmodia, funghi and parasites has since been observed 
(Fitzgerald et al., 2006; Semple et al., 2011; Yeaman, 2014).  
The suggested consequences of platelet-pathogen interactions range from trapping of 
pathogens in the platelet open canalicular system (White, 2005, 2006), more broadly to trap-
ping of pathogens in circulatory beds of the lung and the liver in order to prevent dissemina-
tion throughout the circulation (Tocantins, 1938; Wong et al., 2013), as well as to the direct 
killing of a range of bacteria by platelets through the release of a variety of platelet microbi-
cidal proteins including β defensin-1, platelet factor 4 (PF4, CXCL4), and platelet microbi-
cidal proteins (PmPs) -1 and -2 (Kraemer et al., 2011a; Drago et al., 2013; Hamzeh-Cognasse 
et al., 2015).  
Platelets may also act as ‘sentinel cells’, acting as the primary sensors of PAMPs in vivo, 
as TLR4 expressed on platelets is important for mounting lung platelet recruitment responses 
to intraperitoneal LPS in mice (Andonegui et al., 2005), although in the context of Gram-
negative infection, deletion of MyD88, a critical mediator of signalling downstream of TLR4, 
exclusively in platelets of mice had no detected effect on responses to systemic or lung infec-
tion with K. pneumoniae (de Stoppelaar et al., 2015). 
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The nature of platelet activation responses following interaction with pathogenic stimuli 
are highly context-dependent even when isolated platelets are exposed to a purified pathogen 
component such as bacterial lipopolysaccharide (LPS) (Tocantins, 1938; Walker and Casey, 
1985; Middleton et al., 2016). A great number of studies have looked at isolated platelet 
responses to LPS and the variation in responses of platelets has been recently summarised 
(see Table 2 in Middleton et al., 2016). With the example of platelet aggregation as a readout, 
LPS can induce (Nocella et al., 2017), enhance (Montrucchio et al., 2003), inhibit (Matera et 
al., 1992; Lopes-Pires et al., 2012), or have no detected effect (Nystrom et al., 1993) on 
platelet aggregation depending on the experimental set-up and origin of LPS.  
Measurements of platelet activation response to LPS stimulation have also produced com-
plex results, with a wide range of activation responses reported (Middleton et al., 2016). Some 
of this variation in platelet responses to LPS preparations may be explained by the ability of 
platelets to mount different responses to different serotypes of LPS, suggestive of TLR4-
independent mechanisms through which LPS alters platelet function (Berthet et al., 2012). 
It is of note that despite their lack of a nucleus, platelets retain mRNA and transcriptional 
apparatus and isolated platelets can produce new proteins in vitro, as revealed in experiments 
exposing platelets to LPS. One example of a protein produced de novo by platelets is the 
inflammatory cytokine interleukin-1β (IL-1β), the mRNA of which is spliced, transcribed into 
protein and released, and responsed to by further platelets as part of an autocrine feedback 
loop induced by exposure to LPS (Shashkin et al., 2008; Brown et al., 2013). 
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1.2.4 Platelet interactions with leukocytes and endothelium in inflammation 
Adhesion molecules mediating platelet-cell interactions 
As well as independently mounting responses to pathogens, the presence of inflammatory 
stimuli can also promote the interaction of platelets and leukocytes, leading to the formation 
of platelet-leukocyte conjugates which have been found free flowing in blood, on the endothe-
lial wall, extravascularly in inflamed tissue, and can be induced to form in vitro (Page and 
Pitchford, 2013; Middleton et al., 2016; Pitchford et al., 2017). Platelet leukocyte conjugates 
are increased in the blood following a variety of inflammatory stimuli, including following 
LPS inhalation (Kornerup et al., 2010; Ortiz-Muñoz et al., 2014), or allergen challenge in 
mice (Pitchford et al., 2003; 2005), as well as in human volunteers exposed to LPS (Thomas 
et al., 2015) and patients with sepsis (Gawaz et al., 1995), COPD (Maclay et al., 2011), or 
with asthma (Pitchford et al., 2003; Kowal et al., 2006). 
Platelet-endothelial cell interactions may also be upregulated in inflammation, as platelets 
from human volunteers exposed to LPS show increased endothelial cell adhesion ex vivo 
(Schrottmaier et al., 2016), and in mice platelet-endothelium adhesion is increased in ischae-
mia-reperfusion injury in the mesenteric circulation (Massberg et al., 1998; Cooper et al., 
2004), in the mouse mesenteric circulation inflamed by TNFα (Frenette et al., 1998), and in 
the cremaster muscle circulation inflamed by LPS (Rumbaut et al., 2006; Riffo-Vasquez et 
al., 2016). 
Several key adhesion molecule pairings mediating platelet-leukocyte interactions have 
been identified. P-selectin glycoprotein ligand-1 (PSGL-1, CD162) is a membrane receptor 
expressed by leukocytes but also by platelets and endothelial cells (Carlow et al., 2009). The 
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classical binding partner of PSGL-1 is P-selectin (CD62P, GMP-140) released to the surface 
of platelets and endothelial cells from their respective α-granules and Weibel-Palade bodies 
during activation (Page and Pitchford, 2013), but E-selectin (CD62E), synthesised de novo 
by endothelial cells during inflammation, and L-selectin (CD62L), expressed most strongly in 
leukocytes and downregulated following activation of neutrophils, can also interact with 
PSGL-1 (Page and Pitchford, 2013). As platelets also express functional PSGL-1, so it is 
possible that platelet PSGL-1 and endothelial P or E-selectins could mediate platelet-endo-
thelium interactions in inflammation (Frenette et al., 2000).  
Interactions mediated through PSGL-1-selectin binding are thought to be mainly transi-
ent, but if activation signals are sustained, platelets and leukocytes can also be held together 
through stronger interactions involving the integrin αLβ2 (CD11a/CD18, LFA-1) on leuko-
cytes, and platelet ICAM-2 (CD102) (Diacovo et al., 1994), or the integrin αMβ2 
(CD11b/CD18, Mac-1, complement receptor 3) on leukocytes and platelet GPIbα (Diacovo 
et al., 1996b), or junctional adhesion molecule (JAM)-C (Santoso et al., 2002). Interactions 
between endothelial vWF and platelet αIIbβ3 or GP1b may also mediate platelet-endothelial 
cell interactions when endothelial cells are activated by inflammation (Bombeli et al., 1998; 
André et al., 2000). 
Platelet-cell interactions can alter function of platelets and cells 
There is strong evidence that platelet-leukocyte, as well as possibly platelet-endothelium, 
interactions are functionally important for leukocyte recruitment in inflammation, as this 
process can be impaired in a variety of contexts with disruption of the function of P-selectin 
(Mulligan et al., 1992; Singbartl et al., 2001; Pitchford et al., 2005; Pan et al., 2015), PSGL-
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1 (Asaduzzaman et al., 2009b; Hara et al., 2010; Kornerup et al., 2010; Lam et al., 2011; 
Stadtmann et al., 2013)3, ICAM-2 (Diacovo et al., 1994; Weber et al., 2004; Basit et al., 2006), 
αLβ2 (Diacovo et al., 1996b; Basit et al., 2006; Asaduzzaman et al., 2008; Stadtmann et al., 
2013) and JAMs (Ostermann et al., 2002; Bradfield et al., 2007). 
Many of these adhesion molecules directly regulate signalling that can enhance platelet, 
leukocyte or endothelial activation state, but platelet-cell interactions also enable interaction 
of other platelet and cell surface receptors. These surface receptors include platelet CD40L 
(CD40 ligand, CD154) (Inwald et al., 2003), which is typically associated with expression on 
CD4+ T cells, as well as mast cells, basophils, eosinophils and natural killer T-cells, where it 
classically mediates binding of these cells with CD40 expressed by antigen-presenting cells to 
help guide the induction of an antigen-appropriate appropriate immune response. CD40L 
expression can be upregulated on the surface of platelets activated by stimuli which include 
exposure to LPS (Rahman et al., 2009; Schrottmaier et al., 2016), and interactions between 
platelet CD40L with endothelial CD40 alters endothelial cell function with the end result of 
increasing leukocyte recruitment (Henn et al., 1998). Platelet CD40L is important for neu-
trophil recruitment to lungs and for allergic airway inflammation in mouse models (Rahman 
et al., 2009; Tian et al., 2014). 
                                           
 
3 As well as binding with selectins, PSGL-1 also mediates signalling both through, and inde-
pendently of, selectins interactions, and has a recently-discovered role in checkpoint regulation in 
T-lymphocytes, decreasing T-cell proliferation through promoting exhaustion (Hicks et al., 2003; 
Asaduzzaman et al., 2009b; Tinoco et al., 2016). 
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Also expressed on the surface of platelets is an unknown ligand for the triggering receptor 
expressed on myeloid cells 1 (TREM-1), which enables platelets to promote activation of 
TREM-1-expressing neutrophils with functional outcomes for neutrophil recruitment to lungs 
(Haselmayer et al., 2007). 
Platelets can also release soluble mediators which influence the function of nearby lecu-
kocytes and endothelial cells in inflammation. Platelets are the major store of serotonin, (5-
hydroxytryptamine, 5-HT) in the body outside of the nervous system, and studies in mouse 
inflammation models suggest that release of platelet serotonin is important for neutrophil 
recruitment, including in LPS-inflamed lungs (Duerschmied et al., 2013).  
Studies where apyrase was used to metabolise ADP, and P2Y receptor antagonists have 
been used to block ADP responses, suggest that platelet ADP release is important for both 
neutrophil and eosinophil recruitment to lungs (Amison et al., 2015, 2017). Platelet-derived 
PF4-CCL5 chemokine heteromers are also important for the development of lung inflamma-
tion following LPS inhalation (Grommes et al., 2012) 
Platelet-leukocyte and platelet-endothelial cell interactions also allow the transfer of ara-
chidonic acid metabolites between platelets and cells, enabling the production of different 
bioactive end-products than those that can be produced by individual cell types alone (Folco 
and Murphy, 2006). In a similar manner to how endothelial cells can use platelet-derived 
arachidonic acid metabolites to produce prostacyclin, a potential mechanism through which 
intact endothelial cells limit platelet adhesion (Bunting et al., 1976; Nowak and FitzGerald, 
1989; Karim et al., 1996), neutrophils and monocytes produce leukotriene (LT)A4, which can 
be shuttled to platelets which express LTC4 synthase and so can produce bioactive LTC4 
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(Edenius et al., 1988; Maclouf and Murphy, 1988; Bigby and Meslier, 1989). Platelets can 
also use arachidonic acid metabolites produced by monocytes to synthesis lipoxin A4 (Bigby 
and Meslier, 1989). Bioactive leukotrienes are important in inflammatory reactions, particu-
larly in asthma (Busse, 1998; Montuschi and Peters-Golden, 2010), and lipoxins may be pro-
tective in resolving inflammation in the lung (Serhan et al., 2014). 
 
 
Figure 1.3: Overview of platelet interactions with pathogens, endothelium and leukocytes in 
inflammation. (A) Platelets directly interact with a variety of pathogens in blood and in vitro, 
with some pathogens triggering aggregation and coagulation and some not. (B) Inflammatory 
stimuli and danger signals can promote tethering of individual platelets on endothelial cells. (C) 
Inflammatory and thrombotic stimuli can cause platelet-leukocyte conjugates form in blood and 
in vitro. (D) In some situations, platelets may act as bridges to tether leukocytes to vessel walls. 
(E) Platelets interact with vessel-adherent leukocytes and (F) guide leukocytes to sites for tran-
sendothelial migration. (G) Platelets may be important for preventing bleeding following transen-
dothelial migration of leukocytes. (H) Platelets are important for neutrophil extracellular trap 
formation. (I) Platelets can also migrate across the endothelium, but the influence of leukocytes 
on this event is unknown.  
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Platelet-cell interactions in the leukocyte (and platelet) recruitment cascade 
Advances in imaging technology have revealed interactions of platelets with leukocytes 
and endothelial cells at every step required in the leukocyte recruitment cascade, a set of 
adhesion stages required for the movement of leukocytes from the bloodstream to the endo-
thelial wall and then out into tissue, an integral process in host defence and immune surveil-
lance (Ley et al., 2007). 
In order to leave the bloodstream and become arrested on the endothelial wall, leukocytes 
must overcome the inflammatory shear from passing blood and tether to endothelial cells. In 
several tissue contexts, the rolling of leukocytes along the endothelium is the first step in this 
process. In several models, leukocyte rolling has shown dependence upon platelets, with in-
teractions between P- and E- selectin adhesion molecules expressed by activated endothelial 
cells and platelets, and PSGL-1 on leukocytes have been implicated in this process (Diacovo 
et al., 1996a; Carvalho-Tavares et al., 2000; Salter et al., 2001; Ludwig et al., 2004; Kuckleburg 
et al., 2011).  
However, in other preparations, such as in the capillaries of the lung and kidney glomeruli, 
selectin-mediated rolling is dispensible for leukocyte recruitment, but platelets, and in some 
cases, P-selectin, are still required (Singbartl et al., 2001; Hickey et al., 2006; Kuligowski et 
al., 2006; Zarbock et al., 2006; Kornerup et al., 2010). This may be because platelet-leukocyte 
interactions in free-flowing blood in inflamed tissues that current imaging technologies cannot 
resolve are important, but recent studies have also indicated that platelet interactions with 
endothelium-adhesive leukocytes may also be important in the platelet-dependence of leuko-
cyte recruitment. In inflamed cremaster venules for example, platelets interact with PSGL-1-
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rich uropods of endothelium-adhesive neutrophils, with intravascular crawling greatly dimin-
ished in the absence of platelets, suggesting a requirement for platelet interactions with en-
dothelium-adherent neutrophils for promoting intravascular crawling to sites of neutrophil 
endothelial transmigration (Sreeramkumar et al., 2014). In vitro assays have further revealed 
that platelets can promote neutrophil migration through interactions requiring P-selectin 
(Bengtsson et al., 1999; Kornerup et al., 2010; Amison et al., 2015). 
As well as platelet-leukocyte interactions, platelet-endothelium interactions may also be 
important for intravascular crawling towards sites for leukocyte extravasation, as in another 
study in the mouse cremaster preparation, platelets have been proposed to act as guides 
which lead leukocytes to appropriate sites for endothelial transmigration, as platelet adhesion 
can be seen at sites on the endothelium which later become ‘hotspots’ of leukocyte transen-
dothelial migration (Zuchtriegel et al., 2016).  
Furthermore, platelet adhesion has also been observed at sites where leukoytes have pre-
viously emigrated from the bloodstream, a response which has been associated with the pre-
vention of inflammatory bleeding, but contrasts with classical haemostatic plug formation in 
that platelet adhesion appears to be limited to single platelets (Gros et al., 2015). 
Platelet migration beyond the endothelial barrier 
Platelets may also pass through the endothelium and have been found extravascularly 
with leukocytes, or alone, with consequences that are poorly understood. Extravascular plate-
lets have also been observed in pathological samples from human patients with inflammatory 
bowel disease (Weissmüller et al., 2008), tumours (Miyashita et al., 2015), aspirin exacerbated 
respiratory disease (Laidlaw et al., 2012), ARDS (Miyashita et al., 2016), and asthma 
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(Metzger et al., 1987). Furthermore, platelets have been found outside of blood vessels with-
out evidence of bleeding in models of skin inflammation in guinea pigs (Feng et al., 1998), in 
lungs following intravenous platelet activating factor challenge in guinea pigs (Lellouch-
Tubiana et al., 1985), in allergic mouse airways (Pitchford et al., 2008), in LPS-inflamed 
mouse lung airspaces (Ortiz-Muñoz et al., 2014), and in healthy mouse high endothelial ven-
ules (Herzog et al., 2013). Platelet microparticles have also been found in increased numbers 
in the inflamed synovia of mice with inflammatory arthritis (Boilard et al., 2010). 
This accumulating evidence of the extravascular presence of platelets in response to in-
flammatory signals, and the intimate involvement of platelets with the process of the leuko-
cyte recruitment cascade, suggests the presence of platelets extravascularly might be as a 
secondary consequence of leukocyte migration. However, platelets display motility that sug-
gests they might independently be able to achieve transendothelial migration, as in vitro 
human platelets can exhibit random motility (Valone et al., 1974), and directed motility 
towards a chemotactic gradient (Lowenhaupt, 1978; Lowenhaupt et al., 1982; Czapiga et al., 
2005; Kraemer et al., 2010, 2011b). Platelets from mice have also been shown to achieve 
directed migration towards chemotactic gradients (Pitchford et al., 2008; Schmidt et al., 
2012).  
Signalling through phosphoinositol 3-kinase, serum and glucocorticoid-regulated kinase 1 
(SGK1) signalling, and elevated cytoplasmic Ca2+, actin polymerisation and focal adhesion 
formation, and the chemotactic stimuli fMLP, stromal cell-derived factor 1α (SDF-1α) and 
antigen-antibody-Fc receptor interactions have been implicated in these in vitro studies 
(Pitchford et al., 2008; Kraemer et al., 2010, 2011b; Schmidt et al., 2012), and provide further 
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evidence that platelets have the capacity to migrate across the endothelial barrier into in-
flamed tissue. Recently-developed microfluidic models have also demonstrated that migrating 
neutrophils can ‘pick up’ and ‘drop’ platelets as the neutrophils move towards a source of 
chemokine, providing another way in which platelets may migrate from blood into inflamed 
tissues (Frydman et al., 2017).  
Methods are required for enabling the imaging and quantification of platelet transendo-
thelial migration in inflammation in vivo for further investigation into mechanisms of platelet 
migration in inflamed tissues and establishing what roles extravascular platelets in play in 
health and disease. 
1.2.5 Lung platelet recruitment in inflammation 
Platelet recruitment to lungs in inflammation 
As many of the functions of platelets reviewed above require spatio-temporally limited 
juxtacrine and paracrine signalling it is conceivable that, like platelet adhesion in haemostatic 
responses and leukocyte recruitment in inflammation responses, the platelet responses that 
mediate the platelet-dependence of inflammation depend on local platelet recruitment. 
Lung platelet recruitment has previously been demonstrated across a range of non-human 
animal models showing that platelet recruitment to the lung is an evolutionarily conserved 
response elicited by a wide range of stimuli (See overview in Table 1.3). There is evidence 
that some of this recruitment may be because platelets are slowed by interactions with cells 
in the lung as they travel through the pulmonary circulation (Bierman et al., 1951; Kien et 
al., 1971; Doerschuk et al., 1990; Eichhorn et al., 2002). 
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Platelets may also be deposited in the lung in inflammatory states as a result of micro-
vascular thrombosis, or disseminated intravascular coagulation, responses to interplay be-
tween inflammation responses with processes involved in regulating thrombosis, coagulation 
and fibrinolysis (Vesconi et al., 1988; Davis et al., 2016).  
It is also of note that the platelet content of the lungs can be influenced by local produc-
tion, as lungs contain ‘embolised’ megakaryocytes which produce proplatelets and platelets 
locally, as well as progenitor stem cells capable of differentiating into megakaryocytes 
(Aschoff, 1893; Howell and Donahue, 1937; Trowbridge et al., 1984; Lefrançais et al., 2017). 
Little is known of the effects of lung inflammation on the quantity and duration of pulmonary 
thrombopoiesis, although megakaryocytes in mice produce functionally altered platelets after 
LPS exposure through a TLR4-independent mechanisms (Jayachandran et al., 2007). 
Further to studies in non-human animal models, increased quantities of platelets have 
also been found inside and outside of blood vessels in autopsy samples of lungs from human 
sufferers of ARDS (Bone et al., 1976; Miyashita et al., 2016), activated platelets have been 
found in arterial blood samples of patients with COPD and pulmonary hypertension 
(Rostagno et al., 1991), and platelets have been detected in the bronchoalveolar spaces of 
asthmatic patients (Metzger et al., 1987), indicative of involvement of lung platelet recruit-
ment, activation and transendothelial migration in human inflammatory lung disease pathol-
ogy. 
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Table 1.3: In vivo inflammation studies showing platelet recruitment to lungs. Model organ-
ism, inflammatory stimulus and references to studies where lung platelet recruitment has been 
measured in the context of inflammation. 
 
Animal Stimulus Reference 
Dogs Systemic trauma (Ljungqvist et al., 1971) 
Dogs Disintegrated Pseudomonas i.v. 
(Myrvold and Brandberg, 1977; 
Myrvold and Lewis, 1977) 
Dogs Oleic acid i.v. or E. coli i.v. (Hechtman et al., 1978) 
Dogs LPS i.v. (Almqvist et al., 1983) 
Rabbits fMLP i.v. (Issekutz et al., 1983) 
Rats Hyperoxia (Barry and Crapo, 1985) 
Guinea pigs LPS aerosol (Beijer et al., 1987) 
Rabbits Ragweed allergen aerosol (Metzger et al., 1987) 
Sheep LPS i.v. (Al-Sarraf et al., 1988, 1989) 
Baboons Paf-acether i.t. (Arnoux et al., 1988) 
Aged rats LPS i.v. (Durham et al., 1989) 
Guinea Pigs fMLP i.v. or PAF-acether i.v. (Bureau et al., 1989) 
Mice LPS i.v. (Shibazaki et al., 1996, 1999) 
Rats LPS i.v. (Itoh et al., 1996) 
Mice Ovalbumin allergen i.v. (Yoshida et al., 2002) 
Mice LPS i.p. (Andonegui et al., 2005) 
Rabbits LPS i.v. (Kiefmann et al., 2006) 
Mice Ovalbumin allergen aerosol (Pitchford et al., 2008) 
Mice LPS i.t. + anti-MHCI i.v. (Looney et al., 2009) 
Mice LPS i.t. (Ortiz-Muñoz et al., 2014) 




Lung platelet recruitment following intravenous versus inhaled inflammatory stimuli 
Interestingly, these previous studies show that lung platelet recruitment can be elicited 
following intravenous administration of inflammatory stimuli (Table 1.3), which may result 
in lung platelet recruitment due to systemic platelet aggregation and embolism in the lung 
microvasculature, but lung platelet recruitment can also be provoked when lung inflammation 
is induced by hyperoxia (Barry and Crapo, 1985), challenge with inhaled allergen (Metzger 
et al., 1987; Pitchford et al., 2008), or LPS inhalation (Beijer et al., 1987; Ortiz-Muñoz et al., 
2014). In these models the lung is the focus of inflammation and the agent used for inflam-
matory challenge is primarily encountered by cells facing the airspaces so is unlikely to be 
directly causing systemic platelet aggregation leading to subsequent pulmonary thromboem-
bolism. 
Traces from noninvasive recordings where thoracic radioactivity was measured over time 
in animals infused with 111In-labelled platelets show that the time courses of responses to 
intravenous versus inhaled LPS are contrasting. Intravenous LPS at a high dose in rats cause 
a lung platelet recruitment response which dissipated within 30 minutes (Figure 1.4), whereas 
when LPS was given via the inhaled route as an aerosol in guinea pigs, lung platelet recruit-
ment was sustained for over 2 hours (Figure 1.5), a time course more closely resembling that 
of recruitment of radiolabelled neutrophils to LPS-inflamed lungs, which was sustained be-
yond 30 minutes in rabbits (Jones et al., 2002). 




Figure 1.4: Non-invasive measurement of lung platelet recruitment following intravenous LPS 
injection into rats. Thoracic radioactivity over time in rats transfused with 111In-labelled platelets, 
with 10 mg/kg of LPS given i.v. at 0 minutes. Means ± standard error, n=6. Adapted from Itoh 
et al., (1996) with permission from Elsevier. 
 
 
Figure 1.5: Non-invasive measurement of lung platelet recruitment following LPS inhalation 
in guinea pigs. Thoracic radioactivity over time in guinea pigs transfused with 111In-labelled 
platelets, or red blood cells as a perfusion control (RBC, dashed line). At 0 minutes guinea pigs 
were exposed to saline aerosol (Control) or LPS aerosol at the concentrations indicated (RBC 
group was given LPS at 50 µg/ml. Means ± standard error, n=6-11. Reproduced from Beijer et 
al., (1987) with permission from Wiley-Blackwell Publishing.  
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Pharmacological studies investigating lung platelet recruitment following LPS inhalation 
have identified that in guinea pigs, treatment with platelet activating factor antagonists CV-
3988 and brotizolam, the anti-coagulant and anti-inflammatory molecule heparin, the pros-
tacyclin analogue ZK 36374, or high doses of the COX inhibitor indomethacin, might reduce 
inflammatory lung platelet recruitment (Beijer et al., 1987), whilst in mice this response 
might be decreased by treatment with high doses of aspirin (Ortiz-Muñoz et al., 2014). How-
ever, lung platelet recruitment in response to inhaled inflammatory stimuli is little-character-
ised when compared to the processes of platelet recruitment in haemostasis, and leukocyte 
recruitment in inflammation, which have both been extensively studied with the use of the 
wide range of imaging technologies and genetic, antibody and pharmacological interventions 
that are now available for use in mice. A mouse model and techniques were therefore sought 
for use in the study of lung platelet recruitment following LPS inhalation in mice. 
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1.3 Aims and objectives 
1.3.1 Methods for measuring LPS-induced lung platelet recruitment 
Characterising an LPS inhalation model of lung inflammaiton 
As reviewed above, platelet responses to LPS in vitro have been widely studied, and the 
platelet dependence of responses to LPS-treatment has been explored in a variety of animal 
models, many of which showed that removal of platelets reduced the extent of inflammation 
or other pathological measurements (Table 1.1).  
LPS models offer the advantages of relative reproducibility and rapidity of use, and are 
widely used as models for the study of processes which are hallmarks of the ARDS, and that 
also occur in COPD, such as lung neutrophil recruitment, cytokine production in the lungs, 
and plasma extravasation into airspaces (Matute-Bello et al., 2008). LPS inhalation is also 
more generally used to study the phenomonen of directed neutrophil migration into lung 
airspaces (Pan et al., 2015), a response which is protective in host defence against lung infec-
tions, but could also be pathophysiological when neutrophil recruitment is excessive, unre-
solving or unwarranted (Munford, 2008). LPS inhalation has also been used more specifically 
to study occupational byssinosis which is thought to be caused by inhalation of dust contain-
ing residual LPS (Rylander et al., 1981).  
Previous studies have demonstrated the platelet dependence of lung neutrophil recruit-
ment following intranasal (Kornerup et al., 2010; Pan et al., 2015) or aerosolised (Grommes 
et al., 2012), inhalational challenge with LPS (Table 1.1). Lung inflammation following LPS 
Chapter 1. Introduction  38 
 
 
inhalation appears to involve platelet mechanisms which contrast with those involved in hae-
mostasis and thrombosis. For example inflammation following LPS inhalation depends on 
platelet P-Rex and Vav guanine nucleotide exchange factors which are dispensible for hae-
mostasis, and in contrast to thrombotic responses show a greater dependence on signalling 
through the P2Y1 than the P2Y12 purinergic G-protein coupled receptor (Amison et al., 2017). 
Furthermore, LPS inhalation appears to cause lung platelet recruitment in mice with 
platelets also migrating into airspaces, responses that are reduced when other elements of the 
inflammatory response are inhibited (Ortiz-Muñoz et al., 2014). 
The initial aim of this project was therefore to characterise a mouse LPS inhalation model 
similar to those used in the previous experiments showing platelet dependence of neutrophil 
recruitment and lung platelet recruitment in order to enable the study of lung platelet re-
cruitment and platelet migration into lung airspaces, as well as lung neutrophil recruitment, 
following inflammation originating in the lung airspaces. 
Immunohistochemistry 
Platelets are prevalent in the blood which perfuses all tissues, but as they are anucleate 
and chemical stains allow for limited discrimination of platelets in tissues4, individual platelets 
can be easily overlooked in conventional histological preparations stained for example with 
                                           
 
4 Wright’s stain allowed for association of blood platelets with megakaryocytes in cytological 
samples (Wright, 1906; Lee et al., 2002), but is less useful in tissue preparations, particularly when 
platelets are not aggregated into large thrombi, as is the case with Carstairs’ stain for fibrin and 
platelets (Carstairs, 1965). Transmission electron microscopy methods also allow for identification 
of platelets but with a low throughput (Feng et al., 1998). 
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haematoxylin and eosin. The position and number of platelets can, however, be revealed with 
the use of immunohistochemistry techniques to deposit dyes or fluorophores at sites of high 
density of expression of epitopes highly restricted to the megakaryocyte/platelet lineage, as 
pioneered by Carstairs (1965). Examples of platelet-specific epitopes used in the present body 
of work to immunostain platelets are regions of CD41 (ITGA2B, Integrin αIIb, a component 
of the receptor for fibrinogen and vWF) and CD42b (GP1BA, Glycoprotein Ibα, a component 
of the receptor complex for vWF). 
Previous studies have demonstrated increased CD41 staining in inflamed lungs, but few 
have quantified platelets made visible using immunohistochemistry. In the present body of 
work, a novel approach was therefore employed combining rapid collection of mouse lung 
samples, snap freezing, and staining for platelet CD41 or CD42b. DAB reporters were used 
as they are highly sensitive and do not suffer from photobleaching, so samples are perma-
nently stained and could be imaged using a new bright field microscope available in our 
laboratory. This method was quantified through the deconvolution of DAB reporter signal 
(Ruifrok and Johnston, 2001) with the use of automated counting methods for increased 
throughput, and supported by immunofluorescence staining using tiling methods which al-
lowed for viewing high resolution images of relatively large areas of tissue (Preibisch et al., 
2009).  
Immunohistochemistry can also be applied to human samples, so platelets were also im-
munostained in samples previously generated from human ex vivo blood-perfused lungs ex-
posed to LPS intrabronchially (Hamid et al., 2017), as a proof-of concept study exploring the 
suitability of the use of this method in human tissue.  




With excellent depth of penetration and improving spatial resolution, platelets and other 
cells can be tracked throughout the body using radiolabelling and radioimaging methods, and 
radiolabelled autologous platelets have established clinical use for studying platelet lifespan 
and fate in the context of thrombocytopenia (Mathias and Welch, 1984). 
Early experiments using radiolabelled platelet methods in laboratory animals permitted 
measurement of platelet aggregation noninvasively in vivo through the quantification of lung 
platelet aggregate trapping following intravenous injection of platelet agonists using the index 
of increased thoracic radioactivity (Page et al., 1982). Similar noninvasive methods have been 
applied to the measurement of increases in lung platelet signal following the inhalation of 
LPS in guinea pigs (Beijer et al., 1987) (Figure 1.5), and also following intravenous injections 
of LPS into rats (Itoh et al., 1996).  
Platelet responses to LPS, or any other inflammatory stimuli, have not been measured 
non-invasively using platelet radiolabelling in mice, but the method for non-invasively meas-
uring thromboembolism in the lungs has been scaled down for use in mice (Tymvios et al., 
2008). Destructive organ biodistribution studies in mice have been carried out and have re-
vealed increases in platelet signal in lungs of mice following intraperitoneal injection of LPS 
(Andonegui et al., 2005), and in mouse lungs after induction of a model of transfusion-induced 
acute lung injury involving inhalation of LPS followed by intravenous anti-MHCI antibody 
(Looney et al., 2009), but have been minimally studied following LPS inhalation alone 
(Looney et al., 2009).  
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We therefore sought to develop a method in a mouse LPS model for non-invasive meas-
urements of thoracic platelet content as an index of lung platelet recruitment. This was com-
bined with a more sensitive, but destructive, organ biodistribution approach to measure plate-
let accumulation in lungs as well as their major sites of clearance in the liver and spleen, and 
also in samples of bronchoalveolar lavage (BAL)  in order to quantify extravascular movement 
of platelets into the lung airspaces. 
Intravital microscopy 
Intravital microscopy renders dynamic cellular processes visible in their living context. 
The first quantitative studies of leukocyte and platelet recruitment to blood vessel walls using 
intravital videomicroscopy started the research field of investigating the different mechanisms 
by which leukocytes and platelets are recruited from the blood to the endothelial lining 
(Atherton and Born, 1972, 1973a, 1973b), and a wide variety of methods for intravital imaging 
platelets in blood vessels are now available. 
The imaging of cellular processes in lungs has been challenging relative to other tissues 
due to the situation of the lungs inside the ribcage and the motion of the lungs which is 
required for efficient ventilation. Lung imaging is important as many processes occur differ-
ently in the systemic and pulmonary vasculature – for example LPS-induced neutrophil re-
cruitment in the pulmonary circulation does not appear to require P-selectin (Kornerup et 
al., 2010), whilst the same process in the liver circulation does (Klintman et al., 2004). Other 
vascular beds widely used for intravital microscopy studies due to their ease of access and 
stability for example the cremaster muscle or mesentery preparations, are not in ‘barrier’ 
tissues directly exposed to pathogenic stimuli, and do not normally become inflamed. 
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Advances in intact lung microscopy allowed for the discovery of the pulmonary capillaries 
(Malpighi, 1661), the use of a vacuum window permitted stabilised imaging of the living 
pulmonary microcirculation in closed-chest conditions in of dogs (Terry, 1939), and ex vivo 
fluorescent labelling of platelets allowed for the first imaging and quantification of recruitment 
of activated platelets to the capillaries and venules of the lungs of rabbits (Eichhorn et al., 
2002). Similar technology has also allowed for the first microscopy studies of platelet recruit-
ment to rabbit lungs following intravenous LPS infusions (Kiefmann et al., 2004, 2006).  
Intravital microscopy methods have more recently been adapted and developed upon for 
imaging lungs of mice (Tabuchi et al., 2007; Looney et al., 2011; Ortiz-Muñoz et al., 2014; 
Headley et al., 2016; Lefrançais et al., 2017). Coupling the enhanced depth of penetration 
possible with multiphoton microscopy with the use of a mouse strain in which platelet mem-
branes are genetically labelled with green fluorescent protein has allowed for the imaging of 
a complete population of endogenously labelled platelets, proplatelets and megakaryocytes in 
physiological quantities in living lungs (Lefrançais et al., 2017).  
Using the same mouse strain and similar microscopy methods as thosed used by Lefrançais 
et al, (Lefrançais et al., 2017), a pilot study was carried out using intravital multiphoton 
microscopy to image and quantify platelet adhesion in the lungs of healthy control mice and 
mice treated intranasally with LPS. 
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1.3.2 Exploring mechanisms of LPS-induced lung platelet recruitment 
Dependence of LPS-induced lung platelet recruitment on neutrophils 
Both platelets and neutrophils are under consideration as targets for therapeutic inter-
ventions for inflammatory diseases. Understanding how the recruitment of both of these cell 
types depends upon the recruitment of the other will be important for predicting and inter-
preting any anti-inflammatory efficacy or side-effects that might result from interventions 
targeting platelet or neutrophil recruitment to lungs. 
Neutrophils are amongst the earliest cellular responders to a variety of inflammatory 
insults, and make up the vast majority of recruited cells following LPS inhalation. In a study 
where the effects of platelet depletion, neutrophil depletion, and depletion of both cell types 
were compared head-to head, all treatments inhibited LPS-induced lung inflammation to a 
similar extent (Grommes et al., 2012). Several experiments in mouse models of lung inflam-
mation suggest that lung neutrophil recruitment largely depends on the presence and function 
of platelets, including in LPS inhalation models (Kornerup et al., 2010; Grommes et al., 2012; 
Ortiz-Muñoz et al., 2014; Pan et al., 2015; Amison et al., 2017), following acid inhalation 
(Zarbock et al., 2006), and in response to LPS priming and anti-MHCI antibody model of 
transfusion-associated lung injury (Looney et al., 2009).  
As lung platelet recruitment may be a key mechanism for the platelet dependence of lung 
neutrophil recruitment, it is of interest whether neutrophil depletion affects lung platelet 
recruitment following LPS inhalation. The neutrophil dependence of lung platelet recruitment 
following LPS inhalation has not been previously explored, but several studies have found 
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platelet recruitment to require neutrophils in other contexts. These at least partially neutro-
phil-dependent responses include platelet deposition on infarcted myocardium in dog models 
(Bednar et al., 1985), ischemia-induced platelet adhesion in mesenteric postcapillary venules 
of mice (Cooper et al., 2004), intravenous LPS-induced platelet adhesion in the cremaster 
muscle microcirculation (Rumbaut et al., 2006), as well as platelet recruitment to the lungs 
following treatment of mice with intraperitoneal LPS (Andonegui et al., 2005), and following 
inhaled LPS priming and intravenous anti-MHCI antibody to induce lung injury (Looney et 
al., 2009).  
Antibody-based neutrophil depletion technologies for use in mouse models that have im-
proved selectivity have relatively recently become available. These new neutrophil depleting 
antibodies target Ly6-G+ neutrophils without also depleting functionally important Ly6C+ 
inflammatory monocytes which were depleted together with neutrophils by earlier anti-Gr-1 
antibodies used in all of the mouse models investigating neutrophil dependence of platlet 
recruitment listed above (Daley et al., 2008). A neutrophil depletion strategy was therefore 
validated and used to compare platelet response to LPS inhalation in mice depleted of neu-
trophils with anti-Ly6-G antibody, to neutrophil replete controls in order to test whether 
whether platelet depletion was neutrophil-dependent. 
PSGL-1, P-selectin and lung platelet recruitment 
P-selectin and PSGL-1 are attractive molecules for an investigation into platelet recruit-
ment to inflamed lungs as P-selectin and PSGL-1 are required for platelet-leukocyte, platelet-
endothelium and leukocyte-endothelium interactions. In LPS inhalation models PSGL-1 has 
been implicated as an important mediator of platelet-dependent lung inflammation (Kornerup 
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et al., 2010), and P-selectin has been suggested to mediate LPS-induced neutrophil rolling in 
the airway vasculature (Pan et al., 2015). Furthermore, platelet recruitment to the pulmonary 
circulation in rabbits during endotoxaemia showed evidence of P-selectin dependence 
(Kiefmann et al., 2006). 
P-selectin and PSGL-1 interactions are important to investigate as these adhesion mole-
cules are targets for drugs in development for a variety of diseases. The P-selectin inhibitor 
crizanlizumab recently showed efficacy in clinical trials for preventing pain crises in sickle cell 
disease (Ataga et al., 2017), and P-selectin also has been implicated in lung inflammation in 
cobra venom factor intravenous administration models (Mulligan et al., 1992), in postis-
chaemic renal failure in mice (Singbartl et al., 2001), acid inhalation-injuced lung injury 
(Zarbock et al., 2006), as well as in the formation of NETs (Etulain et al., 2015).  
Likewise, inhibitors of PSGL-1 function are currently in development (Kanabar et al., 
2016), and blocking PSGL-1 has previously also shown efficacy in reducing inflammation in 
in vivo models of atherosclerosis (Phillips et al., 2003), caecal ligation and puncture 
(Asaduzzaman et al., 2009b) , anti-MHCI antibody-induced lung injury (Sreeramkumar et 
al., 2014). It should be noted that the anti-inflammatory effects of blocking PSGL-1 appear 
to extend beyond those of blocking interactions with selectins as recombinant PSGL-1, which 
blocks all PSGL-1 interactions, is anti-inflammatory at 1/30 of the dose required to inhibit 
leukocyte rolling (Hicks et al., 2003), and in a mouse caecal ligation and puncture model, the 
effects of PSGL-1 blockade on reducing lung neutrophil recruitment occurred in addition to 
the effects of following platelet depletion (Asaduzzaman et al., 2009b).  
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The effects of blockade of P-selectin or PSGL-1 on lung platelet recruitment and inflam-
mation following LPS inhalation in mice were therefore investigated to clarify the involvement 
of these mediators in this model. 
Drugs targeting platelet P2Y ADP receptors and lung platelet recruitment 
Platelets sense extracellular ADP, a danger signal for cellular damage or the release of 
dense granules from activated platelets, through the expression of the purinergic GPCRs 
P2Y1 and P2Y12, as well as through the ion channel P2X1. 
P2Y12 expression is relatively restricted to platelets, and antagonists of P2Y12 possess 
potent antithrombotic activity which underlies the clinical success of P2Y12 inhibitors includ-
ing clopidogrel, prasugrel, cangrelor and ticagrelor in the treatment of cardiovascular diseases 
(Jackson and Schoenwaelder, 2003; Cattaneo, 2010).  
The expression of P2Y1 is less restricted to the megakaryocyte-platelet lineage than P2Y12 
– P2Y1 is also expressed in the brain and the respiratory epithelium amongst other tissues – 
and so there has been caution around the targeting P2Y1 in humans. However, antagonists 
with relative P2Y1 selectivity have been produced and retain interest in the thrombosis field 
as studies in mice, rabbits and cynomolgus monkeys suggest that P2Y1 inhibitors may in-
crease bleeding risk to a lesser extent than P2Y12 inhibitors whilst retaining an equivalent 
degree of anti-thrombotic activity towards ADP (Yang et al., 2014; Wong et al., 2016). 
Inhibition of P2Y1, but not P2Y12, reducs lung leukocyte recruitment in both allergen 
challenge and LPS inhalation models, without greatly increasing bleeding time (Amison et 
al., 2015, 2017). Exposure of platelets to ADP concentrations insufficient to promote platelet 
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aggregation also enhances platelet-dependent leukocyte chemotaxis towards macrophage de-
rived chemokine (MDC), suggestive that P2Y1 inhibitors may act through reducing the ability 
of platelets to enhance leukocyte endothelial transmigration (Amison et al., 2015).  
Other groups have also explored the dependence of lung and LPS-induced inflammation 
on platelet P2Y1 and P2Y12 receptors in other models involving systemic exposure to LPS, 
reaching a range of different conclusions. Genetic deletion of P2Y1 in mice failed to prevent 
intraperitoneal LPS-induced pulmonary leukocyte trapping (Liverani, 2017), and in a similar 
model inhibition of P2Y12 worsened LPS-induced inflammatory responses (Liverani et al., 
2014). Conversely, in the mouse caecal ligation and puncture model of polymicrobial sepsis, 
pretreatment with the P2Y12 inhibitor ticagrelor reduced both pulmonary neutrophil recruit-
ment and lung oedema (Rahman et al., 2014).  
In humans dosed with intravenous LPS, P2Y12 inhibition with ticagrelor reduced levels of 
inflammatory cytokines and coagulation markers in one study (Thomas et al., 2015), but had 
no effect on either in another human trial (Schoergenhofer et al., 2016). 
The effects of inhibition of platelet P2Y receptors on lung platelet recruitment in inflam-
mation are unknown, so the effects of P2Y1 and P2Y12 inhibition on LPS-induced lung platelet 
recruitment in mice were investigated using the same treatments, as previously described 
(Amison et al., 2015, 2017). 
Aspirin and lung platelet recruitment 
Aspirin is an irreversible inhibitor acting through inhibitory acetylation of cyclooxygenase 
(COX) enzymes which convert free arachidonic acid to the unstable intermediate PGH2, a 
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necessary step for the subsequent production of the bioactive mediators (TXA2, PGD2, PGE2, 
PGF2, PGI2) by other downstream enzymes in cells where these are expressed (Fuster and 
Sweeny, 2011).  
There are two known isoforms of COX, and inhibition of COX-1 is thought to mediate 
the clinically proven anti-platelet action of aspirin through inhibition of the production of 
TXA2 by COX-1 in anucleate platelets, which have a limited ability to synthesise replacements 
for the irreversibly aspirin-inhibited COX enzymes (Fuster and Sweeny, 2011). Although as-
pirin shows some selectivity for COX-1, at higher doses it can also inhibit the other COX 
isoform, COX-2 (Mitchell et al., 1993). COX-2 is expressed primarily in stromal cells and 
leukocytes, but also in megakaryocytes and newly-formed platelets (Rocca et al., 2002), with 
expression constitutive in the brain but induced in other cells in inflammation (Flower, 2003). 
Increased prostaglandin mediator production by COX-2 is particularly important in the sig-
nalling leading to inflammation and pain, and selective inhibitors of COX-2 have clinically 
proven anti-inflammatory action in the treatment of inflammatory conditions (Flower, 2003).  
As inhibition of COX-2 function was previously associated with anti-inflammatory effects, 
the observation that COX-2-/- mice, and mice treated with a COX-2 inhibitor, had increased 
lung inflammation after acid inhalation-induced lung injury was surprising (Fukunaga et al., 
2005). Interestingly, lung inflammation in acid-injured mice treated with high dose aspirin 
was unaltered, but was still increased in mice treated with high dose aspirin and a COX-2 
inhibitor (Fukunaga et al., 2005). The production of pro-resolution, anti-inflammatory lipox-
ins by COX-2 was identified as the cause of increased lung inflammation in the absence of 
COX-2. In contrast to action of reversible COX-2 inhibitors, acetylation by aspirin can alter 
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COX-2 function in such a way that it produces 15-R-hydroxyeicosatetraenoic acid from ara-
chidonic acid, which can result in increased production of the anti-inflammatory aspirin-
triggered lipoxin 15R-epi-lipoxin A4 in the context of COX-2 induction in LPS-induced in-
flammation (Kirkby et al., 2013). 
Other groups have reported that aspirin treatment could reduce lung inflammation fol-
lowing acid-inhalation (Zarbock et al., 2006), LPS inhalation and intravenous anti-MHC-I 
antibody treatment (Looney et al., 2009), and LPS inhalation (Ortiz-Muñoz et al., 2014; 
Tilgner et al., 2016). Further experiments in LPS models identified increases in the aspirin-
triggered lipoxin 15R-epi-lipoxin-A4 acting through formyl peptide receptors 2 and/or 3 as a 
pathway mediating the anti-inflamamtory effects of aspirin, rather than the assumed TXA2 
(Ortiz-Muñoz et al., 2014). 
The preclinincal work described above, combined with data from several observational 
clinical studies (Toner et al., 2015), has led to interventional studies measuring the effects of 
aspirin on inflammation following inhalational exposure to LPS in ex vivo blood-perfused 
human lungs and healthy volunteers, both of which showed an anti-inflamamtory effect of 
aspirin (Hamid et al., 2017), as well as a clinical trial of aspirin in prevention of ARDS in at-
risk intensive care patients, in which aspirin had no detected effect (Kor et al., 2016b). 
As previous work has suggested that reversible COX inhibition might reduce LPS-induced 
lung platelet recruitment as indomethacin reduced radiolabelled platelet recruitment to lungs 
of guinea pigs following LPS inhalation (Beijer et al., 1987), and LPS-induced lung platelet 
recruitment assessed by IHC was suggested to be greatly decreased with aspirin treatment in 
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mice (Ortiz-Muñoz et al., 2014), we sought to investigate the effect of aspirin on lung platelet 
recruitment and inflammatory readouts in a mouse LPS inhalation model.  
1.3.3 Summary of aims and objectives 
 Establish a mouse model of LPS inhalation in which platelet responses can be 
observed, and use: 
o Immunohistochemistry in order to image and quantify platelets in lungs. 
o Blood microsampling in order to monitor blood platelet counts over time. 
o Radiolabelled platelet tracking in order to study the fate of platelets across 
the body. 
o Intravital microscopy in order to measure platelet adhesion in lungs. 
 Use human lung tissue from ex vivo blood-perfused lung experiments with 
intrabronchial LPS challenge for immunostaining to assess the potential for use of 
platelet immunostaining in the human setting. 
 Use the mouse model of LPS inhalation to explore:  
o Whether there is any evidence for inflammation-induced platelet 
transendothelial migration. 
o Whether platelet recruitment to lungs following LPS inhalation is dependent 
upon neutrophils, using neutrophil depleting antibody treatment. 
o Whether platelet recruitment to lungs following LPS inhalation is dependent 
upon P-selectin or PSGL-1, using blocking antibody interventions. 
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o Whether platelet recruitment to lungs following LPS inhalation is dependent 
upon purinergic signalling through P2Y1 or P2Y12, or is sensitive to aspirin 
treatment, using pharmacological intervention. 
 





2.1.1 Reagents and equipment 
Table 2.1: List of reagents used for experiments and suppliers of the reagents. 
 
Reagent Supplier 







3,3'-Diaminobenzidine tetrahydrochloride hydrate 
(DAB) 
Sigma-Aldrich, UK 
ACD (Acid-citrate dextrose) anticoagulant Sigma-Aldrich, UK 
Acid-alcohol differentiation solution Sigma-Aldrich, UK 
Adenosine diphosphate (ADP) Sigma-Aldrich, UK 
Anti-CD41 (biotinylated) [MWReg30] antibody Abcam, UK 
Anti-CD41 [K-18] antibody Santa Cruz Biotechnology, USA 
Anti-CD41 [MWReg30] antibody Abcam, UK 
Anti-CD42b [SP219] antibody Abcam, UK 
Anti-DNA (peroxidase) [MCA-33] antibody Roche/Sigma-Aldrich, UK 
Anti-GPIbα (R300) (no azide) platelet depletion anti-
body 
Emfret, Germany 
Anti-histone H3 (citrulline R2 + R8 + R17) (ab5103, 
ChIP grade) 
Abcam, UK 
Anti-Ly6-G [1A8] antibody BioXCell, USA 
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Anti-neutrophil elastase (polyclonal ab68672) antibody Abcam, UK 
Anti-P-selectin (no azide) [RB40.34] antibody Becton Dickinson (BD), USA 
Anti-PSGL-1 (no azide) [4RA10] antibody BioXCell, USA 
Anti-rabbit IgG (AlexaFluor488) antibody ThermoFisher Scientific, UK 
Anti-rabbit IgG (biotinylated) antibody Vector Laboratories,  USA 
Anti-rat IgG (AlexaFluor594) antibody ThermoFisher Scientific,  UK 
Anti-trinitrophenol (no azide) [2A3] monoclonal rat 
control IgG antibody 
BioXCell,  USA 
AR-C 66096 tetrasodium salt Tocris, UK 
Aspirin Sigma-Aldrich, UK 
Bovine Serum Albumin (BSA), heat shock fraction, 
>98% 
Sigma-Aldrich, UK 
BSA standard solution 2mg/ml ThermoFisher Scientific, UK 
Cell death detection ELISA plus kit Roche/Sigma-Aldrich, UK 
D-Glucose Sigma-Aldrich, UK 
DPX mountant Sigma-Aldrich, UK 
Dulbecco's modified Eagle's meadium (DMEM) Gibco, ThermoFisher Scientific, UK 
DuoSet ELISA kit 96 well high-binding plate R&D Systems, UK 
DuoSet ELISA kit wash buffer concentrate R&D Systems, UK 
DusoSet ELISA kit reagent diluent concentrate R&D Systems, UK 
Ethylemediaminetertraacetic acid (EDTA) Sigma-Aldrich, UK 
Fluoromount G mountant Southern Biotech, USA 
Haematoxylin Sigma-Aldrich, UK 
Hoechst 33258 Sigma-Aldrich, UK 
Hydrogen peroxide (30%) Sigma-Aldrich, UK 
Industrial ethanol Sigma-Aldrich, UK 
Isocare isoflurane anaesthetic Baxter International, USA 
KCl Sigma-Aldrich, UK 
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Ketamine Sigma-Aldrich, UK 
Kwik Diff differental stain ThermoFisher Scientific, UK 
L-Glutamine Gibco, ThermoFisher Scientific, UK 
LPS (O111:B4, E. coli, prepared by phenol extraction) Sigma-Aldrich, UK 
LPS (O55:B5, E. coli, prepared by phenol extraction) Sigma-Aldrich, UK 
MgCl2 Sigma-Aldrich, UK 
MRS2500 tetraammonium salt Tocris, UK 
Na2HPO4 Sigma-Aldrich, UK 
NaCl Sigma-Aldrich, UK 
NaHCO3 Sigma-Aldrich, UK 
NH4Cl Sigma-Aldrich, UK 
Optimal Cutting Temperature (OCT) compound VWR International,  UK 
Paraformaldehyde (37%) Sigma-Aldrich, UK 
PBS tablets ThermoFisher Scientific Oxoid, UK 
PGE1 Sigma-Aldrich, UK 
RM1(E) diet Special Diets Services, UK 
Stromatol platelet counting solution Mascia Brunelli, Italy 
Total protein BCA assay kit ThermoFisher Scientific, UK 
Tris(hydroxymethly)aminomethane (tris) Sigma-Aldrich, UK 
Tri-sodium citrate Fisher Scientific, UK 
Tropolone Sigma-Aldrich, UK 
Türk's solution Merck Millipore, USA 
Tween 20 Fisher Scientific, UK 
Urethane Sigma-Aldrich, UK 
Vectastain Elite ABC HRP kit (Peroxidase, standard) Vector Laboratories, USA 
Xylazine Sigma-Aldrich, UK 
 




Table 2.2: List of equipment used for experiments and suppliers of the equipment. 
 
Equipment Supplier 
LSRII Flow Cytometer Becton Dickinson (BD), USA 
Model OT Cryostat Bright Instruments, UK 
Liquid blocker (PAP pen) Cosmo Bio, Japan 
Single Point Extended Area Radiation (SPEAR) detec-
tor 
eV Microelectronics (now i3  
electronics),  USA 
Single edge razor blades Fisher Scientific,  UK 
Incell Analyzer 6000 microscope system GE Healthcare, USA 
Minivent ventilator Harvard Apparatus, UK 
Neubauer improved haemocytometer Hawksley, Sigma Life Sciences, UK 
DM2000 LED bright field microscope Leica Microsystems,  UK 
DFC295 bright field microscope camera Leica Microsystems,  UK 
Leica RM2125 RT rotary microtome,  Leica Microsystems,  UK 
A1R multiphoton microscope Nikon Instruments, USA 
Tender Cooker microwave pressure cooker Nordic Ware, USA 
Amvex vacuum regulator Ohio Medical, USA 
Heated stage controller Omega Engineering, USA 
Genesis haematology analyzer Oxford Science, USA 
Mai Tai DeepSee infrared laser Spectra Physics, USA 
UCS30 spectrometer Spectrum Techniques, USA 
Intravital window 90° angle post clamp Thor Labs, USA 
Small animal recovery chamber VetTech Solutions, UK 
Superfrost plus slides VWR International, UK 
Compugamma gamma counter Wallac (now LKB  
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Instruments/Perkin Elmer), UK 
2.1.2 Buffer solutions 
Aqueous buffers were made up in ultrapure deionised water and sterile filtered at 0.2 µm 
where required. Phosphate buffered saline (PBS) contained 137 mM NaCl, 3 mM KCl, 8 mM 
Na2HPO4 and 1.5 mM KH2PO4 at pH 7.3 and was prepared in deionised water from tablets 
(Oxoid). Sterile filtered citrate-dextrose solution (ACD) was purchased ready-made and used 
as an anticoagulant for blood collection.  
Calcium and Magnesium-free Tyrode’s solution (CFTS) consisted of 134 mM NaCl, 2.7 
mM KCl, 5.55 mM D-glucose, 11.9 mM NaHCO3 and 0.21 mM Na2HPO4. CFTS was also 
mixed with (ACD) (9 volumes of CFTS with 1 volume of ACD) and supplemented with 2.5 
µM of the platelet activation inhibitor, PGE1 in order to produce Tyrode’s-ACD-PGE1 (TAP) 
buffer.  
HEPES-buffered Tyrode’s solution contained 20 mM 2-[4-(2-hydroxyethyl)piperazin-1-
yl]ethanesulfonic acid (HEPES), 134 mM NaCl, 2.92 mM KCl, 12 mM NaHCO3, 0.34 mM 
Na2HPO4 and 1 mM MgCl2 with pH adjusted to 7.4. 
For enzyme-linked immunosorbent assays, concentrates in DuoSet ancillary reagent kits 
(R&D Systems) were used to prepare ELISA reagent diluent (1% BSA in PBS) and ELISA 
wash buffer (0.05% vol/vol Tween 20 in PBS). Red blood cell lysis buffer was 155 mM NH4Cl, 
12 mM NaHCO3 and 0.1 mM EDTA. 
  




2.2.1 Wild type mice used at King’s College London 
Mice (Female, 6-12 weeks of age) used at King’s College London were of the Balb/C strain 
from Charles River, housed in non-barrier facilities. Animals were given unlimited access to 
RM1(E) diet (Special Diets Services), and water. Animal experiments were conducted follow-
ing local ethical approval and in accordance with the Animals (Scientific Procedures) Act, 
1986 and amended regulations of 2012. Mice were monitored at least daily during experiments 
and if mice showed visible signs of sickness all animals in that experiment were provided with 
moistened food. Terminal anaesthesia was achieved using urethane (3 g/kg delivered i.p. in 
PBS) with euthanasia confirmed with exsanguination or cervical dislocation. 
2.2.2 PF4-cre × mTmG mice used at UCSF 
For experiments at University of California, San Francisco (UCSF), all experiments were 
approved and conducted by experimenters with training approved by the institutional animal 
care and use committee. Mice were bred in specific pathogen-free facilities at UCSF. PF4-cre 
× mTmG mice (Lefrançais et al., 2017) were generated from from crosses of PF4-cre mice 
(C57BL/6-Tg(Pf4-icre)Q3Rsko/J, Jackson), in which expression of the Pf4 gene (encoding 
platelet factor-4 or CXCL4) drives the expression of Cre recombinase in cells committed to 
the megakaryocyte lineage (Tiedt et al., 2007; Pertuy et al., 2015), and mTmG mice 
(Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J, Jackson), in which a membrane targeted tandem 
dimer of tomato fluorescent protein (Tomato, mT) is constitutively expressed, with the ex-
ception of cells expressing Cre recombinase, in which the Cre/loxP recombination system 
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turns off Tomato expression and activates expression of membrane-targeted enhanced green 
fluorescent protein (GFP, mG) (Muzumdar et al., 2007).  
PF4-cre × mTmG mice were phenotyped by assaying an unstained submandibular blood 
microsample for GFP and Tomato fluorescent protein positivity using a BD LSR II flow 
cytometer at least 2 weeks before mice were used for further experiments (Figure 2.1). Male 
mice at 6-12 weeks of age were used for intravital microscopy experiments due to their larger 
size. Terminal anaesthesia was induced with 125 mg/kg ketamine combined with 12.5 mg/kg 
xylazine delivered i.p. in PBS. 
 
 
Figure 2.1: Phenotyping PF4-cre × mTmG mice. Left: flow cytometry density plot from blood 
sample from mouse with no mTmG phenotype and unknown Pf4-cre status, Right: density plot 
from sample from PF4-cre × mTmG mouse. GFP+Tomato- events are platelets or cells expressing 
PF4, GFP-Tomato+ events are cells with no PF4 expression, double positive events are platelet-
leukocyte aggregates.  
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2.3 LPS challenge in mice 
In order to provoke lung inflammation, mice were briefly anaesthetised with inhaled isoflu-
rane, then challenged with LPS (from E. coli, O55:B5 serotype, prepared by phenol extrac-
tion), or PBS vehicle control, by intranasal delivery at 2 µl/g body weight using a 200 µl 
pipette tip to deposit the dose in the nostrils. Mice were held upright for 30 seconds after 
dosing and delivery was confirmed by audible chest crackling. This method has been shown 
to deliver ~55% of the prepared dose into the lower airways and lung (Southam et al., 2002; 
Su et al., 2004). 
A dose of 5 mg/kg LPS was chosen based on the dose used previously with LPS-induced 
lung platelet recruitment reported (Ortiz-Muñoz et al., 2014). A lower dose of 0.05 mg/kg 
LPS was also tested but in preliminary studies this lower dose did not show significant lung 
platelet recruitment. 
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2.4 Immunohistochemistry studies 
2.4.1 Collection of mouse lungs for histology 
Mice were terminally anaesthetised, and the trachea was opened and the diaphragm was 
exposed and dissected along the ventral ribcage to collapse the lungs. A tracheal cannula was 
swiftly introduced and the lung was inflated with 0.5 ml of OCT (optical cutting temperature 
coumpound, VWR International) delivered over 2 seconds. The heart was then excised to 
stop circulation, left and right lung lobes were rapidly removed, cross-sectioned in half later-
ally, placed cut face down in plastic 15×15 mm moulds (VWR International), and surrounded 
with OCT. Samples were then snap frozen from the bottom up by placing on a lead heat sink 
which was cooled by partial immersion in liquid nitrogen. Samples were then stored at -80 °C 
until required for use. 
2.4.2 Human ex vivo blood-perfused lungs 
Formalin-fixed paraffin embedded human lung samples generated from the work of Hamid 
et al., (2017) were generously provided by Dr. Cecilia O’Kane, Queen’s University Belfast, 
and were used for experiments testing the effect of aspirin treatment on LPS intralobar in-
stillation in isolated human lung preparations using a method adapted from that previously 
reported by Lee et al., (2009). 
Briefly, human lungs were obtained with donor consent given to International Institute 
for the Advancement of Medicine and local ethics board approval at Queen’s University Bel-
fast. Ex vivo human lung experiments were carried out at Queen’s University Belfast. Lungs 
were free of exterior contusions, had no air leak on ventilation, and were collected under 
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aseptic conditions 0-60 minutes from cessation of blood circulation, and used within 48 hours 
of collection. Upon arrival at Queen’s University Belfast, the pulmonary artery was connected 
to a peristaltic pump and a bronchus intubated, and the lungs suspended inside sealed acrylic 
container. Lungs were rewarmed by perfusion with DMEM containing L-glutamine and 5% 
albumin for 1 hour until at 35 °C, and then ventilated with 95% O2 + 5% CO2 with 10 cmH2O 
continuous positive airway pressure. Normal alveolar fluid clearance (>10% concentration of 
protein in a 125 ml PBS + 5% albumin instillation within 1 hour) was confirmed before lungs 
were used.  
To induce inflammation LPS (6 mg of O111:B4 from E. coli in 10 ml 0.9% saline + 5% 
albumin) was introduced into the right middle lobe or left lower lobe, and 100 ml of whole 
blood (treated ex vivo with vehicle or 24 mg aspirin 1 hour previously), from a healthy 
volunteer was added 1:10 to the perfusate. At 4 hours after LPS exposure, BAL was collected, 
and samples from the LPS-challenged lobe were fixed in formalin before routine dehydration 
and paraffin embedding. 




Figure 2.2: Isolated blood-perfused human lungs.  Human donor lungs were ventilated with 10 
cmH2O continuous positive airway pressure (CPAP), and perfused with blood 1:10 in DMEM+L-
Glutamine and 5% albumin. Pulmonary arterial pressure (PAP) was maintained at 10-12 mmHg, 
and blood was allowed to flow freely from the pulmonary vein into the perfusate reservoir before 
recirculation. LPS was instilled by intralobar instillation into either the right middle lobe or left 
lower lobe. Diagram based on Lee et al., (2009).  
 
2.4.3 Frozen sections 
Frozen 10 µm cross-sections of tissue (6-9 per mouse) were made using a Bright Model 
OT cryostat and thaw-mounted onto superfrost plus slides then air dried overnight in a fume 
hood. 
2.4.4 Paraffin wax sections 
Sections of formalin-fixed paraffin-embedded tissue (9 per human lung lobe) were sec-
tioned at 6µm thickness using a Leica RM2125 RT rotary microtome, and mounted using a 
water bath onto superfrost plus slides before overnight drying in a fume hood. 
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2.4.5 Immunohistochemistry using DAB reporter 
Dried frozen sections were immersed in 4% vol/vol paraformaldehyde in PBS and fixed 
for 15 minutes. Following a tap water wash, endogenous peroxidase activity was blocked by 
immersion in 3% vol/vol hydrogen peroxide in ethanol (99% industrial grade), which also 
served to bleach endogenous pigment. Slides were then washed with PBS before nonspecific 
binding was blocked with 1% BSA in PBS for 10 minutes. The reagent diluent for primary 
and secondary antibodies as well as the avidin-biotinylated HRP complex (ABC) was also 
1% w/vol BSA in PBS. Primary antibodies were incubated with the sample for 2 hours at 
room temperature. Because future experimental plans involved giving mice depleting, block-
ing, or control antibodies raised in cells from rats, platelet staining methods not reliant on 
anti-rat IgG reporters were sought and IHC preparations tested for minimal cross-reactivity 
with rat antibodies. Primary antibody details are listed in Table 2.3. 
Table 2.3: Antibodies used for immunohistochemistry experiments in mouse tissue.  
Target Catalogue # Clonality Clone Host Dilution factor 
CD41 ab33661 Monoclonal MWReg30 Rat 1/500 
CD41 (biotin) ab95727 Monoclonal MWReg30 Rat 1/250 
CD42b ab183345 Monoclonal SP219 Rabbit 1/200 
Neutrophil elas-
tase 
ab68672 Polyclonal n/a Rabbit 1/50 
 
Formalin-fixed paraffin embedded human lung sections were stained using similar meth-
ods, but were first dewaxed in xylenes, rehydrated, endogenous peroxides blocked as described 
above, and subjected to heat-induced epitope retrieval carried out with 10 mM tri-sodium 
citrate with 0.05% vol/vol Tween 20 at Ph 6.0, 100 °C using a microwave pressure cooker. 
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Slides were then cooled with tap water, then blocked with 1% BSA in PBS and then incubated 
with primary antibodies as described above. Antibody titrations are listed in Table 2.4. 
 
Table 2.4: Antibodies used for immunohistochemistry experiments in human tissue. 
Target Catalogue # Clonality Clone Host Dilution factor 
CD41 sc-6604 Polyclonal K-18 Goat 1/500 
CD42b ab183345 Monoclonal SP219 Rabbit 1/250 
Neutrophil 
elastase 
ab68672 Polyclonal n/a Rabbit 1/100 
 
Following a PBS wash, samples incubated with rabbit primary antibodies were incubated 
with biotinylated anti-rabbit IgG (1:200, Vector), samples incubated with goat primary anti-
bodies were incubated with biotinylated anti-sheep IgG 50% cross reactive with goat IgG 
(1:200, Vector). After 1 hour, sections were washed again and incubated for 1 hour with 
avidin and biotinylated HRP (Vector, PK1600 components A and B mixed to form ABC both 
at 1:200 at 30 minutes before use). For samples stained with biotinylated primary antibodies, 
the secondary antibody incubation step was omitted. After a final PBS wash slides were then 
developed in 1.2 mM DAB (3,3-diaminobenzidine tetrahydrochloride) in 0.1 M Tris buffer 
(pH 7.6) also containing 0.03% vol/vol hydrogen peroxide substrate for 10 minutes.  
Developed slides were then rinsed in tap water, counterstained with Gill’s no. 2 haema-
toxylin which was differentiated by 10× immersions of ~1 s duration in acid alcohol before 
dehydration with industrial ethanol, clearing with xylenes and coverslipping with DPX 
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mountant. Fidelity of staining is shown across serial sections in Figure 2.3 (mouse) and Figure 
2.4 (human). 
In a blinded fashion, 6× fields of 447×596 µm of the respiratory portion of lung were 
captured across each section, with 6 sections collected per mouse, using a 20× objective on a 
Leica DM 2000 LED bright field microscope with Leica DFC295 camera and Leica Applica-
tion Suite acquisition software v4.4. 
 Separate blinded analyses were also conducted on the same microscope using a 63× 
objective to capture 50 image fields of 189×142 µm of fields of the respiratory portion of the 
lung from each mouse in order to enable the imaging of platelets which appeared outside of 
the pulmonary circulation in the bronchoalveolar space. These platelets which were spatially 
dis-associated with the pulmonary circulation were manually counted by an independent op-
erator.  
 




Figure 2.3: Mouse lung immunohistochemistry using DAB reporter. Serial sections from LPS-
challenged mouse lungs incubated with or without primary antibodies were compared to assess 
fidelity of immunostaining. DAB reporter positivity in brown, haematoxylin counterstain in blue. 
(A) CD41 staining using biotinylated rat primary antibody. Single platelets are visible in blood 
vessel (bottom), false positive staining on respiratory epithelium (top left). (B) CD42b and neu-
trophil elastase staining using rabbit primary antibodies. CD42b+ platelets are visible in the 
blood vessel in centre field, neutrophil elastase positivity can be seen in the alveolar-capillary 
network surrounding. Scale bar = 20 µm.  
 




Figure 2.4: Human lung immunohistochemistry using DAB reporter.  Serial sections from LPS-
challenged human lungs incubated with or without primary antibodies were compared to assess 
fidelity of immunostaining. DAB reporter positivity in brown, haematoxylin counterstain in blue. 
(A) CD41 staining using goat primary antibody. CD41+ platelets are visible in blood vessel (cen-
tre). (B) CD42b and neutrophil elastase staining using rabbit primary antibodies. CD42b+ plate-
lets are visible in the blood vessel in centre field, neutrophil elastase positivity can be seen in the 
blood vessel and in the neighbouring airway wall and alveolar-capillary units. Scale bar = 20 µm.  
 
2.4.6 Immunohistochemistry using fluorescent reporters 
For immunofluorescence experiments, lungs were sectioned, and sections were dried and 
fixed as described above. After blocking non-specific binding for 10 minutes using 1% BSA in 
PBS, rat anti-mouse CD41 primary antibody and rabbit anti-mouse/human neutrophil elas-
tase primary antibody (Table 1) were coincubated with the sample in 1% BSA in PBS. 
Following a PBS wash, anti-mouse IgG conjugated to the fluorophore AlexaFluor 594 (1:500), 
anti-rabbit IgG conjugated to the fluorophore AlexaFluor 488 (1:500) and Hoechst 33258 
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DNA stain (1:20,000) were incubated together on the sample in 1% BSA in PBS for 1 hour 
before a final PBS wash. Slides were then coverslipped using Fluoromount G mountant and 
stored in the dark at 4°C for up to a week before imaging. 
Fluorescence micrographs (Figure 2.5) were captured using an Incell Analyser 6000 sys-
tem (GE Healthcare) with 20× objective, open aperture, excitation/emission wavelength filter 
sets for AlexaFluor 595: 561/605nm, Alexafluor 488:  488/525nm and Hoechst 33258: 
405/455nm. Image fields were 665.6×665.6µm. Tiled acquisition was used with 15% overlap 
for stitching and both IR laser autofocus on the slide/section interface and software autofocus 
on the Hoechst channel to maintain focus whilst tiling across the entire section. Fidelity of 
staining in serial sections is shown in Figure 2.5. 
 
Figure 2.5: Mouse lung immunohistochemistry using fluorescent reporters. (A) Diagram show-
ing indirect staining method used for fluorescence microscopy studies into CD41 and neutrophil 
elastase tissue distribution. (B) Serial sections from an inflamed lung showing a pulmonary blood 
vessel (centre, dashed white line for emphasis) with alveolar-capillary network (bottom left) and 
small airway (top right, dotted white line for emphasis). CD41 is shown as red, neutrophil elastase 
is in green and nuclei are shown as blue. Scale bar = 20µm.  
 
Chapter 2. Methods  69 
 
 
2.4.7 Image analysis 
Macros for automated platelet counting were developed using ImageJ 1.48 (National In-
stitutes of Health).5 The colour deconvolution plugin produced by G. Landini, University of 
Birmingham,6  was used to split the brown DAB stain and blue haematoxylin stain from 
RGB images into separate greyscale images (Figure 2.6), as previously described (Ruifrok 
and Johnston, 2001), and positive staining was defined using an intensity threshold based on 
no primary control and positively stained sections (typically intensities >150 out of 255 on 
an 8 bit depth). For platelet counts a size filter was used to remove objects smaller than 0.45 
µm2.  
The ImageJ particle analysis module was then used to count the number of platelets per 
mm2 of section imaged as well as the percentage of sample covered by positive staining. 
During inflammation, neutrophil elastase is released from neutrophils, and neutrophils form 
bundles during transendothelial migration, so cell segmentation was not used and this antigen 
was quantified using only percentage of sample fields stained positive. 
                                           
 
5 ImageJ, NIH: https://imagej.nih.gov/ij/ 
6 Colour deconvolution: http://www.mecourse.com/landinig/software/cdeconv/cdeconv.html 




Figure 2.6: Counting platelets with ImageJ using colour deconvolution and particle analysis. 
Original RGB colour images with CD41 staining in brown and haematoxylin staining in blue were 
deconvoluted to split our the colour channels corresponding to DAB staining in a separate grey-
scale image. An intensity threshold was then set on the greyscale image to define areas of positiv-
ity. Particle analysis was then used to count platelet sized objects. Scale bar = 20µm.  
 
CD41+ platelets and neutrophil elastase coverage was also quantified in fluorescence mi-
crographs of mouse lungs using ImageJ with similar methods, although for these images 
colour deconvolution was not required as channels were already separate. CD41+ bodies with 
proplatelet morphology were counted following identification by size (>55 µm2) and circular-
ity (circularity = 4  = <0.5, where 1.0 is a perfect circle).  
For counting rarer events in lungs, such CD41+ platelets inside of airways, and cells with 
CD41+ cytoplasm surrounding a large nucleus,, whole lung section stitches were prepared for 
manual inspection using the ImageJ Grid/Collection stitching plugin produced by S. 
Preibisch, Max Delbrück Center (Preibisch et al., 2009)7. 
                                           
 
7 Example zoomable stitched images produced using the GMap Cutter tool (Centre for Ad-
vanced Spatial Analysis, UCL, and Google Maps), used for surveying whole lung sections, are 
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Spatial association of platelet CD41 immunostaining with neutrophil elastase was inves-
tigated using the relate objects module of CellProfiler to make separate counts of CD41+ 
platelets with any overlap with neutrophil elastase staining and those that did not.8 
2.4.8 Blood microsampling 
Mice were placed in a heated chamber (37 °C) for 10 minutes before relocation to a 
custom-made box which exposed only the tail. A 1-2 mm cut was made with a scalpel blade 
across the lateral tail vein. Using a micropipette, 2 µl of blood was rapidly diluted 1:100 into 
stromatol solution for platelet counts, a further 2 µl diluted 1:50 in Türk’s solution for leu-
kocyte counts (both using a Neubauer improved haemocytometer), and 4 µl was taken for a 
blood smear stained with Kwik-Diff modified Romanowsky stain to be used for leukocyte 
differential counts (200 cells identified per smear).  
Gentle pressure was applied to the cut until cessation of bleeding and any future serial 
samples were taken from alternate sides of the tail at sites further upstream of veins relative 
to previous cuts (towards the end of the tail, care was taken to avoid damaging the central 
tail artery). Manual counts were made with the experimenter blinded to identity of samples 
within treatment groups. 
  
                                           
 
privately hosted at http://bit.do/PBSlung and http://bit.do/LPSlung. CD41=red, Neutrophil 
elastase=green, Nuclei=blue. 
8 CellProfiler cell image analysis software, Broad Institute, http://cellprofiler.org. 
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2.5 Radiolabelled platelet studies 
2.5.1 Radiolabelling platelets with 111In-tropolonate 
Platelets were labelled using a technique adapted from previously reported experiments 
labelling mouse platelets with 111In-oxine (Tymvios et al., 2008; Moore et al., 2011; Solomon 
et al., 2013; Smyth et al., 2015). With the number of donor mice equal to the number of 
recipients, blood was collected by cardiac puncture from terminally anaesthetised donor mice 
into a syringe containing 0.2 ml of ACD using a 26 gauge needle.  
After gentle mixing, blood samples were centrifuged at 300 rcf for 3 minutes and the 
resulting supernatant (platelet-rich plasma, PRP) was collected. Remaining blood was then 
gently mixed with 0.4 ml of TAP buffer in order to prevent platelet activation, and centrifuged 
again at 300 rcf for 3 minutes for collection of further PRP. Pooled PRP was then centrifuged 
at 200 rcf for 2 minutes to sediment out any contaminating erythrocytes and leukocytes, and 
the purified PRP separated. Purified PRP was then centrifuged at 1500 rcf for 7 minutes, 
supernatant removed and the platelet pellets resuspended together in 600 µl TAP buffer for 
every 4 mice used. A 2 µl sample was taken for dilution in 198 µl Stromatol for platelet 
counts. 
Pooled platelet suspensions from every batch of 4 donor mice (with a platelet density of 
6.12±0.88 ×108 platelets/ml) were then added to a mixture of a volume of containing 1.8 
MBq 111InCl3 in sterile 0.9% w/vol NaCl (Mallinckrodt, UCL Hospital via the Radiopharmacy 
Department, Guy’s and St Thomas’ Hospitals Trust) which was mixed 5 minutes earlier with 
one-fifth volume of 90 mM tropolone in HEPES-buffered Tyrode’s solution in order to pro-
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duce lipophilic 111In-(tropolone)3 complexes which can penetrate cell membranes and dissoci-
ate inside cells, with cytoplasmic retention of 111In, but not free tropolone, leading to the 
cytoplasmic accumulation of 111In (Dewanjee et al., 1982). Similar labelling and chelation 
methods are used clinically for imaging sites of platelet sequestration and clearance in patients 
with idiopathic thrombocytic purpura (Cuker and Cines, 2010; McKiddie et al., 2016), and 
111In is retained in platelets after degranulation and aggregation (Thakur et al., 1981). 
Platelets were incubated with 111In at room temperature for 10 minutes and during this 
time, a single point extended area radiation (SPEAR) gamma detector containing a CdZnTe 
5×5×5 mm3 detector crystal, with a UCS30 spectrometer powered by USX 1.2 software was 
calibrated to record photon energies from decay of 111In (Figure 2.7A). This gamma detector 
was then used to measure radioactivity of the sample during labelling. The platelet suspension 
was centrifuged again at 1500 rcf for 7 minutes. Radioactive supernatant was removed and 
the platelet pellet resuspended in a volume of CFTS equivalent to the volume of platelets 
plus the volume of InCl3 solution and volume of tropolone solution used that day in order to 




The volume of the platelet suspension was then adjusted to 200 µl per recipient plus 38 
µl per recipient of syringe dead space allowance, and after 45 minutes of time allowed for of 
the biological effects of PGE1 to diminish, recipient mice were each infused with 200 µl bolus 
injection of the 111In-labelled platelets via a lateral tail vein. Assuming 100% recovery of 
platelets after the wash step, and accounting for syringe dead space, mice each received an 
estimated 2.75±0.30 ×108 platelets labelled with 0.24±.02 MBq 111In. 





Figure 2.7: Measuring 111In signal using SPEAR probes. (A) Energy spectra from background 
signal (grey line) and signal from 111In (black line). Peaks arise from 111In decay photon energies 
at 23, 171 and 245 keV but due to unavailability of reference radionuclides x axis units are given 
as uncalibrated channels (arbitrary units on a bit depth of 1024). In order to exclude background 
and maximise signal from 111In, lower and upper energy limits were set so that only photon energies 
in the grey shaded region were recorded. (B) Mice transfused with 111In-labelled platelets were 
anaesthetised using isoflurane, with repeated recordings made over the same region of thorax by 
clamping a gamma detector at a fixed position relative to a tooth bar and custom cradle attached 
to the isoflurane mask. Signal from the gamma detector was deconvoluted using a UCS30 spec-
trophotometer and data logged on a computer running USX software.  
  
2.5.2 Non-invasive radiolabelled platelet tracking 
After 1 hour had elapsed following injection of radiolabelled platelets, noninvasive record-
ings of thoracic radioactivity were made in terminally anaesthetised mice. Successful meas-
urement of the extent of thromboembolism was confirmed by measuring responses to 4 mg/kg 
ADP i.v. in PBS. For experiments over 4 to 48 hours, sample recordings over 5 minutes were 
made under isoflurane anaesthesia using the equipment described in Figure 2.7B. These meas-
urements were then repeated at later intervals for noninvasive monitoring of thoracic platelet 
content over time. 
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2.5.3 Platelet biodistribution studies 
In order to track the fate of radiolabelled platelets, 2 µl of the radiolabelled platelet 
suspension was collected before intravenous injections (1% of injected dose) and stored diluted 
in PBS. At +4 or +48 hours after intranasal challenge, mice transfused with radiolabelled 
platelets were terminally anaesthetised, and 100 µl of whole blood was collected by cardiac 
puncture and diluted in 400 µl PBS. Bronchoalveolar lavage (BAL, 3x separate washes and 
recoveries of 0.5 ml PBS through a tracheal cannula, pooled) was then collected, and lung, 
liver and spleen were collected into scintillation vials after removal of exterior clots by rolling 
the organ surface on guaze. 
BAL was divided into cell pellet and supernatant by centrifugation of 750 µl of neat BAL 
at 1500 rcf for 7 min and collection of resultant supernatant and cell pellet resuspended in 
750 µl PBS in scintillation vials. In order to confirm an inflammatory response in lungs, BAL 
was also used to measure total leukocyte counts (50 µl BAL in 50 µl Türk’s solution counted 
using haemocytometer), and BAL leukocyte differential counts using BAL cytospin prepara-
tions (50 µl BAL in 50 µl PBS, 113 rcf for 1 minute using Cytospin 2, ThermoFisher Scien-
tific), stained with KwikDiff (ThermoFisher Scientific). 
Blood, BAL, organ, 1% injected dose, and blank controls were then analysed in scintilla-
tion vials using a Compugamma gamma counter (LKB Wallac) to record gamma radiation 
emitted from each sample over 1 minute. Blood radioactivity was expressed as percentage of 
injected dose per ml, and BAL and organ radioactivity is expressed as percentage of injected 
dose recovered in BAL or per organ, divided by percentage of dose per ml of blood, as previ-
ously described (Andonegui et al., 2005; Looney et al., 2009).  
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2.6 Intravital microscopy 
2.6.1 Preparation of mice for intravital microscopy  
At 48 hours after PBS or LPS (5 mg/kg) inhalation PF4-cre × mTmG mice were termi-
nally anaesthetised. The dorsal left ribcage was shaved and the trachea cannulated and the 
mouse moved onto a Mini Vent ventilator with isoflurane and oxygen supplied at 130× 250 
µl breaths per minute with 2 cmH2O of positive end expiratory pressure.  
Mice were then moved onto a heated stage at 37 °C and were given 0.5 ml of PBS i.p. as 
fluid support. Skin over the shaved region was removed to expose the ribcage, and an approx-
imately 1 cm long intercostal incision was carefully made to expose the ventilated left lung 
and allow the surface of the visceral pleura to fall away from the parietal pleura. 
As previously reported (Looney et al., 2011; Headley et al., 2016), a custom-made thoracic 
window (Figure 2.8) was then inserted to sit between two ribs, secured onto a 90° angle post 
clamp attached to the stage and ~4 kPa negative pressure was applied between the visceral 
pleura of the lung and the inner surface of the window using an Amvex vacuum regulator in 
order to immobilise the lung, and to remove air from the pleural cavity.  
2.6.2 Intravital multiphoton microscopy  
After around 10 minutes of stabilisation, the lung was brought into focus on a customised 
Nikon A1R multiphoton microscope coupled with a MaiTai DeepSee infrared excitation laser 
tuned to 920 nm for simultaneous excitation of GFP and tomato excitation, using a 20× 
Nikon water immersion objective, and emission filters set for Tomato at 570-620 nm and for 
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GFP at 500-550 nm. Image capture was controlled using NIS Element AR software with high 
resolution Galvano scanning over 512×512 pixels. 
 
Figure 2.8: Intravital multiphon microscopy setup.  (A) diagram showing positioning of Pf4 
×mTmG mouse, microscope objective and window for intravital imaging. (B) Cross section of the 
implanted thoracic window showing lung immobilisation method. (C) Micrograph of a field of Pf4-
cre × mTmG mouse lung from the intravital multiphoton microscope showing Tomato+ lung cells 
(red) and GFP+ platelets (green). Scale bar = 50µm.  
 
The internal surface of the final generation of alveoli, a densely networked capillary bed, 
was brought into focus and then using a Z-drive the imaging plane was moved 10 µm deeper 
into the lung to establish an imaging plane of at a consistent depth into the lung. Video 
recordings at the maximum speed possible using Galvano scanning (0.91 frames per second) 
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were then made in order to produce datasets where platelets adhesive in the lung microvas-
culature could be quantified. For each mouse, 8× videos of 230×230 µm fields with a duration 
of 5 minutes were sampled at different sites across the window. 
In order to confirm inflammatory response in mice used for imaging, BAL was collected 
after sacrifice (3× washes of the same 1 ml volume of PBS with 5 mM EDTA) and leukocytes 
in this sample automatically counted using a haematology analyser system (Genesis). 
2.6.3 Platelet adhesion tracking for analysis of intravital microscopy 
Videos were analysed using NIS Elements 4.5 (Nikon). An intensity threshold, with size 
filters set to remove events smaller than 0.1 µm2 in order to reduce noise, was set to binarise 
platelet events in each image. The NIS tracking module was then used to match events over 
time, tracking adhesive platelets which had a between-frame speed of less than 2 µm per 
second and a position in neighbouring frames less than 5 standard deviations (SD) away from 
between-frame positions predicted using a random motion model.9 
  
                                           
 
9A video demonstrating the intravital microscopy platelet adhesion tracking method is hosted 
at http://bit.do/intravital  
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2.7 Antibody and anti-platelet drug treatments 
2.7.1 Neutrophil depletion. 
Neutrophil depletion was achieved with three intraperitoneal doses of 1A8 monoclonal 
anti-Ly6-G antibody (BioXCell BE0075-1) at 25 mg/kg in 200 µl PBS at -24, -1 and +24 
hours relative to intranasal challenge with route of administration and dose based on previ-
ously reported work (Daley et al., 2008). Depleted animals were compared against animals 
treated with equivalent dose of control IgG (either Chrompure polyclonal rat IgG, Jackson, 
or monoclonal 2A3 anti-trinitrophenol, BioXCell). Clearance of neutrophils following expo-
sure to 1A8 is mediated by macrophage/monocytes (Bruhn et al., 2016), and the 1A8 clone 
is selective for the Ly6-G epitope and does not deplete Ly6C+ inflammatory monocytes which 
are depleted with neutrophils by the [Gr-1] monoclonal antibody that has been used for 
neutrophil depletion in previously reported studies (Daley et al., 2008). Tail blood mi-
crosamples were made immediately before doses of antibodies were given in order to test if 
blood neutrophil counts were recovering before further doses of anti-Ly6-G antibody were 
given. 
2.7.2 Blocking P-selectin and PSGL-1 function. 
Mice were treated with no-azide, low-endotoxin antibodies for experimental blockade of 
adhesion molecule function, either anti-P-selectin monoclonal antibody (clone [RB40.34], BD 
Biosciences), and an anti-PSGL-1 monoclonal antibody (clone [4RA10] BioXCell), compared 
against clone [2A3] control rat IgG raised against trinitrophenol (BioXCell). Doses were given 
at 4 mg/kg i.v. in PBS at -1 and +24 hours relative to intranasal LPS challenge and with 
dose and frequency selected based on previously published work from our laboratory in a 
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mouse LPS inhalation model (Kornerup et al., 2010), and further supported by reports using 
other models showing efficacy at similar doses (Bosse and Vestweber, 1994; Phillips et al., 
2003; Zanardo et al., 2004; Sreeramkumar et al., 2014; Biswas et al., 2015). 
2.7.3 Anti-platelet drug dosing 
Dosage of the purinergic antagonists used to suppress  P2Y1 receptor (MRS2500) or P2Y12 
receptor (AR-C 66096) function (both 3 mg/kg i.v. in 100 µl PBS at -1 and +24 hours relative 
to intranasal challenge) and of aspirin to inhibit cycoloxygenase activity (100 mg/kg i.p. in 
200 µl 2% vol/vol DMSO in PBS at -1 and +24 hours relative to intranasal challenge) was 
based on those successfully used for reducing inflammatory responses or for causing increased 
bleeding time in similar mouse models (Ortiz-Muñoz et al., 2014; Amison et al., 2015, 2017). 
In order to reduce the number of mice required to carry out experiments, aspirin-treated mice 
also received intravenous PBS vehicle, and MRS2500 and AR-C 66096 treated mice were 
given 2% vol/vol DMSO in PBS vehicle i.p., with PBS and LPS vehicle control mice receiving 
vehicles by both routes.  
2.7.4 Platelet depletion 
Blood platelets were depleted by the intravenous administration of 1 mg/kg anti-GP1bα 
antibodies (R300, Emfret), a proprietary mixture of two monoclonal anti-GP1bα antibodies 
([p0p3] and [p0p4]) which have previously been shown to cause profound platelet depletion 
within 1 hour of dosing lasting between 24 and 48 hours (Bergmeier et al., 2000; Nieswandt 
et al., 2000). Platelet depleted mice were compared to control mice receiving 1 mg/kg control 
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IgG (BioXCell [2A3]). Depletion over 48 hours was ensured by dosing at -1 and +24 hours 
relative to intranasal challenge. 
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2.8 Analysis of protein, NETs and red blood cell content of BAL 
2.8.1 Total protein assay 
Protein in supernatant from neat BAL supernatant samples (25 µl, prepared by centrifu-
gation of whole BAL at 1500 rcf for 7 minutes) was quantified using the bicinchoninic acid 
(BCA) assay (Smith et al., 1985), using serial dilutions of a 2 mg/ml BSA standard in PBS 
as a reference according to the protocol provided by the manufacturer (ThemoFisher Scientific 
Pierce BCA assay kit). Samples were incubated with 200 µl of reagent diluent (reagants A:B 
50:1) for 20 minutes at room temperature, then an absorbance plate reader was used to 
measure at 562 nm. Background values were subtracted and experimental samples were in-
terpolated against dilutions of the BSA standard using a 4-parameter logistic curve fit.10 
2.8.2 PF4 ELISA 
Platelet factor-4 (PF4, CXCL4) was quantified using the DuoSet DY595 mouse PF4 
ELISA kit (R&D Systems). For ELISA analysis, blood plasma was prepared by centrifugation 
of ACD-anticoagulated blood at 1500 rcf for 7 minutes for collection of plasma supernatant, 
BAL supernatant was collected from BAL using the same centrifugation method, and samples 
were stored at -80 °C. 
PF4 ELISAs were carried out according to instructions on the kit. High-binding plates 
were coated at room temperature overnight with capture antibody, plates were washed (3 
                                           
 
10 Curve fitting for total protein and ELISA assays was carried out using the MyAssays Ltd 
4-parameter logistic fit tool: http://www.myassays.com 
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times with 200 µl ELISA wash buffer), plates were blocked with addition of reagent diluent 
for 1 hour, washed again before addition of appropriately diluted experimental samples and 
recombinant PF4 standards which were incubated on plates for 2 hours. Plates were then 
washed again, biotinylated detection antibody added for 1 hour, followed by a further wash, 
addition of streptavidin-HRP for 1 hour, a final wash and development with 100 µl of the kit 
tetramethylbenzidine substrate solution for 20 minutes. The reaction was then stopped with 
50 µl 2 N H2SO4 and plates were read at 450 nm with optical correction by subtracting 
readings at 540 nm. 
2.8.3 NETs ELISA 
Neutrophil extracellular traps (NETs) are highly decondensed chromatin structures re-
leased from neutrophils which contain DNA, histone proteins that are characteristically hy-
percitrullinated by peptidylarginine deiminase 4 to promote decondensation, and neutrophil 
granule contents such as neutrophil elastase and myeloperoxidase (Li et al., 2010; Hirose et 
al., 2014; Masuda et al., 2016).  
NETs were quantified in BAL by removal of cells by centrifugation of BAL at 1500 rcf for 
7 minutes in order to yield only extracellular contents of the BAL. The quantity of extracel-
lular citrullinated histone H3-DNA complexes (NETs) in BAL supernatant samples were then 
quantified using an ELISA approach. Briefly, this involved coating a 96 well high-binding 
plate with the rabbit polyclonal anti-histone H3 (citrulline R2 + R8 + R17) at (1 in 1000) 
in PBS overnight, washing (3 × 200 µl washes with ELISA wash buffer), non-specific binding 
blocking with ELISA reagent diluent (1% BSA in PBS), washing again, and then a 2 hour 
capture step involving incubation of samples (diluted 1 in 2 or 1 in 4 in reagent diluent) and 
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a serial dilution of a biological standard containing pooled BAL supernatant from 12 mice 
exposed to 5 mg/kg LPS intranasally, diluted serially from a top 1 in 2 dilution in reagent 
diluent. 
The plate was then washed again, incubated with a peroxidase-conjugated anti-DNA an-
tibody [MCA-33] for 1 hour, washed again and then incubated for 1 hour with ABTS reporter 
substrate solution (from Roche Cell death detection ELISA plus kit). Oxidation of ABTS 
was quantified by reading the well absorbance at 405 nm at 1 hour. NETs values are expressed 
as relative units compared with 4-parameter logistic fitting of the pooled standard curve (1 
NET unit is bioequivalent to the concentration of NETs detected in the 1× pooled standard), 
with background readings from a blank sample subtracted from all wells. 
2.8.4 Red blood cell content of BAL 
BAL red blood cell content was also measured as an index of bleeding into lung airspaces 
by measuring the optical density at 405 nm of the lysed BAL cell pellet in a similar manner 
to that previously described for measuring inflammatory bleeding into lungs (Deppermann et 
al., 2017). Whole BAL (125 µl) was centrifuged at 1500 rcf for 7 minutes and BAL superna-
tant removed to yield a BAL cell pellet. The cell pellet was resuspended in 125 µl red cell 
lysis buffer to selectively lyse red blood cells. Remainining cells were then pelleted by centrif-
ugation at 1500 rcf for 7 minutes and the optical density of 100 µl of the resultant supernatant 
measured at 405 nm as an index of free haemoglobin concentration. 
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2.9 Experimental design and statistical analysis 
Where feasible, randomised balanced or imbalanced latin square designs were used for 
blocking application of treatments within and across cages to minimise potential confounding 
effects of treatment order or cage. Measurements were made with the experimenter blinded 
to the treatment group of samples. In cases where previous knowledge from literature or pilot 
studies was available, power analysis was used to set sample sizes required to see an effect 
size considered biologically meaningful at 80% power.  
Parametric statistics were used to analyse continuous numerical data where possible in 
order to maximise power. For each test, residuals versus predicted plots and normal proba-
bility plots were considered to determine whether data transformation was required (trans-
formation approaches used were Y=logY, with 1 added to all Y values if zero values were 
present, or Y=√Y).  
Simple comparisons between single independent measurements from two groups were 
made using two-tailed unpaired Student’s t-tests or Mann-Whitney U-tests where appropri-
ate. Depending on experimental design, single or repeated measures 1-way anlaysis of variance 
(ANOVA), 2-way ANOVA, or 3-way ANOVA were used to test for effects of interventions. 
Repeated measures analysis of covariance (ANCOVA) approaches with baseline values fit as 
covariates were used to analyse datasets with high baseline variability (body weight and non-
invasive radiolabelled platelet tracking), as recommended by Bate and Clark (2014).  
The threshold for statistical significance was set at P<0.05. P-values reported are from t-
tests, or where necessary multiplicity-adjusted P-values (Dunnett’s or Holm’s adjustments 
where appropriate), with the exception of direct reference to ANOVA or ANCOVA main 
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effect results, where Fisher’s F-statistic for the relevant effect is reported with the P-value in 
the format “F(numerator, denominator) = F-value, P-value”. 
Correlations were analysed using Pearson’s test to derive the R2 value describing goodness 
of fit, and P-values are the results of an F-test for the probability that an R2 value as high as 
each R2 value generated from experimental data would have arisen from randomly generated 
datasets with no correlation. 
Effect sizes and variances are reported in text as group means ± standard error with 
relevant P-values from group comparisons. Data are graphed and reported as means ± stand-
ard error with raw or normalised individual data points plotted where sensible. Group sizes 
(n) are listed in figure legends. 
The software packages Excel 2016 (Microsoft Office), InVivoStat 3.6 (InVivoStat), and 
Prism 6.0 (Graphpad) were used for tabulation, statistical analysis and graphing.
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3 Results I: Measuring LPS-induced lung platelet recruitment 
3.1 Immunohistochemistry and LPS model characterisation 
3.1.1 Background – immunohistochemistry and LPS model characterisation 
A mouse model in which lung platelet recruitment following LPS inhalation could be 
studied was sought. In mice, LPS from O55:B5 serotype of E. coli given at 5 mg/kg body 
weight intratracheally was previously suggested, based on increased immunostaining of plate-
let CD41, to cause lung platelet recruitment at 48 hours after challenge (Ortiz-Muñoz et al., 
2014), with neutrophil migration into airspaces detected by 4 hours after LPS inhalation 
(Ortiz-Muñoz et al., 2014). Aspirin and exogenous 15-epi-lipoxin A4 treatment decreased lung 
neutrophil recruitment in this model (Ortiz-Muñoz et al., 2014), and in similar studies from 
our laboratory where mice were administered the same serotype of LPS intranasally, anti-
PSGL-1 antibody treatment, platelet depletion and P2Y1 receptor antagonism could also 
reduce lung neutrophil recruitment, suggesting that this response is both preventable and 
platelet-dependent (Kornerup et al., 2010; Ortiz-Muñoz et al., 2014; Pan et al., 2015; Amison 
et al., 2017).  
The effect of LPS inhalation on the number of platelets detected in lungs using immuno-
histochemisty has not yet been quantified. Development of such methods would allow the use 
of tools available for mouse models to characterise inflammatory lung platelet recruitment 
responses. In order to investigate their recruitment to lungs, the quantity of platelets and 
neutrophil elastase was measured using immunohistochemical staining in frozen lung sections, 
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and platelets and neutrophils in blood were counted using microsamples from tail veins, in 
order to test the effect of inhalation of LPS (O55:B5, 5 mg/kg i.n.) versus PBS vehicle control 
at 4 and 48 hours after challenge. 
LPS from E. coli (O111:B4) had also been instilled into human lungs for recently pub-
lished ex vivo blood-perfused lung studies (Hamid et al., 2017), so platelets and neutrophil 
elastase were also immunostained for imaging in samples from these inflamed human lung 
samples kindly provided by Dr. Cecilia O’Kane, Queen’s University Belfast. 
3.1.2 Results – immunohistochemistry and LPS model characterisation 
Effect of LPS inhalation on quantity of CD41+ platelets in the lung 
Inhalation of LPS caused significant increases in the number of CD41+ platelets detected 
in lungs 48 hours after intranasal challenge (PBS vs. LPS: 9±4 vs. 68±14 platelets/mm2 of 
lung field, P<0.001), but no difference from PBS control was detected with the earlier 4 hour 
time point (PBS vs. LPS: 1.1±0.5 vs. 3.8±1.2 platelets/mm2 of lung field, P=0.392) (Figure 
3.1). 




Figure 3.1: Effect of LPS inhalation on quantity of CD41+ platelets in lungs measured using 
bright field microscopy. Mice were administered PBS or LPS intransally, and lungs harvested at 
4 hours and 48 hours. (A) CD41+ platelets were stained in 10 µm frozen lung sections using 
immunohistochemical methods (brown) with a haematoxylin counterstain (blue) (top and middle 
rows). The brown CD41 staining was deconvoluted for quantification of platelets (bottom row). 
Scale bar = 20 µm. (B) Results of platelet quantification. PBS groups n=4, LPS groups n=8. 
Two-way ANOVA with Holm’s test within time points, ***=P<0.001.  
 
 Further lungs were collected at 48 hours after mice were challenged intranasally with 
LPS or PBS control, and stained for fluorescence microscopy analysis. LPS inhalation again 
increased the number of CD41+ platelets in lung fields (PBS vs. LPS: 752±106 vs. 1205±41 
platelets/mm2 of lung field in mice challenged with LPS, P=0.001) (Figure 3.2B). 




Figure 3.2: Effect of LPS inhalation on quantity of lung CD41 and neutrophil elastase de-
tected using immunofluorescence. Mice were administered PBS or LPS intransally, and lungs 
harvested at 48 hours.(A) Platelet CD41 and neutrophil elastase were stained in frozen lung sec-
tions using immunofluorescence. Sample fields are shown as merges, where CD41+ platelets are 
in red, neutrophil elastase stainingis in green and Hoechst-stained nuclei are in blue (top two 
rows), as well as CD41+ events (second from bottom row), and neutrophil elastase (bottom row) 
shown separately, Scale bar = 20µm. (B) Quantification of number of CD41+ platelets, (C) size 
of CD41+ platelets and (D) neutrophil elastase staining. PBS group n=6, LPS group n=7, un-
paired t-test, **=P<0.01, ***=P<0.001. 
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Detection of a more complete population of the platelets in lungs allowed for analysis of 
the size of the CD41+ platelets. LPS inhalation increased the size of platelets seen in lung 
sections (Area of CD41+ events detected in PBS vs. LPS lung fields: 5.3±0.2 vs. 8.8±0.4 
µm2, P=0.001), although the majority of platelets seen in LPS-challenged lungs appeared to 
be alone, with a minority appearing as doublets, or potentially as microthrombi or CD41+ 
events with the elongated morphology of proplatelets (Figure 3.2). The respiratory lung did 
not contain gross thrombi as can be seen following intravenous administration of platelet 
agonists, which occlude small blood vessels and take up areas of ~400 µm2 in fields of respir-
atory lung sections (see Figure 3.5). 
Dual immunofluorescence staining allowed for analysis of whether platelets were spatially 
associated or not spatially associated with neutrophil elastase in lung sections.11 LPS inhala-
tion appeared to increase both the quantity of platelets not associated with neutrophil elas-
tase in lungs (709±105 vs. 882±43 platelets per mm2 of lung fields, P=0.037) which remained 
in the majority in lungs of both PBS and LPS challenged mice, as well as the quantity of 
neutrophil elastase associated platelets detected in lungs (42±6 vs. 323±22 platelets per mm2 
of lung fields, P=0.003).  
                                           
 
11 The term “spatially associated” is used here rather than colocalised as confocal microscopy 
was not used to narrow the focal plane, so neutrophil elastase-associated platelets may not be in 
direct contact with neutrophil elastase but could therefore appear in images without direct con-
tact. Platelets not visisbly spatially associated within this section may also be in contact with 
neutrophil elastase outside of the region of tisse in the section and focal plane.   
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Perhaps unsurprisingly given the large LPS-induced increase in extent of neutrophil elas-
tase staining in lungs together with the LPS-induced increase in lung platelet numbers, LPS 
inhalation increased the percentage of platelets spatially associated with neutrophil elastase 
(PBS vs. LPS: 6±1 vs. 27±2 % of platelets spatially associated with neutrophils, P<0.001). 
The increase in neutrophil elastase-associated platelets did not occur to the same extent as 
the increase in neutrophil elastase coverage of lungs as with LPS inhalation neutrophil elas-
tase became less densely decorated with spatially-associated platelets (PBS vs. LPS: 
12467±1467 vs. 7576±624 neutrophil elastase-associated platelets per mm2 of neutrophil elas-
tase staining). 
 




Figure 3.3: Effect of LPS inhalation on spatial association of platelets with neutrophil elas-
tase in lungs. Mice were challenged with PBS or LPS intranasally and lungs collected after 48 
hours for immunostaining platelet CD41 and neutrophil elastase. (A) CellProfiler was used to 
separate platelets into two populations, those not visibly associated with neutrophil elastase (red), 
and platelets associated with neutrophil elastase (magenta/white). Scale bars = 20 µm. (B) (C) 
The percentage of platelets associated with neutrophil elastase (D) The number of platelets asso-
ciated with neutrophil elastase per mm2 of neutrophil elastase staining. Mean ± standard error, 
2-way ANOVA with repeated measures and Holm’s test for effects of LPS inhalation, or unpaired 
t-test, *=P<0.05, ** = P<0.01, ***=P<0.001.  
 
Immunofluorescence allowed for detected and segmentation of a more complete population 
of platelets than the bright field method using DAB reporter, and also allowed the simulta-
neous imaging of neutrophil elastase. Unfortunately this immunofluorescence method required 
the use of an anti-rat secondary antibody reporter to amplify CD41 immunostaining, which 
introduced interference in cell depletion and adhesion molecule blocking experiments where 
mice were dosed in vivo with antibodies raised in rats.  
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In order to ensure that a more complete population of lung platelets were detected, a 
method was developed for immunostaining CD42b using a monoclonal antibody raised in 
rabbits, which allowed for signal amplification with an anti-rabbit reporter antibody, revealing 
a more complete population of platelets, particularly in PBS control mice, with numbers more 
closely resembling the numbers seen with immunofluorescence than initial experiments using 
anti-CD41 antibody and bright-field microscopy (Figure 3.1, Figure 3.2, and Figure 3.4) 
Lungs were also collected from mice 1 minute after induction of pulmonary thromboem-
bolism with an intravenous bolus dose of collagen to demonstrate the appearance of gross 
thrombus formation in the lung. CD42b+ thromboemboli seen after collagen administration 
were much larger than platelet staining seen in lungs following inhalation of PBS or LPS 
(Figure 3.5). 
 




Figure 3.4: Immunostaining CD42b+ platelets in lungs.  Mice were challenged with LPS or PBS 
control and 48 hours later lungs were collected for immunostaining platelet CD42b (brown) with 
haematoxylin counterstain (blue). Top and middle row:  Bottom row: deconvolution of brown 
DAB CD42b immunostaining for quantification. Scale bars = 20µm. 
 




Figure 3.5: Effect of intravenous collagen on lung CD42b+ platelet staining. Mice were given 
collagen (bolus i.v. via tail vein, 50 µg/kg) in order to induce pulmonary thromboembolism. 
CD42b+ platelet staining (brown) and haematoxylin counterstain (blue) are shown. Scale bars = 
20 µm. 
 
Effect of LPS inhalation on blood platelet counts 
In order to confirm that increases in lung section platelet content were due to lung platelet 
recruitment rather than just an increase in circulating blood platelet content, platelets were 
counted in tail blood microsamples. Inhalation of LPS caused a decrease in tail blood platelet 
counts at 4 hours after intransal challenge (PBS vs. LPS: 1.02±0.10 vs. 0.78±0.05 ×109 
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platelets per ml of blood, P=0.025), with platelet counts then returning to levels not signifi-
cantly different from PBS controls by 48 hours after intranasal challenge (PBS vs. LPS: 
1.03±0.04 vs. 1.14±0.05 ×109 platelets per ml of blood, P=0.426) (Figure 3.6). This lack of 
difference between blood platelet counts at 48 hours after intranasal challenge is supportive 
of the increased lung platelet staining resulting from lung platelet recruitment, rather than 
from an increase in platelets in blood perfusing the lung. 
 
Figure 3.6: Effect of LPS inhalation on blood platelet counts.  Platelets were counted by phase 
contrast microscopy in tail blood microsamples diluted 1 in 100 in stromatol, taken at 4 and 48 
hours after intranasal administration of PBS or LPS PBS groups: n=4, LPS groups: n=8. Two-
way ANOVA with Holm’s test within time points, *=P<0.05.  
 
Effect of LPS inhalation on the presence of platelets in the bronchoalveolar space 
Immunofluorescence images had clear CD41+ platelet discrimination with the absence of 
false positive staining around airways, which allowed for identification of extravascular plate-
lets in the airspaces of small airways. CD41+ platelets were detected in the lumen of small 
airways of 5 of 7 LPS-challenged mice, with no airway platelets detected in lung sections from 
PBS controls. The total number of airway lumen platelets was added up for each lung section 
analysed and divided by the total area of the lung section, and mice challenged with LPS had 
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0.046±0.017 airway lumen platelets/mm2 of lung section (P=0.021 vs. PBS controls with a 
Mann-Whitney test) (Figure 3.7). Platelets in airway lumen were mainly associated with 
nuclear staining, with some extravascular platelets clearly spatially associated with neutrophil 
elastase (Figure 3.7). 
 




Figure 3.7: Effect of LPS inhalation on quantity of platelets inside airways. Mice were admin-
istered PBS or LPS intransally, and lungs collected at 48 hours. (A) Airways (dashed line) were 
identified in lung sections stained for CD41 (red), neutrophil elastase (green) and nuclei (blue) 
(top panels). Bottom panels: CD41 stain only. Airway lumen platelets are highlighted with arrow-
heads. Scale bar: 20µm. (B) The number of CD41+ platelets within airways was quantified and 
expressed as number per total area of sections surveyed. Mean ± standard error, comparisons are 
Mann-Whitney test, PBS: n=6, LPS: n=7, *=P<0.05.  
Chapter 3. Results I  100 
 
 
Separately, images of fields of alveolar-capillary networks stained for platelet CD42b were 
captured with a high-power 63× objective and used for manual counting of platelets that 
were not visibly within alveolar capillaries or pulmonary blood vessels and so appeared ex-
travascular in the alveolar airspaces. LPS inhalation caused a significant increase in these 
extravascular platelets (PBS vs. LPS: 55±5 vs. 252±65 platelets with extravascular appear-
ance per mm2 of lung fields, P=0.004) (Figure 3.8). 
 




Figure 3.8: Effect of LPS inhalation on quantity of platelets appearing extravascularly in the 
alveolar airspaces. Mice were challenged with PBS or LPS intranasally and lungs collected 48 
hours later. Lung sections immunostained for CD42b (brown) with haematoxylin counterstain 
(blue). (A) Platelets appearing extravascularly with intra-alveolar neutrophils (black arrowhead) 
and alone (black arrow) inside alveolar airspaces (dotted lines) are shown. Scale bars = 20 µm. 
(B) Quantification of CD42b+ platelets detected in alveolar airspaces. Mean ± standard error, 
comparisons are Mann-Whitney test, PBS: n=4, LPS: n=8, **=P<0.01. 
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Effect of LPS inhalation on lung CD41+ objects with proplatelet morphology and CD41+ cells 
In addition to CD41+ platelets, CD41+ proplatelets and megakaryocytes have also been 
observed in mouse lungs (Zhang et al., 2013; Lefrançais et al., 2017). In order to assess the 
contribution of these CD41+ objects to lung platelet recruitment measurements, and in order 
to investigate whether LPS inhalation had a detectable effect on lung thrombopoiesis, CD41+ 
objects with proplatelet morphology and cells with large nuclei surrounded by CD41 positiv-
ity were quantified from immunofluorescence micrographs (Figure 3.9). 
LPS inhalation increased the quantity of CD41+ objects with the large and elongated 
morphology of proplatelets detected in lungs (PBS vs. LPS: 1.1±0.5 vs. 7.6±1.8 CD41+ 
objects with proplatelet morphology per mm2 of lung fields, P=0.010) (Figure 3.9), although 
these objects were a small minority (<1%) of the total number of CD41+ objects counted as 
platelets in sample fields of lung sections (Figure 3.2). 
LPS inhalation also increased the number of CD41+ cells detected across whole lung 
sections which were less frequently observed than objects with proplatelet-like morphology 
(PBS vs. LPS: 0.01±0.01 vs. 0.06±0.01 CD41+ cells per mm2 of lung fields, P=0.014) (Figure 
3.9). 
 




Figure 3.9: Effect of LPS inhalation on quantity of CD41+ objects wth proplatelet 
morphology and CD41+ cells in lungs. Mice were administered PBS or LPS intransally, and 
lungs collected 48 hours later. (A) CD41+ objects with proplatelet morphology (area >55 µm2, 
circularity <0.5, cyan in lower images) in lung sections. (B) Large nuclei surrounded by CD41+ 
cytoplasm in lungs. Scale bars = 50 µm. (C) Quantification of proplatelet events in sampled fields 
and (D) quantification of CD41+ cell events across whole lung sections. Mean ± standard error, 
comparisons are unpaired t-test or Mann-Whitney U-test, PBS: n=6, LPS: n=7, *=P<0.05.  
Effect of LPS inhalation on lung neutrophil elastase 
In order to confirm the presence of neutrophilic lung inflammation following LPS chal-
lenge, neutrophil elastase was also quantified in serial lung sections relative to those used for 
platelet quantification.  
LPS inhalation caused increased lung neutrophil elastase staining at 4 hours (PBS vs. 
LPS: 0.027±0.006% vs. 0.408±0.106% of lung fields covered by neutrophil elastase positivity, 
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P<0.001), and at 48 hours (PBS vs. LPS: 0.038±0.003% vs. 3.136±0.662% of lung fields 
covered by neutrophil elastase positivity, P<0.001) after LPS inhalation (Figure 3.10). 
 
 
Figure 3.10: Effect of LPS inhalation on lung neutrophil elastase staining.  Mice were admin-
istered PBS or LPS intransally, and lungs collected at 4 and 48 hours. (A) Neutrophil elastase 
was stained in 10µm frozen lung sections using immunohistochemical methods (brown) with a 
haematoxylin counterstain (blue) (top and middle row). The brown neutrophil elastase staining 
was deconvoluted for quantification of neutrophil elastase coverage of the lung fields (lower panels). 
Scale bar = 20µm. (B)  Quantification of neutrophil elastase in fields sampled from lungs at 4 and 
at 48 hours after challenge. PBS groups n=4, LPS groups n=8. Two-way ANOVA with Holm’s 
test within time points, ***=P<0.001. Lung neutrophil elastase was also quantified from lung 
sections prepared for immunofluorescence. At 48 hours after challenge, LPS inhalation also 
increased the quantity of neutrophil elastase in lungs detected using this method (PBS vs. 
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LPS: 0.038±0.003% vs. 3.136±0.662% of lung fields covered by neutrophil elastase positivity, 
P<0.001) (Figure 3.2C). 
Effect of LPS inhalation on blood neutrophil counts 
LPS inhalation had no detected effect on blood neutrophil counts at 4 or 48 hours after 
challenge (Figure 3.11), so LPS-induced increases in lung section neutrophil elastase staining 
represented lung neutrophil recruitment rather than an increased in circulating blood neu-
trophil content of the pulmonary circulation. 
Although blood neutrophil counts were maintained, LPS inhalation caused a decrease in 
total blood leukocyte counts which was due to a decrease in blood mononuclear leukocyte 
counts (see appendix Figure 4.26). 
 
Figure 3.11: Effect of LPS inhalation on blood neutrophil counts.  Mice were administered PBS 
or LPS intransally, and tail blood microsamples taken at 4 and 48 hours. Blood neutrophil counts 
were estimated from total leukoyte counts combined with blood  smear differential cell counts. 
PBS groups: n=4, LPS groups: n=8. Two-way ANOVA with Holm’s test within time points. 
Effect of LPS inhalation on body weight 
Body weight was monitored as an index of general health status of mice. Inhalation of 
LPS resulted in body weight loss detectable at 24 and 48 hours after challenge, whilst PBS 
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inhalation had no effect on body weight (24 hours after challenge, PBS vs. LPS: 0.0±2.1% 
vs. -9.0±0.8 change from baseline body weight, 48 hours after challenge, PBS vs. LPS: 
0.0±2.0% vs. -13.7±1.4% change from baseline body weight) (Figure 3.12). 
 
Figure 3.12: Effect of LPS inhalation on body weight. Mice were administered PBS or LPS 
intransally. Body weight was measured at baseline (immediately before intranasal challenge), then 
at 24 and 48 hours after intranasal challenge. Data are means ± standard error, PBS group: n=4, 
LPS group: n=8, repeated measures 2-way ANCOVA with baseline weights fit as covariates, 
Holm’s test for LPS effect within time points, ***=P<0.001.  
Immunostaining of platelets and neutrophil elastase in LPS-challenged human lungs 
Human lung samples obtained from ex vivo blood perfused lung studies exposed to LPS 
via intrabronchial instillation in a previous study (Hamid et al., 2017), were also im-
munostained for CD41 or CD42b for detection of platelets as well as for neutrophil elastase 
content. 
Platelets and neutrophil elastase were successfully stained in human lungs challenged with 
LPS, and platelet and neutrophil elastase staining had a similar appearance to those in mouse 
lungs. No overt thrombosis was seen in the microvasculature but many single platelets could 
be seen in CD41 and CD42b-stained sections (Figure 3.13).  
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Similarly to mouse lungs following LPS inhalation (Figure 3.7), inside inflamed human 
airways exposed to LPS, clusters of cells were seen together with fibrous bodies with extra-
cellular haematoxylin and neutrophil elastase positivity, indicative of neutrophil extraceullar 
trap (NET) release (Masuda et al., 2016). These bodies in the airway lumen also contained 
platelets, as confirmed by immunostaining for both CD41 and CD42b in serial sections (Fig-
ure 3.14). 
 




Figure 3.13: Imaging platelets and neutrophil elastase in human LPS-exposed lungs.  Human 
lungs were perfused ex vivo with blood and exposed to 6 mg O111:B4 LPS via intrabronchial 
instillation. At 4 hours after LPS challenge, lung samples were collected from the LPS-challenged 
lobe for histological examination. Representative fields of alveolar capillary units with im-
munostaining (brown) for platelet CD41 (left column) platelet CD42b (centre column) and neu-
trophil elastase (right column) are shown with haematoxylin counterstain (blue) (top and middle 
rows). Output of DAB deconvolution is shown on the bottom row. Scale bar = 20µm.  




Figure 3.14: Presence of platelets in the airway lumen of human lungs challenged with LPS. 
Serial sections of an airway following LPS-induced inflammation are shown from top to bottom 
with an image collected with a 20× objective on the left and 63× objective on the right. Im-
munostaining (DAB reporter) is brown, haematoxylin (Htox) counterstain in blue. The airway 
lumen contained bodies with cellular and acellular haematoxylin staining also containing (from 
top to bottom) CD41+ platelets, CD42b+ platelets (highlighted with black arrowheads on 63× 
objective images), and neutrophil elastase positivity. Staining was absent when primary antibodies 
were omitted in control samples. Non-inflamed control lung samples were not available at time of 
writing. Representative of 3 samples. Scale bars = 20 µm. 
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3.1.3 Summary – immunohistochemistry and LPS model characterisation 
At 48 hours after LPS inhalation, mice had increased lung platelet counts with no signif-
icant alterations in circulating blood platelet counts, demonstrating platelet recruitment to 
lungs. LPS inhalation caused events counted as platelets to appear larger than in control 
lungs, but the formation of gross thrombi as seen following aggregatory stimuli was not ob-
served in lungs challenged with LPS. Platelets in lungs were seen in increased amounts with 
LPS inhalation both spatially associated, and not spatially associated with neutrophil elas-
tase. 
Lung platelet recruitment was not detected at 4 hours after LPS inhalation whilst lung 
neutrophil recruitment was, suggesting that lung neutrophil recruitment might precede the 
platelet recruitment, although blood platelet counts were decreased at this earlier time point 
suggesting that a platelet response to LPS had occurred at this time point. 
At 48 hours after LPS inhalation, increased numbers of platelets were detected in the 
bronchoalveolar spaces, so it is possible that LPS inhalation may induce transendothelial 
platelet migration in lungs after LPS-induced inflammation, as previously observed following 
LPS inhalation (Ortiz-Muñoz et al., 2014), and in the context of allergic airway inflammation 
(Pitchford et al., 2008). 
Proplatelets and megakaryocytes did not appear to make a major contribution to the 
increase in CD41+ objects counted as platelets in lungs, although LPS inhalation did increase 
the quantity of objects with proplatelet and megakaryocyte morphology detected in lungs, so 
lung inflammation may increase the frequency, or the duration, of lung thrombopoiesis events. 
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Successful immunostaining of platelets and neutrophil elastase in human lung samples 
suggest that immunohistochemistry methods for quantifying platelet recruitment to mouse 
lungs be adapted to experiments in the human tissue context, and observations of platelets 
in human lung airways inflamed by LPS instillation ex vivo are suggestive that platelet mi-
gration might occur into inflamed human airspaces, Platelets in airspaces were also observed 
both spatially associated with, and not spatially associated with, neutrophil elastase positive, 
haematoxylin-staining bodies which had the appearance characteristic of NETs (Caudrillier 
et al., 2012; de Buhr and von Köckritz-Blickwede, 2016).  
LPS inhalation also caused body weight loss, allowing for a simple, repeated measures, 
non-invasive measurement of a marker of general health status following LPS inhalation. 
Previous studies using systemic LPS exposure have associated body weight loss with de-
creased water intake, decreased food intake, and muscle wastage (Braun et al., 2013; Martin 
et al., 2013; Harris et al., 2017). 
Studying lung platelet recruitment using immunohistochemistry allows for the direct im-
aging of platelets in specific anatomical compartments, but necessitates the killing of experi-
mental animals in order to collect lung samples. Many mice are therefore required in order 
to quantify a dynamic response using immunohistochemistry, so non-invasive methods for 
measuring recruitment of platelets to mouse lungs were sought. 
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3.2 Non-invasive radiolabelled platelet tracking 
3.2.1 Background – non-invasive radiolabelled platelet tracking 
Tracking thoracic radiolabelled platelet count has allowed for the non-invasive continuous 
study of lung platelet recruitment following LPS inhalation in guinea pigs within 2 hours of 
challenge with LPS aerosol (Beijer et al., 1987). Dynamic lung platelet recruitment responses 
can be quantified in real time noninvasively in mice following intravenous injection of agonists 
which cause thromboembolism in the lungs (Tymvios et al., 2008). This mouse method has 
been also used to investigate the effects of diesel exhaust particle inhalation on extent of 
thromboembolism (Solomon et al., 2013; Smyth et al., 2017), but has not been applied to 
measurement of lung platelet recruitment responses induced by inflammatory stimuli. 
The non-invasive radiolabelled platelet tracking method was therefore adapted for testing 
the effect of LPS inhalation on thoracic radiolabelled platelet content as an index of lung 
platelet content. 
3.2.2 Results – non-invasive radiolabelled platelet tracking 
Effects of ADP infusions on non-invasive measurements of thoracic radiolabelled platelet 
content 
In order to to validate the method for measuring radiolabelled platelet recruitment to 
lungs, ADP was injected intravenously in order to cause reversible platelet thromboembolism 
in the lung as previously described (Page et al., 1982; Moore and Emerson, 2012). The signal-
to-noise ratio was enhanced by addition of a lead collimating tube around the detector to 
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maximise the detection of radiolabelled platelets in the region of the thorax containing the 
pulmonary circulation directly beneath the probe (Figure 3.15). 
 
 
Figure 3.15: Effect of collimation of detector probe on non-invasive measurements of ADP-
induced thromboembolism. (A) Single trace showing increase in thoracic radioactivity following 
injection of 4 mg/kg ADP i.v. into a mouse transfused 1 hour previously with 111In-labelled plate-
lets. (B) amplitude of the same response in the same mouse is increased by collimation of the 
gamma detector.  
 
When responses to ADP injections were recorded using collimated probes at 48 hours 
after infusion of mice with 111In-labelled platelets, increases in thoracic radioactivity were 
detected following ADP injections (Maximal percentage change in thoracic radioactivity from 
5 minute baseline over the 2 minutes before ADP dose vs. 2 minutes post ADP dose: 11±3% 
vs. 23±4%, P=0.001, Figure 3.16B; 2 minute AUC pre ADP vs. post ADP: -45±11 vs. 
224±113 arbitrary units, P=0.002, Figure 3.16C), showing that the thoracic radiation moni-
toring method could detect the recruitment to lungs of viable, labelled platelets at 48 hours 
after 111In-labelled platelet infusions (Figure 3.16).  




Figure 3.16: ADP-induced thromboembolism detected noninvasively 48 hours after infusion 
of radiolabelled platelets. (A) Responses to i.v. injections of 4 mg/kg ADP in mice infused 48 
hours previously with 111In-labelled platelets. Analysis of pre and post ADP signal showing (B) 
maximal percentage increases in time periods relative to the baseline and (C) area under the curve 
(AUC, arbitrary units (AU)), 2 minutes either side of the ADP injection. Data are mean ± stand-
ard error where error bars are shown, comparisons are paired t-tests, n=6, **=P<0.01.  
 
Effects of LPS inhalation on thoracic radioabelled platelet content 
In initial experiments, mice were terminally anaesthetised and transfused with platelets 
radiolabelled with 111In-tropolonate. Baseline thoracic radioactivity levels were established for 
5 minutes before intranasal treatment with LPS or PBS vehicle control with recordings of 
thoracic radioactivity were made during and following the intranasal challenge. No obvious 
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increase in thoracic platelet content was found during the time period within which it was 
possible to keep mice alive under terminal anaesthesia without more advanced ventilation 
and fluid support (1-2 hours, Figure 3.17). 
 
Figure 3.17: Acute effects of LPS inhalation on quantity of thoracic radiolabelled platelets. 
Single trace showing response to LPS inhalation in a terminally anaesthetised mouse. The mouse 
stopped breathing at around 60 minutes after challenge.  
 
Two problems were identified when acute responses to LPS inhalation were recorded. 
Firstly, intranasal dosing in terminally anaesthetised mice caused choking and gasping not 
seen in other mice used for recording responses to intravenous ADP, or in other mice briefly 
anaesthetised for intranasal dosing, perhaps because of inhibitory effects of terminal anaes-
thesia on respiratory drive. Secondly, based on data from IHC experiments, radiolabelled 
platelet recruitment to lungs may be occurring over days rather than minutes, so maintenance 
of anaesthesia for continuous recordings would be technically challenging, and would have a 
low throughput.  
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The experimental set-up was therefore adapted to involve measurements of thoracic radi-
oactivity under brief isoflurane anaesthesia over 5 minute sampling windows at baseline (im-
mediately before intranasal challenge), and then at 2, 4, 24, and 48 hours after intranasal 
challenge with PBS control or LPS, with the mouse held in a fixed position relative to probes 
with a tooth bar and body cradle (Figure 3.18A). 
Instead of an increase in thoracic radioactivity in LPS-treated mice compared to PBS 
controls that would be indicative of lung platelet recruitment, no significant effect of LPS 
inhalation was detected on thoracic radiolabelled platelet content at any of the time points 
at which measurements were made (ANCOVA main effect of LPS on thoracic radioactivity: 
F(1,7)=3.93, P=0.088) (Figure 3.18B).  
Comparison with serial blood platelet counts made from tail blood microsamples in sep-
arate mice (Figure 3.18C), corroborated previous data from terminal sampling (Figure 3.6), 
and demonstrate that changes in the blood platelet count might be a confounding factor for 
simple non-invasive measurement of lung radiolabelled platelet recruitment, where probes 
receive signal from both the pulmonary circulation and the blood supply to the rest of the 
thoracic tissue below the probes, especially if decreases in the blood signal are not entirely 
due to recruitment to lungs. 




Figure 3.18: Effect of LPS inhalation on thoracic radiolabelled platelet content and blood 
platelet counts over 48 hours.  (A) Mice were infused with 111In-labelled platelets, measurements 
of thoracic radioactivity were made at 0, 2, 4, 24, and 48 hours after intranasal challenge with 
positioning of mice maintained with isoflurane anaesthesia and positioning relative to probes using 
a tooth bar and body cradle as shown in diagram. (B) Effect of LPS inhalation on thoracic 
radiolabelled platelet content over time vs. PBS controls, data shown as % change from time 0 
hours) n=5. (B) In separate mice, serial blood platelet counts made from tail microsamples were 
conducted at 0, 4, 24, and 48 hours after PBS or LPS inhalation (n=6). Two way ANCOVA with 
baseline values fit as covariates, or ANOVA, with repeated measures and Holm’s test for effects of 
LPS inhalation within time points, *=P<0.05. 
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3.2.3 Summary – non-invasive radiolabelled platelet tracking 
Non-invasive radiolabelled platelet tracking through the recording of thoracic radioactiv-
ity in mice infused with 111In-labelled platelets allowed for measurement of pulmonary throm-
boembolism following intravenous infusions of ADP but was not sensitive enough to permit 
measurement of LPS-induced lung platelet recruitment. 
As systemic blood platelet counts were reduced, non-invasive measurements of 111In-la-
belled platelet content in the lungs may have been confounded by decreases in the platelet 
content of the systemic circulation of the central veins, heart and the vessels perfusing the 
skin and the tissue making up the ribcage and pleura which would also be detected by the 
gamma probe. This problem would be overcome through use of micro SPECT imaging which 
would enable discrimination between positron emission events from 111In-labelled platelets 
within the pulmonary as opposed to the systemic circulatory beds (Khalil et al., 2011).  
Measuring radiolabelled platelet content of blood microsamples would also allow for the 
discernment of the contribution of platelets flowing in blood versus those retained within 
tissue. Using a gamma counter, the potential utility of this method for measuring platelet 
recruitment was therefore explored using terminal blood and lung samples in radiolabelled 
platelet biodistribution studies. 
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3.3 Biodistribution of radiolabelled platelets 
3.3.1 Background – biodistribution of radiolabelled platelets  
Previous studies have suggested that the decrease in blood platelet counts following LPS 
exposure might be a direct consequence of platelet recruitment to the lungs (Beijer et al., 
1987; Shibazaki et al., 1999; Zhao et al., 2002). However, the lack of temporal association in 
changes in platelet content of the pulmonary circulation with changes in blood platelet counts 
at 4 hours post LPS administration (Figure 3.1 and Figure 3.6), together with no detection 
of increased thoracic radiolabelled content at 4 hours after LPS inhalation (Figure 3.18), 
suggested that the decrease in blood platelet counts might have more complex origins. 
Biodistribution studies were therefore carried out in order to explore the effect of LPS 
inhalation on distribution of radiolabelled platelets between the blood, lung, liver, spleen and 
the bronchoalveolar space. 
3.3.2 Results – biodistribution of radiolabelled platelets 
Effect of LPS inhalation on the quantity of radiolabelled platelets in blood 
LPS inhalation decreased the quantity of 111In-labeled platelets recovered in blood at 4 
hours after challenge (percentage of 111In-labelled platelets remaining in blood, PBS vs. LPS: 
78.5±2.4% vs. 50.0±4.2%, P<0.001), but not at 48 hours from challenge (percentage of 111In-
labelled platelets remaining in blood, PBS vs. LPS: 42.7±4.2% vs. 33.8±3.9%,  P=0.18) 
(Figure 3.19). 




Figure 3.19: Effect of LPS inhalation on radiolabelled platelet content of blood. Mice were 
administered 111In-labelled platelets intravenously, then PBS or LPS intranasally, and cardiac 
blood collected at 4 and 48 hours after intranasal challenge for measurement of platelet retention 
in blood. Mean ± standard error, 4 hours time point: n=6, 48 hour time point: n=9, 2-way 
ANOVA with Holm’s test for LPS effect within time points, ***=P<0.001.  
Effect of LPS inhalation on the quantity of radiolabelled platelets recruited to lungs 
Lungs were collected and surface blood was removed by rolling on blotting paper. In order 
to account for the effect of alterations in remaining blood platelet content, a recruitment 
index was calculated in a similar manner to previously described radiolabelled platelet bio-
distribution studies (Andonegui et al., 2005; Looney et al., 2009), by dividing the percentage 
of injected 111In-labelled platelets in lungs with their retained blood, by the percentage of 
injected 111In-labelled platelets remaining in the blood.  
LPS inhalation had no detected effect on recruitment of 111In-labelled platelets to lungs 
at 4 hours after challenge (PBS vs. LPS lung/blood ratios: 0.074±0.005 vs. 0.093±0.010, 
P=0.156), but at 48 hours after challenge LPS inhalation increased 111In-labelled platelet 
recruitment to lungs (PBS vs. LPS lung/blood ratios: 0.090±0.005 vs. 0.122±0.008, P=0.008) 
(Figure 3.20). 




Figure 3.20: Effect of LPS inhalation on radiolabelled platelet recruitment to lungs. Mice 
were administered 111In-labelled platelets intravenously, then PBS or LPS intranasally. Lungs and 
blood were collected at 4 and 48 hours after intranasal challenge. The % 111In-labelled platelet 
radioactivity of the lungs was divided by the % of injected 111In-labelled platelet radioactivity 
remaining in the blood to measure lung platelet recruitment. Mean ± standard error, 4 hours time 
point: n=6, 48 hour time point: n=9, 2-way ANOVA with Holm’s test for LPS effect within time 
points, **=P<0.01. 
 
Effect of LPS inhalation on the quantity of radiolabelled platelets recruited to the liver 
Livers were collected in a similar manner to lungs. LPS inhalation increased the recruit-
ment of 111In-labelled platelets to the liver at 4 hours after challenge (PBS vs. LPS liver/blood 
ratios: 0.126±0.021 vs. 0.307±0.078, P=0.004). At 48 hours after intranasal challenge liver 
111In-labelled platelet recruitment was not significantly different between PBS and LPS-chal-
lenged mice (PBS vs. LPS liver/blood ratios: 0.819±0.055 vs. 1.146±0.090, P=0.087) (Figure 
3.21). 




Figure 3.21: Effect of LPS inhalation on radiolabelled platelet recruitment to the liver. Mice 
were administered 111In-labelled platelets intravenously, then PBS or LPS intranasally. Livers and 
blood were collected at 4 and 48 hours after intranasal challenge. The % 111In-labelled platelet 
radioactivity of the liver was divided by the % of injected 111In-labelled platelet radioactivity 
remaining in the blood to measure liver platelet recruitment.  Mean ± standard error, 4 hours 
time point: n=6, 48 hour time point: n=9, 2-way ANOVA with Holm’s test for LPS effect within 
time points, ***=P<0.001.  
 
Effect of LPS inhalation on the quantity of radiolabelled platelets recruited to the spleen 
Spleens were collected in a similar manner to lungs. LPS inhalation also increased splenic 
recruitment of 111In-labelled platelets at 4 hours after challenge (PBS vs. LPS spleen/blood 
ratios: 0.162±0.024 vs. 0.297±0.059, P=0.014), but 48 hours after intranasal challenge splenic 
111In-labelled platelet recruitment was not significantly different between PBS and LPS-chal-
lenged mice (PBS vs. LPS spleen/blood ratios: 0.670±0.068 vs. 0.732±0.085, P=0.085) (Fig-
ure 3.22). 




Figure 3.22: Effect of LPS inhalation on radiolabelled platelet recruitment to the spleen.  
Mice were administered 111In-labelled platelets intravenously, then PBS or LPS intranasally. 
Spleens and blood were collected at 4 and 48 hours after intranasal challenge. The % 111In-labelled 
platelet radioactivity of the spleen was divided by the % of injected 111In-labelled platelet radio-
activity remaining in the blood to measure spleen platelet recruitment  Mean ± standard error, 4 
hours time point: n=6, 48 hour time point: n=9, 2-way ANOVA with Holm’s test for LPS effect 
within time points, *=P<0.05.  
Effect of LPS inhalation on the quantity of radiolabelled platelets in BAL 
As immunohistochemistry staining indicated the presence of platelets inside the bron-
choalveolar airspace, the migration of radiolabelled platelets into airspaces was quantified by 
measurement of radioactivity in BAL. 
LPS inhalation had no detectable effect on recovery of 111In-labelled platelets in BAL at 
4 hours after challenge (Percentage of injected 111In-labelled platelets per ml of BAL, PBS vs. 
LPS: 0.009±0.002 vs. 0.007±0.002, P=0.520) but at 48 hours after challenge LPS inhalation 
increased the recovery of 111In-labelled platelets in BAL (Percentage of injected 111In-labelled 
platelets per ml of BAL, PBS vs. LPS: 0.008±0.002 vs. 0.024±0.004, P=0.003) (Figure 3.23). 




Figure 3.23: Effect of LPS inhalation on the quantity of radiolabelled platelets in BAL. Mice 
were administered 111In-labelled platelets intravenously, then PBS or LPS intranasally. BAL fluid 
was collected at 4 and 48 hours after exposure and 111In-platelet content quantified. Mean ± 
standard error, 4 hours time point: n=6, 48 hour time point: n=9, 2-way ANOVA with Holm’s 
test for LPS effect within time points, **=P<0.01.  
 
Effect of LPS inhalation on the quantity of neutrophils in BAL 
In mice used for radiolabelled platelet studies, LPS inhalation increased the number of 
neutrophils detected in BAL at 4 hours after challenge (PBS vs. LPS: 5.1±2.4 ×103 vs. 
1.2±0.4 ×104 neutrophils per ml of BAL, P=0.013), and at 48 hours after challenge (PBS vs. 
LPS: 3.8±2.8 ×102  vs. 2.5±0.3 ×106 neutrophils per ml of BAL, P=0.001), confirming suc-
cessful induction of experimental lung inflammation responses to LPS at each time point in 
mice used for biodistribution experiments (Figure 3.24). 




Figure 3.24: Effect of LPS inhalation on the quantity of neutrophils in BAL. LPS inhalation 
increased the number of neutrophils in BAL fluid at 4 and 48 hours after intranasal challenge in 
mice used for 111In-labelled platelet studies. Mean ± standard error, 4 hours time point: n=6, 48 
hour time point: n=9, 2-way ANOVA with Holm’s test for LPS effect within time points, 
***=P<0.001.  
 
Effect of LPS inhalation on biodistribution of radiolabelled platelets infused 24 hours after 
intranasal challenge 
The effect of LPS inhalation on the biodistribution of radiolabelled platelets infused 24 
hours after intranasal chellenge was also measured in an attempt to decrease the effects of 
radiolabel decay and platelet lifespan on reducing signal over the course of a 48 hour response, 
and to see whether the potentially confounding factor of thrombocytopenia temporally asso-
ciated with hepatic and splenic platelet accumulation at 4 hours after intranasal challenge 
could be circumvented by infusing radiolabelled platelets later on in the course of the inflam-
matory response.  
As blood platelet counts returned to normal levels 24 hours after LPS inhalation (Figure 
3.18), radiolabelled platelets were infused 24 hours after intranasal challenge. When samples 
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were collected at 48 hours after intranasal challenge, no effects of LPS inhalation were de-
tected on the quantity of radiolabelled platelets remaining in blood (percentage of 111In-la-
belled platelets remaining in blood, PBS vs. LPS: 60.6±6.0% vs. 49.4±5.1%,  P=0.184), or 
on the recruitment of radiolabelled platelets to lungs (PBS vs. LPS lung/blood ratios: 
0.080±0.010 vs. 0.088±0.010, P=0.448). Increased radiolabelled platelet recruitment to the 
liver (PBS vs. LPS liver/blood ratios: 0.280±0.017 vs. 0.449±0.032, P<0.001), and the spleen 
(PBS vs. LPS spleen/blood ratios: 0.316±0.035 vs. 0.418±0.023, P=0.049), was however de-
tected in this experiment. 




Figure 3.25: Effect of LPS inhalation on biodistribution of radiolabelled paltelets infused 24 
hours after intranasal challenge.  Mice were administered PBS or LPS intranasally, then 111In-
labelled platelets were given i.v. 24 hours after intranasal challenge. 111In-platelet biodistribution 
measurements were made at48 hours after intranasal chellenge. (A) The percentage of 111In-la-
belled platelets remaining in blood, as well as (B) lung, (C) liver and (D) spleen recruitment ratios 
were measured. Data shown as a ratio of % 111In-labelled platelet radioactivity of the organ of 
interest, divided by the % of injected 111In-labelled platelet radioactivity remaining in the blood.  
Means ± standard error, n=6 , unpaired t-tests, *=P<0.05, ***=P<0.001. 
 
LPS inhalation increased total BAL radiolabelled platelet content (ANOVA main effect 
of LPS inhalation on percentage of injected 111In-labelled platelets per ml of BAL, PBS vs. 
LPS: 0.005±0.001 vs. 0.009±0.001% per ml of BAL, F(1,10)=17.07, P=0.002) (Figure 3.26A).  
In these experiments BAL was also centrifuged to enable the separate measurement of 
the cell pellet containing cells and platelets, and the BAL supernatant potentially containing 
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platelet microparticles, which have size and density properties which mean that they would 
not be pelleted by the centrifugation cycle used (Lacroix et al., 2013), or 111In released from 
cleared platelets that had moved into the lung with plasma protein. LPS inhalation increased 
radiolabelled platelet content of both BAL cell pellet (Percentage of injected 111In-labelled 
platelets per ml of BAL, PBS vs. LPS: 0.001±0.0004 vs. 0.003±0.0004, P=0.011) and BAL 
supernatant (Percentage of injected 111In-labelled platelets per ml of BAL, PBS vs. LPS: 
0.004±0.001 vs. 0.006±0.001, P=0.005) (Figure 3.26A). As a greater amount of radiolabel 
was detected in the supernatant of samples from both PBS and LPS-treated mice, it is pos-
sible that the majority of the 111In radiolabel detected in airspaces was no longer platelet-
associated at this time point. 
BAL neutrophil content was also increased with inhalation of LPS (PBS vs. LPS: 4.9±4.1 
×103  vs. 3.8±0.4 ×106 neutrophils per ml of BAL, P=0.001) (Figure 3.26B). 
 
 
Figure 3.26: Effect of LPS inhalation on BAL platelet and neutrophil content when radio-
labelled platelets were infused 24 hours after intranasal challenge.  Mice were administered 
PBS or LPS intransally, and 24 hours afterwards, 111In-labelled platelets infused intravenously. 
BAL fluid was collected 48 hours after LPS exposure to measure (A)  111In-labelled platelet, and 
(B) LPS neutrophil content. Means ± standard error, n=6 , 2-way ANOVA with repeated 
measures or unpaired t-test, *=P<0.05, **=P<0.01, ***=P<0.001. 




3.3.3 Summary – biodistribution of radiolabelled platelets 
Investigations into the effects of LPS inhalation on the biodistribution of radiolabelled 
platelets allowed for several findings. Firstly, radiolabelled platelet recruitment data was con-
cordant with platelet immunostaining data (Figure 3.1) in that platelet recruitment to lungs 
was detected at 48, but not at 4, hours after LPS challenge. 
The detection of decreased retention of radiolabelled platelets in blood at 4 hours after 
LPS inhalation was also consistent with data from blood platelet counts. 
Increased liver and spleen platelet recruitment at 4 hours after LPS inhalation provides 
an explanation for the decrease in blood platelet counts at this time point, and for the failure 
of non-invasive measurements of thoracic radioactivity to detect radiolabelled platelet recruit-
ment to lungs. It is unclear from this dataset whether the platelets recruited to lungs are 
those recruited earlier to the spleen or liver or are a separate population of platelets, more 
advanced whole-body platelet tracking experiments may prove enlightening. 
Quantification of BAL radioactivity supported data from immunohistochemistry experi-
ments in suggesting that platelets migrate into the bronchaolveolar space following LPS in-
halation, although this increase may also have been the result of increased movement of free 
111In radiolabel released from platelets into the bronchoalveolar space. 
Limitations of studies using radiolabelled platelets include the manipulation of platelets 
required ex vivo for radiolabelling, the supraphysiological blood platelet counts imposed fol-
lowing platelet transfusions, and the requirement of donor mice which increases the number 
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of mice required for experiments. Genetically modified mice expressing fluorescent proteins 
restricted to platelets are available, so a method for investigating genetically labelled platelet 
recruitment to lungs was therefore sought.  
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3.4 Intravital microscopy 
3.4.1 Background – intravital microscopy 
The effect of LPS inhalation on lung platelet-leukocyte interactions made visible using 
intravital microscopy has been previously explored using genetic labelling of platelets in mice 
(Ortiz-Muñoz et al., 2014), but total lung platelet recruitment and the nature of lung platelet 
recruitment was not studied in these experiments. Platelets and megakaryocytes can now be 
observed more clearly at lower laser powers using multiphoton microscopy to image the lungs 
of mice with platelet and megakaryocyte membranes labelled with GFP (PF4-cre × mTmG 
mice) (Lefrançais et al., 2017).  
In order to directly image the effects of LPS inhalation on platelets in the living pulmo-
nary circulation, intravital multiphoton microscopy video recordings were made in lungs of 
PF4-cre × mTmG mice at 48 hours after intranasal exposure to LPS or PBS control during 
a two month travelling fellowship to the laboratory of Prof. Mark Looney at UCSF. 
3.4.2 Results – intravital microscopy 
Effects of LPS inhalation on total quantity of platelets in the lung microcirculation 
Platelets could be detected in the lungs of PF4-cre × mTmG mice using intravital mul-
tiphoton microscopy. The total flux of detected platelets was measured frame-by-frame with 
a 0.91 frames per second acquisition rate. There was no significant effect of LPS inhalation 
detected on the total platelet flux detected in lung fields (PBS vs. LPS: 1,599±105 vs. 
1,884±256 platelets per mm2 of lung field/frame, P=0.223) (Figure 3.28). Single platelets 
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were successfully identified but this method may favour detection of slower-moving platelets 
as some platelets appeared blurred by motion. 
 
 
Figure 3.27: Effect of LPS inhalation on lung platelet flux. (A) Pf4+ platelets (green) and Pf4- 
cells (red) were imaged in lungs of PF4-cre × mTmG mice at 48 hours after PBS control (top 
row) or LPS inhalation (bottom row). (B,C) Quantification of total detected flux of platelets. 
Scale bars = 20µm. Means ± standard error, n=4. 
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Effects of LPS inhalation on the quantity of adhesive platelets in the lung microcirculation 
In order to focus analysis on adhesive platelets, tracking software was used to isolate a 
population of adhesive platelets which did not move between frames too fast (velocity <2 µm 
per second) or too far (position <5 SD from that predicted by a random motion model), to 
be considered as  free flowing in the blood circulation.12 LPS inhalation increased the number 
of adhesive platelets detected in lungs (PBS vs. LPS: 714±59 vs. 1,050±81 adhesive platelets 
per mm2 of lung field/frame, P=0.017) (Figure 3.28A,B,C). Adhesion events were largely 
transient, occurring over seconds, with no significant effect of LPS inhalation detected on 
adhesion duration (Duration of platelet adhesion events:, PBS vs. LPS: 3.2±0.3 vs. 4.5±0.5, 
P=0.054) (Figure 3.28D). 
                                           
 
12 Representative videos and a demonstration of the platelet adhesion tracking method can be 
seen at http://www.bit.do/intravital. 




Figure 3.28: Effect of LPS inhalation on lung platelet adhesion. (A) Pf4+ platelets (green or 
blue) and Pf4- cells (red) were imaged in lungs of PF4-cre × mTmG mice at 48 hours after PBS 
control (top row) or LPS inhalation (bottom row). Adhesive platelets were tracked between frames 
(blue, emphasised with white arrowheads). (B,C) Quantification of adhesive platlets over time. 
(D) Duration of platelet adhesion event. Scale bars = 20µm. Means ± standard error, n=4, un-
paired t-tests, *=P<0.05. 
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Effects of LPS inhalation on BAL neutrophils in mice observed with intravital microscopy 
BAL was collected from mice used for intravital microscopy after imaging was completed 
in order to provide evidence that neutrophil recruitment had occured. LPS inhalation in-
creased neutrophil counts in BAL (PBS vs. LPS: 0.00±0.00  vs. 2.37±1.09 ×106 neutrophils 
per ml of BAL, P<0.001), confirming experimental induction of lung inflammation in these 
mice.  
 
Figure 3.29: Effect of LPS inhalation on BAL neutrophil content of mice used for intravital 
microscopy. Mice were administered PBS or LPS intranasally, and BAL was collected after in-
travital microscopy at 48 hours following exposure. Means ± standard error, n=4, unpaired t-test, 
***=P<0.001. 
 
3.4.3 Summary – intravital microscopy 
Intravital microscopy videos revealed that platelet recruitment to the lungs appeared to 
involve platelet adhesion. Similarly to lung platelet staining using immunohistochemistry, 
there was no apparent sign of gross thrombotic events. The adhesive platelets were not visibly 
attached to neutrophils, although this method did not allow for clear detection of neutrophils, 
and capillaries with adhesive platelets appeared perfused as platelets could be seen moving 
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through the vasculature of all preparations, and the majority of adhesion events occurred 
transiently before release back into the circulation. 
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3.5 Summary – methods for measuring LPS-induced lung platelet recruitment 
In summary, three different methods for measuring lung platelet recruitment were suc-
cessfully adapted for use with a mouse LPS inhalation model, and each enabled the charac-
terisation of different aspects of the phenomenon of lung platelet recruitment following lung 
inflammation induced by LPS inhalation (Table 3.1). 








Detected effect of 
LPS inhalation  
on platelets: 
↑ platelet content of 
sample fields of lungs 
↑ platelet recruitment 
to whole lung 
↑ platelet adhesion in 
sample fields of lungs 
↑ platelet content of bronchoaveolar space  
 
In order to further investigate the mechanistic basis of the lung platelet recruitment re-
sponse, studies were carried out to test the effects of interventions targeting neutrophils, 
neutrophil platelet interactions, and receptors expressed by platelets. The immunohistochem-
ical quantification of CD42b+ platelets in lungs was chosen as the first method to use for 
measuring LPS-induced lung platelet recruitment in interventional studies as this method 
had relatively high throughput and sensitivity compared to radiolabelling studies, revealed a 
more complete population of lung platelets than the method for CD41 immunostaining, did 
not suffer from interference from administration depleting or blocking antibodies, and was 
readily available in our laboratory.
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4 Results II: Investigations into mechanisms of LPS-induced lung 
platelet recruitment 
4.1 Effects of treatment with neutrophil-depleting antibodies 
4.1.1 Background – neutrophil depletion 
Lung neutrophil recruitment following LPS inhalation can depend on the presence of 
platelets (Kornerup et al., 2010; Grommes et al., 2012; Pan et al., 2015), which is suggestive 
that platelet recruitment might precede and enable neutrophil recruitment. However, lung 
neutrophil recruitment was detected before lung platelet recruitment in the LPS inhalation 
model used in this study, and platelet interactions with neutrophils could also conceivably 
mediate lung platelet recruitment, as has previously been demonstrated in platelet recruit-
ment to lungs following intraperitoneal LPS (Andonegui et al., 2005), and following priming 
with inhaled LPS and acute lung injury with subsequent intravenous anti-MHCI antibody 
treatment (Looney et al., 2009). 
The neutrophil dependence of platelet recruitment following LPS inhalation in the ab-
sence of any exogenous intravascular or systemic pro-inflammatory stimulus is so far unex-
plored, and the method of neutrophil depletion used in previous studies investigating the 
neutrophil dependence of platelet responses also used depletion methods which targeted func-
tionally important Ly6-C+ Ly6-G- inflammatory monocytes in addition to Ly6-C- Ly6-G+ 
neutrophils (Daley et al., 2008). 
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The effect of antibody treatment-mediated neutrophil depletion through selective target-
ing of Ly6-G on platelet recruitment induced by LPS inhalation was therefore investigated. 
4.1.2 Results – neutrophil depletion 
Effects of LPS inhalation and anti-Ly6-G treatment on blood neutrophil counts 
Blood neutrophil counts were made from serial tail microsamples in order to confirm 
experimental neutrophil depletion (Figure 4.1).  
Treatment with anti-Ly6-G antibody caused a profound and sustained removal of poly-
morphonuclear neutrophils from the systemic circulation over the course of the experiment 
in both PBS control mice and mice challenged with LPS. Anti-Ly6-G antibody administration 
caused neutrophil depletion immediately before intranasal challenge (0h) (PBS+control IgG 
vs. PBS+anti-Ly6-G: 1.04±0.13 vs. 0.07±0.05 ×106 neutrophils per ml; LPS+control IgG vs. 
LPS+anti-Ly6-G: 8.02±0.92 vs. 2.15±1.22 ×105 neutrophils per ml, both P<0.001). 
Neutrophil depletion was maintained 4 hours (PBS+control IgG vs. PBS+anti-Ly6-G: 
2.30±0.36 vs. 0.05±0.02 ×106 neutrophils per ml; LPS+control IgG vs. LPS+anti-Ly6-G: 
1.71±0.39 vs. 0.06±0.01 ×106 neutrophils per ml, both P<0.001), 24 hours (PBS+control 
IgG vs. PBS+anti-Ly6-G: 9.08±1.20 vs. 0.45±0.15 ×105 neutrophils per ml; LPS+control 
IgG vs. LPS+anti-Ly6-G: 1.23±0.30 vs. 0.06±0.01 ×106 neutrophils per ml, both P<0.001), 
and 48 hours after intranasal challenge (PBS+control IgG vs. PBS+anti-Ly6-G: 1.28±0.19 
vs. 0.04±0.01 ×106 neutrophils per ml; LPS+control IgG vs. LPS+anti-Ly6-G: 2.10±0.60 vs. 
0.06±0.01 ×106 neutrophils per ml, both P<0.001) (Figure 4.1).  
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No effect of LPS inhalation on blood neutrophil counts was detected at any of the time 
points investigated when comparing control IgG or anti-Ly6-G-treated mice (ANOVA main 
effect of LPS inhalation on blood neutrophil counts F(1,44)=0.67, P=0.418, Figure 3.24). 
 
Figure 4.1: Effect of LPS inhalation and anti-Ly6-G antibody treatment on blood neutrophil 
counts. Mice were administered either control IgG or anti-Ly6-G antibody at -24h, -1h, and +24h 
in relation to intranasal administration of PBS or LPS. Serial tail blood microsamples were used 
to quantify blood neutrophils immediately before (0h), and at +4h, +24h, and +48h after PBS 
or LPS administration. One data point in the +48h LPS+control IgG group (8.25×106 neutrophils 
per ml of blood) is off the scale of the graph, but was included in the analysis. Mean ± standard 
error, n=12, 3-way ANOVA with repeated measures and Holm’s test for LPS and anti-Ly6-G 
treatment effects, ***=P<0.001. 
 
Blood mononuclear cell counts were unaltered with anti-Ly6-G antibody treatment, with 
the exception of LPS-treated mice at 4 hours after intranasal challenge, possibly due to the 
involvement of monocytes in neutrophil clearance, or due to a reduction in the cytokine 
response triggering mobilisation of inflammatory monocytes (See Appendix Figure 4.27). 
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Effects of LPS inhalation and neutrophil depletion on quantity of neutrophil elastase in lungs 
Neutrophil depletion with anti-Ly6-G antibody treatment decreased the quantity of neu-
trophil elastase detected in both PBS control mice (PBS+control IgG vs. PBS+anti-Ly6-G: 
0.06±0.02 vs. 0.01±0.01% of lung fields neutrophil elastase positive, P=0.001), and in mice 
exposed to intranasal LPS (LPS+control IgG vs. LPS+anti-Ly6-G: 7.85±2.81 vs. 1.58±0.40% 
of lung fields neutrophil elastase positive, P=0.003). Although the LPS-induced increase in 
lung neutrophil elastase staining was reduced by ~80%, the quantity of lung neutrophil elas-
tase was increased by LPS inhalation in both control mice (P<0.001), and neutrophil depleted 
mice (P<0.001). 




Figure 4.2: Effect of neutrophil depletion on LPS-induced increases in lung neutrophil elas-
tase staining. Mice were administered either control IgG or anti-Ly-6G antibody at -24h, -1h, 
and +24h in relation to intranasal administration of PBS or LPS, and lungs were harvested at 
+48h and processed for immunohistochemistry (A) Neutrophil elastase was immunostained in 
lung sections, and in sample fields neutrophil elastase DAB reporter positivity (brown in top row) 
was deconvoluted (black in bottom row, from same images as top row) for image analysis. Scale 
bar = 20 µm. (B) Quantification of neutrophils in lung sections. Mean ± standard error, n=6, 2-
way ANOVA with Holm’s test for LPS and anti-Ly6-G treatment effects, **=P<0.01, 
***=P<0.001.  
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Effects of LPS inhalation and neutrophil depletion on BAL neutrophil counts 
Neutrophil depletion with anti-Ly6-G antibody treatment decreased the quantity of neu-
trophils in the bronchoalveolar space following intranasal LPS challenge (LPS+control IgG 
vs. LPS+anti-Ly6-G: 3.72±0.06 vs. 0.55±0.13 ×106 neutrophils per ml of BAL, P<0.001), 
with no detected effect of anti-Ly6-G treatment on PBS control mice (PBS+control IgG vs. 
PBS+anti-Ly6-G: 880±553 vs. 0±0 neutrophils per ml of BAL, P=0.867) (Figure 4.3). 
LPS inhalation resulted in increased BAL neutrophil counts in both control IgG-reated 
mice (P<0.001), and anti-Ly6-G antibody treated mice (P<0.001), indicating that neutrophil 
recruitment to the bronchoalveolar airspaces was still occurring in neutrophil-depleted mice, 
although reduced in magnitude by ~85% (Figure 4.3). 
 
Figure 4.3: Effects of LPS inhalation and neutrophil depletion on BAL neutrophil counts.  
Mice were administered either control IgG or anti-Ly6-G antibody at -24h, -1h, and +24h in 
relation to intranasal administration of PBS or LPS, and BAL was conducted at +48h . Mean ± 
standard error, n=6, 2-way ANOVA with Holm’s test for LPS and anti-Ly6-G treatment effects, 
**=P<0.01, ***=P<0.001.  
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The number of monocyte/macrophages recovered in BAL was not significantly altered by 
anti-Ly6-G antibody treatment (see Appendix Figure 4.28). 
Effects of LPS inhalation and neutrophil depletion on lung CD42b+ platelet recruitment 
LPS inhalation increased the number of platelets detected in lungs in both control IgG 
treated mice (PBS+control IgG vs. LPS+control IgG: 74±12 vs. 829±111 CD42b+ platelets 
per mm2 of lung fields, P<0.001), and neutrophil depleted mice (PBS+anti-Ly6-G vs. 
LPS+anti-Ly6-G: 149±39 vs. 661±57 CD42b+ platelets per mm2 of lung fields, P<0.001) 
(Figure 4.4). 
There was no detected effect of anti-Ly6G antibody treatment on quantity of CD42b+ 
platelets in lung fields between mice exposed to intranasal PBS control (P=0.173), or between 
LPS-challenged mice (P=0.527) (Figure 4.4). 




Figure 4.4: Effect of neutrophil depletion on LPS-induced increases in lung CD42b platelet 
staining. Mice were administered either control IgG or anti-Ly6-G antibody at -24h, -1h, and 
+24h in relation to intranasal administration of PBS or LPS, and lungs were collected at +48h 
and processed for immunohistochemistry (A) Platelet CD42b was immunostained in lung sections, 
and in sample fields CD42b DAB reporter positivity (brown in top row) was deconvoluted (black 
in bottom row, from same images as top row) for image analysis. Scale bar = 20 µm. (B) Quan-
tification of platelets in lung sections. Mean ± standard error, n=6, 2-way ANOVA with Holm’s 
test for LPS and anti-Ly6-G treatment effects, ***=P<0.001.  
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Effects of LPS inhalation and neutrophil depletion on blood platelet counts 
Blood platelet counts were also made from serial tail blood microsamples, primarily to 
investigate the effects of neutrophil depletion on the previously observed LPS-induced de-
crease in blood platelet counts at 4 hours after intranasal challenge.  
Both LPS inhalation and neutrophil depletion were found to have additive and temporally 
distinct effects towards causing decreases in blood platelet counts (Figure 4.5). There was no 
detected effect of anti-Ly6-G treatment immediately before intranasal challenge (0h). At 4 
hours after intranasal challenge  LPS inhalation reduced blood platelet counts in both control 
IgG-treated mice (PBS+control IgG vs. LPS+control IgG: 1.16±0.05 vs. 0.87±0.04×109 
platelets per ml of blood, P=0.002), and neutrophil-depleted mice (PBS+anti-Ly6-G vs. 
LPS+anti-Ly6-G: 8.48±0.32 vs. 5.91±0.33 ×108 platelets per ml of blood, P<0.001). Neutro-
phil depletion caused further reductions in blood platelet counts in both mice challenged with 
PBS control (P<0.001), and LPS-challenged mice (P<0.001). 
At 24 hours after intranasal challenge there was no longer a significant LPS-induced re-
duction in blood platelet counts in mice treated with control IgG (PBS+control IgG vs. 
LPS+control IgG: 1.16±0.05 vs. 0.87±0.04×109 platelets per ml of blood, P=0.002), but 
neutrophil depleted mice still had significantly lower blood platelet counts if they were chal-
lenged with LPS (PBS+anti-Ly6-G vs. LPS+anti-Ly6-G: 1.11±0.05 vs. 0.58±0.03 ×109 plate-
lets per ml of blood P<0.001). The effect of neutrophil depletion on decreasing blood platelet 
counts remained in both PBS control mice (P<0.001), and mice challenged with LPS 
(P<0.001). 
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At 48 hours after intranasal challenge there was no detected effect of LPS inhalation in 
either control or depleted mice, but neutrophil depletion had reduced blood platelet counts 
in both PBS (PBS+control IgG vs. PBS+anti-Ly6-G: 1.18±0.07 vs. 0.89±0.05 ×109 platelets 
per ml of blood P<0.001), and LPS (LPS+control IgG vs. LPS+anti-Ly6-G: 1.06±0.08 vs. 
0.74±0.04 ×109 platelets per ml of blood, P<0.001), challenged mice. 
 
Figure 4.5: Effects of LPS inhalation and neutrophil depletion on blood platelet counts. Mice 
were administered either control IgG or anti-Ly6-G antibody at -24h, -1h, and +24h in relation 
to intranasal administration of PBS or LPS, and serial tail blood microsamples were used to 
quantify blood platelet counts. Mean ± standard error, n=12, 3-way ANOVA with repeated 
measures and Holm’s test for LPS and anti-Ly6-G treatment effects, **=P<0.01, ***=P<0.001. 
 
Effects of LPS inhalation and neutrophil depletion on the quantity of PF4 in BAL and blood 
plasma 
The quantity of PF4 in BAL and blood plasma was measured as an index of platelet α-
granule release in the lung airspaces and in systemic blood.  
LPS inhalation increased the quantity of PF4 detected in BAL in both control IgG-treated 
mice (PBS+control IgG vs. LPS+control IgG: 13±13 vs. 134±16 pg of PF4 per ml of BAL 
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supernatant, P<0.001), and anti-Ly6-G antibody-treated mice (PBS+anti-Ly6-G vs. 
LPS+anti-Ly6-G: 5±3 vs. 160±48 pg of PF4 per ml of BAL supernatant, P<0.001). There 
was no detected effect of anti-Ly6-G treatment between PBS (P=0.999) or LPS-challenged 
mice (P=0.999) (Figure 4.6A). 
LPS inhalation had no effect on the quantity of PF4 detected in blood plasma in both 
control IgG-treated mice (PBS+control IgG vs. LPS+control IgG: 213±55 vs. 268±34 ng of 
PF4 per ml of BAL supernatant, P=0.721), or in anti-Ly6-G antibody-treated mice 
(PBS+anti-Ly6-G vs. LPS+anti-Ly6-G: 345±54 vs. 221±64 ng of PF4 per ml of BAL super-
natant, P=0.324). There was no detected effect of anti-Ly6-G treatment between PBS 
(P=0.324) or LPS-challenged mice (P=0.721) (Figure 4.6B). 
 




Figure 4.6: Effects of neutrophil depletion and LPS inhalation on the quantity of PF4 in 
BAL and plasma. Mice were administered either control IgG or anti-Ly6-G antibody at -24h, -
1h, and +24h in relation to intranasal administration of PBS or LPS, and PF4 was measured by 
ELISA in BAL supernatant and blood plasma collected at 48 hours after intranasal challenge. 
Mean ± standard error, n=6, 2-way ANOVA and Holm’s test for LPS and anti-Ly6-G treatment 
effects, ***=P<0.001. 
 
Effects of LPS inhalation and neutrophil depletion on body weight change 
Body weight was monitored over the course of the experiment as an index of general 
health status, starting from 24 hours before intranasal challenge at the first injection of con-
trol or dpleting antibody treatment. Both LPS inhalation and neutrophil depletion had effects 
on decreasing body weight (Figure 4.7). Immediately before intranasal challenge (0h, 24 hours 
after first antibody doses and baseline weight recordings), a small decrease in body weight 
change was detected in PBS controls (PBS+control IgG vs. PBS+anti-Ly6-G: 2.0±0.7 vs. -
0.4±0.4% change in body weight, P=0.041), but there was no significant effect of neutrophil 
depletion detected between the groups of mice subsequently challenged with LPS (LPS+con-
trol IgG vs. LPS+anti-Ly6-G: 0.9±0.5 vs. -0.7±0.6% change in body weight, P=0.096). 
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At 24 hours after intranasal challenge an effect of LPS inhalation on decreasing body 
weight was detected in both control mice and neutrophil depleted mice (both P<0.001). 
Neutrophil depletion decreased body weight relative to controls in mice receiving PBS in-
tranasally (PBS+control IgG vs. PBS+anti-Ly6-G: 2.0±0.7 vs. -0.4±0.4% change in body 
weight, P=0.001). No effect of neutrophil depletion was detected in LPS treated mice 
(LPS+control IgG vs. LPS+anti-Ly6-G: -10.8±0.6 vs. –11.2±1.0% change in body weight, 
P=0.631). 
At 48 hours after intranasal challenge an effect of LPS inhalation on decreasing body 
weight was detected in both control mice and neutrophil depleted mice (both P<0.001). 
Additionally, neutrophil depletion decreased body weight relative to controls when comparing 
mice receiving PBS intranasally (PBS+control IgG vs. PBS+anti-Ly6-G: 0.9±0.8 vs. -
1.7±0.6% change in body weight, P=0.031) and in mice exposed to LPS intranasally 
(LPS+control IgG vs. LPS+anti-Ly6-G: -16.2±0.7 vs. –18.3±0.9% change in body weight, 
P=0.041). 




Figure 4.7: Effects of LPS inhalation and neutrophil depletion on body weight change. Mice 
were administered either control IgG or anti-Ly6-G antibody at -24h, -1h, and +24h in relation 
to intranasal administration of PBS or LPS, and mice were weighed at 0h +24h and +48h. Means 
± standard error, 3-way ANCOVA with baseline values at 24 hours before intranasal challenge fit 
as covariates, Holm’s test for within-time point LPS and anti-Ly6-G treatment effects, *=P<0.05, 
**=P<0.01, ***=P<0.001. 
 
Associating lung platelet content with lung neutrophil elastase content 
With the hypothesis that if increases in lung platelet content were dependent on neutro-
phils, lung CD42b+ platelet counts would be expected to have a positive correlation with the 
percentage of lung fields covered by neutrophil elastase, the quantity of CD42b+ platelets 
and neutrophil elastase detected in lungs of mice in LPS groups with no additional treatment 
shown in Figure 4.4, Figure 4.11, and Figure 4.16 were pooled for correlation analysis.  
Pearson’s correlation was used to test goodness of fit (R2) and P-values are reported 
representing the probability of obtaining an R2 value as high as that which was observed from 
experimental data from randomly selected data points as calculated with an F-test. 
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No evidence of positive correlation was found with raw data (R2=0.040, P=0.371) (Figure 
4.8A), or when this dataset was log transformed (R2=0.080, P=0.202) (Figure 4.8B). As 
results from in vivo experiments and quantification of immunohistochemistry varied from 
batch to batch, data from the three experiments carried out at different times were normalised 
to the means of each individual dataset. Normalised data showed no positive correlation 
(R2=0.117, P=0.119) (Figure 4.8C). and when normalised data were logarithmically trans-
formed the line of best fit became significantly non-zero but the correlation was still only 
weakly positive (R2=0.220, P=0.028) (Figure 4.8D). 
Conclusions of correlation analyses were unaltered with removal of the very high neutro-
phil elastase value (notable in Figure 4.8A, value where % of lung field neutrophil elastase+ 
is >20), with the exception of normalised, log transformed data, where the R2 value became 
not significantly different from that would be expected with randomly selected data points 
(R2=0.144, P=0.090). 




Figure 4.8: Association of lung platelet content and lung neutrophil elastase content follow-
ing LPS inhalation. At 48 hours after LPS (+control IgG or vehicle) treatment, CD42b+ platelets 
and neutrophil elastase were quantified in lung sections (pooled data from Figure 4.4, Figure 
4.11, and Figure 4.16). Correlations were measured using (A) raw data, (B) log transformed data, 
(C) data normalised to average values for the 3 separate datasets, and (D) log normalised data. 
Line of best fit and 95% confidence bands shown, n=22, Pearson’s correlation, R2 values and 
results of F-test for significantly non-zero slope are shown, * = P<0.05. 
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4.1.3 Summary – neutrophil depletion 
Treatment with anti-Ly6-G antibody caused neutrophil depletion in the blood sustained 
over the course of the experiment, reduced LPS-induced increases in neutrophil elastase in 
lungs by ~80%, and reduced LPS-induced neutrophil recruitment to the bronchoalveolar space 
by ~85%. In contrast, neutrophil depletion had no detected effect on LPS-induced lung plate-
let recruitment, suggesting that neutrophils are not critical for the lung platelet recruitment 
response. 
The fact that no effect of neutrophil depletion was detected on LPS-induced lung platelet 
recruitment despite decreased blood platelet counts in neutrophil depleted mice, and the 
observation that the quantity of neutrophil elastase and platelets in LPS-inflamed lungs dis-
played an absence of, or a weak, positive correlation, both lend further support to the hypo-
theisis that lung platelet recruitment occurred independently of neutrophils. 
Furthermore, the detection of increased quantities of PF4 following LPS inhalation in 
BAL supernatant, but not in blood plasma, are suggestive of platelet α-granule release in the 
lungs, and the lack of any detected effect of neutrophil depletion on the BAL PF4 increase 
response is suggestive that LPS-induced platelet activation in lungs, and potentially in lung 
airspaces, does not show neutrophil-dependence. However, these data should be interpreted 
with some caution, as PF4 levels are high in plasma, and so increases in PF4 content of BAL 
may be a result of movement of blood plasma into airspaces, and so further methods for 
measuring platelet activation are required. 
Although the neutrophil depletion strategy used in this model reduced LPS-induced lung 
neutrophil recruitment, the lung neutrophil recruitment  response to LPS inhalation was not 
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completely prevented, so it is possible that activity of remaining neutrophils may have been 
sufficient to promote neutrophil-dependent responses, and neutrophil depletion may have had 
some adverse effects on mice as depleted mice showed increased weight loss and decreased 
blood platelet counts. Methods for more specifically targeting platelet-neutrophil interactions 
were therefore sought.  
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4.2 Effects of treatment with blocking antibodies against P-selectin or PSGL-1 
4.2.1 Background – P-selectin or PSGL-1 blockade 
The adhesion and signalling molecules P-selectin and PSGL-1 are binding partners which 
can mediate platelet-leukocyte, platelet-endothelial cell and leukocyte-endothelial cell inter-
actions (Page and Pitchford, 2013), with both P-selectin and PSGL-1 expressed by platelets 
(Frenette et al., 2000; Pan et al., 2015). P-selectin has been implicated in the recruitment of 
platelets to rabbit lungs following LPS infusion into rabbits (Kiefmann et al., 2006), whilst 
in mice exposed to LPS via inhalation, blockade of PSGL-1, but not P-selectin, reduced 
neutrophil recruitment to BAL (Kornerup et al., 2010), whereas at an earlier time point 
blockade of P-selectin reduced LPS-induced neutrophil rolling and adhesion in the tracheal 
circulation (Pan et al., 2015). 
The potential involvement of both P-selectin and PSGL-1 in both LPS-induced platelet 
and neutrophil recruitment to lungs offered an opportunity for finding out more about the 
mechanisms of lung platelet recruitment, and the relationship of lung platelet recruitment to 
neutrophil recruitment, so the effects of blockade of P-selectin or PSGL-1 on lung platelet 
recruitment and on inflammatory responses were investigated. 
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4.2.2 Results – P-selectin or PSGL-1 blockade 
Effects of blockade of P-selectin or PSGL-1 on LPS-induced neutrophil recruitment to BAL 
Intranasal challenge with LPS caused an increase in BAL neutrophil content (PBS vs. 
LPS+control IgG: 0.00±0.00 vs. 1.97±0.60 ×106 neutrophils per ml of BAL, P<0.001). Sim-
ilar to the results obtained by Kornerup et al., (2010), P-selectin blockade had no detected 
effect on BAL neutrophil content (1.61±0.45 ×106 neutrophils per ml of BAL, P=0.283 vs. 
LPS+control IgG), but PSGL-1 blocking antibody treatment reduced the quantity of neutro-
phils present in BAL by ~51% (to 0.96±0.23 ×106 neutrophils per ml of BAL, P<0.001 vs. 
LPS+ control IgG) (Figure 4.9). 
 
Figure 4.9: Effect of blockade of P-selectin or PSGL-1 on LPS-induced BAL neutrophil 
recruitment. Mice were administered either control IgG,  anti-P-selectin antibody, or anti-PSGL-
1 antibody at -1h, and +24h in relation to intranasal administration of PBS or LPS, and BAL 
was collected at +48h. Means ± standard error, n=6, one-way ANOVA with Dunnett’s test for 
difference vs. LPS+control IgG group, ***=P<0.001.  
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Effect of blockade of P-selectin or PSGL-1 on LPS-induced increases in lung neutrophil elas-
tase content 
LPS inhalation increased the quantity of neutrophil elastase immunostaining detected in 
images of lungs (PBS+control IgG vs. LPS+control IgG: 0.18±0.03 vs. 2.07±0.27 % of lung 
fields neutrophil elastase positive, P<0.001), with neutrophil elastase staining in lungs signif-
icantly increased with anti-P-selectin blocking antibody treatment (5.45±1.37 % of lung fields 
neutrophil elastase positive, P=0.049 vs. LPS+control IgG), and no detected effect of anti-
PSGL-1 blocking antibody treatment (1.67±0.23 % of lung fields neutrophil elastase positive, 
P=0.758 vs. LPS+control IgG) (Figure 4.10). Unlike quantification of BAL neutrophils quan-
tification of neutrophil elastase in lung sections does not distinguish between intra- and ex-
travascular neutrophils, and effects of P-selectin on blood platelet counts (see Figure 4.13) 
and effects of PSGL-1 on preventing successful neutrophil transendothelial and transepithelial 
migration   




Figure 4.10: Effect of blockade of P-selectin or PSGL-1 on LPS-induced increases in lung 
neutrophil elastase content.  Mice were administered either control IgG,  anti-P-selectin antibody, 
or anti-PSGL-1 antibody at -1h, and +24h in relation to intranasal administration of PBS or LPS, 
and lungs were harvested at +48h and processed for immunohistochemistry (A) Neutrophil elas-
tase was immunostained in lung sections, and in sample fields neutrophil elastase DAB reporter 
positivity (brown in top row, with haematoxylin counterstain in blue) was deconvoluted (black in 
bottom row, from same images as top row) for image analysis. Scale bar = 20 µm. (B) Quantifi-
cation of neutrophil elastase stain in lung sections. Means ± standard error, PBS group: n=4, 
LPS groups: n=8, one-way ANOVA with Dunnett’s test for difference vs. LPS+control IgG group, 
*=P<0.05, ***=P<0.001.  
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Effect of blockade of P-selectin or PSGL-1 on LPS-induced lung CD42b+ platelet recruitment 
LPS inhalation increased the quantity of CD42b+ platelets detected in images of lungs 
(PBS+control IgG vs. LPS+control IgG: 581±157 vs. 1099±204 CD42b+ platelets per mm2 
of lung fields, P<0.001), but no effect was detected on this response of blockade of either P-
selectin (1153±236 CD42b+ platelets per mm2 of lung fields, P=0.973 vs. LPS+control IgG) 
or PSGL-1 (1022±277 CD42b+ platelets per mm2 of lung fields, P=0.799 vs. LPS+control 
IgG) (Figure 4.11). 




Figure 4.11: Effect of blockade of P-selectin or PSGL-1 on LPS-induced lung CD42b+ plate-
let recruitment. Mice were administered either control IgG,  anti-P-selectin antibody, or anti-
PSGL-1 antibody at -1h, and +24h in relation to intranasal administration of PBS or LPS, and 
lungs were collected at +48h and processed for immunohistochemistry (A) Platelet CD42b was 
immunostained in lung sections, and in sample fields CD42b DAB reporter positivity (brown in 
top row, with haematoxylin counterstain in blue) was deconvoluted (black in bottom row, from 
same images as top row) for image analysis. Scale bar = 20 µm. (B) Quantification of CD42b+ 
platelets in lung tissue. Means ± standard error, PBS group: n=4, LPS groups: n=8, one-way 
ANOVA with Dunnett’s test for difference vs. LPS+control IgG group, ***=P<0.001.  
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Effect of blockade of P-selectin or PSGL-1 on the effect of LPS inhalation on blood platelet 
counts  
Similarly to previous studies, LPS inhalation decreased blood platelet counts at 4 hours 
after intranasal challenge (PBS+control IgG vs. LPS+control IgG: 1.43±0.06 vs. 1.02±0.06 
×109 platelets per ml of blood, P<0.001). Neither blockade of P-selectin (1.07±0.07 ×109 
platelets per ml of blood, P=0.868 vs. LPS+control IgG), nor PSGL-1 (1.00±0.05 ×109 plate-
lets per ml of blood, P=0.990 vs. LPS+control IgG), significantly altered this response (Fig-
ure 4.12).  
Similarly to previous experiments, no significant effect of LPS inhalation was detected at 
48 hours after intranasal challenge, and no effect of treatement with either blocking antibody 
was detected at this time point (Figure 4.12). 
 




Figure 4.12: Effect of blockade of P-selectin or PSGL-1 on the effect of LPS inhalation on 
blood platelet counts.  Mice were administered either control IgG,  anti-P-selectin antibody, or 
anti-PSGL-1 antibody at -1h, and +24h in relation to intranasal administration of PBS or 
LPS,and circualting platelet counts were measured at +4h and +48h. Means ± standard error, 
PBS group: n=4, LPS groups: n=8, two-way ANOVA with repeated measures and Holm’s test for 
difference vs. LPS+control IgG group, ***=P<0.001.  
 
Effect of blockade of P-selectin or PSGL-1 and LPS inhalation on blood neutrophil counts 
LPS inhalation increased the quantity of neutrophils detected in blood at 4 hours after 
intranasal challenge (PBS+control IgG vs. LPS+control IgG: 0.77±0.10 vs. 1.85±0.45 ×106 
neutrophils per ml of blood, P=0.035), with neither anti-P-selectin antibody treatment 
(2.69±0.21 ×106 neutrophils per ml of blood, P=0.060), nor anti-PSGL-1 antibody treatment 
(1.55±0.15 ×106 neutrophils per ml of blood, P=0.999), significantly altering blood neutrophil 
counts in the context of LPS inhalation (Figure 4.13). 
At 48 hours after intranasal challenge, LPS inhalation had no detected effect on blood 
neutrophil counts (PBS+control IgG vs. LPS+control IgG: 1.15±0.22 vs. 1.24±0.20 ×106 
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neutrophils per ml of blood, P=0.035), but in the context of LPS inhalation, treatment with 
P-selectin blocking antibody increased blood neutrophil counts (2.49±0.59 ×106 neutrophils 
per ml of blood, P=0.018 vs. LPS+control IgG), whilst treatment with PSGL-1 blocking 
asntibody decreased blood neutrophil counts (0.29±0.05 ×106 neutrophils per ml of blood, 
P<0.001 vs. LPS+control IgG) (Figure 4.13). 
 
Figure 4.13: Effect of blockade of P-selectin or PSGL-1 and LPS inhalation on blood neu-
trophil counts.  Mice were administered either control IgG,  anti-P-selectin antibody, or anti-
PSGL-1 antibody at -1h, and +24h in relation to intranasal administration of PBS or LPS, and 
circulating neutrophil counts were measured at +4h and +48h. One data point from the +48h 
LPS+anti-P-selectin group (6.3 ×106 neutrophils per ml of blood) is off the scale of the graph but 
was included in analysis. Means ± standard error, PBS group: n=4, LPS groups: n=8, two-way 
ANOVA with repeated measures and Holm’s test for difference vs. LPS+control IgG group, 
*=P<0.05;  ***=P<0.001.  
 
Effect of blockade of P-selectin or PSGL-1 on LPS-induced increases in NETs in BAL 
Interactions between activated platelets and neutrophils mediated through P-selectin and 
PSGL-1 have been implicated in the formation of NETs (Caudrillier et al., 2012; Etulain et 
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al., 2015), so the effect of P-selectin or PSGL-1 blockade was investigated on the quantity of 
NETs recovered in BAL supernatant following LPS inhalation. 
LPS inhalation increased the quantity of NETs detected in BAL (PBS+control IgG vs. 
LPS+control IgG: 0.10±0.02 vs. 0.95±0.08 NET units per ml of BAL, P<0.001) with neither 
anti-P-selectin antibody treatment (1.09±0.06 NET units per ml of BAL, P=0.689 vs 
LPS+control IgG), nor anti-PSGL-1 antibody treatment (0.97±0.07 ×106 NET units per ml 
of BAL, P=0.997 vs LPS+control IgG), significantly altering LPS-induced increases in BAL 
NET content (Figure 4.14). 
 
Figure 4.14: Effect of blockade of P-selectin or PSGL-1 on LPS-induced increases in quantity 
of NETs in BAL. Mice were administered either control IgG,  anti-P-selectin antibody, or anti-
PSGL-1 antibody at -1h, and +24h in relation to intranasal administration of PBS or LPS, and 
BAL was collected at +48h and the supernatant assayed for quantity of NETs (CitH3-DNA com-
plexes). Means ± standard error, PBS group: n=4, LPS groups: n=8, one-way ANOVA with 
Dunnett’s test for difference vs. LPS+control IgG group, *=P<0.05, ***=P<0.001.  
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Effect of blockade of P-selectin or PSGL-1 on LPS-induced body weight loss 
Body weight was monitored as an index of general health status of mice. LPS inhalation 
caused body weight loss at 24 hours after intranasal challenge (PBS+control IgG vs. 
LPS+control IgG: 0.03±0.54 vs. -10.9±0.5 % change in body weight, P<0.001), with no 
detected effect of anti-P-selectin blocking antibody treatment (-9.3±0.5 % change in body 
weight, P=0.050 vs. LPS+control IgG), but a significant effect of anti-PSGL-1 blocking an-
tibody treatment towards reducing LPS-induced weight loss (-9.2±0.4 % change in body 
weight, P=0.048 vs. LPS+control IgG) detected at this time point (Figure 4.15). 
LPS inhalation also caused a decrease in body weight detectable at 48 hours after in-
tranasal challenge (PBS+control IgG vs. LPS+control IgG -0.92±0.60 vs. -15.1±0.6 % change 
in body weight, P<0.001). At this time point there was no detected effect of anti-P-selectin 
blocking antibody treatment (-14.1±0.6 % change in body weight, P=0.097 vs. LPS+control 
IgG, but treatment with anti-PSGL-1 blocking antibody significantly reduced the extent of 
LPS-induced body weight loss (-11.2±0.8% change in body weight, P<0.001 vs. LPS+control 
IgG) (Figure 4.15). 




Figure 4.15: Effect of blockade of P-selectin or PSGL-1 on LPS-induced body weight loss.  
Mice were administered either control IgG,  anti-P-selectin antibody, or anti-PSGL-1 antibody at 
-1h, and +24h in relation to intranasal administration of PBS or LPS, and mice were weighed at 
+24h and +48h as measured on change in body weight from baseline values before intranasal 
challenge (0h). Means ± standard error, PBS group: n=10, LPS groups: n=14, two-way ANCOVA 
with repeated measures and baseline weights fit as covariates, with Holm’s test for difference vs. 
LPS+control IgG group, ***=P<0.001.  
 
4.2.3 Summary –P-selectin or PSGL-1 blockade 
Similarly to the findings of Kornerup et al., (2010), treatment with blocking antibody 
targeting PSGL-1, but not P-selectin, caused a reduction in neutrophil recruitment to lung 
airspaces. PSGL-1 blockade also reduced LPS-induced weight loss, suggesting an improve-
ment of general health status of LPS-treated mice with PSGL-1 blocking antibody treatment. 
In contrast, both the lung platelet recruitment and the decrease in blood platelet counts 
which followed LPS inhalation were unaffected by blockade of either P-selectin or PSGL-1, 
suggestive that these platelet responses to LPS occur independently of P-selectin or PSGL-1 
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function, although this observation is perhaps unsurprising given that neutrophil depletion 
studies were suggestive that these platelet responses to LPS occur independently of neutro-
phils. 
The observation of contrasting effects of P-selectin and PSGL-1 blockade on blood neu-
trophil counts following LPS inhalation, with P-selectin blocking antibody treatment increas-
ing and PSGL-1 blocking antibody treatment decreasing blood neutrophil counts, suggests 
that these adhesion molecules may be important in blood neutrophil homeostasis in inflam-
mation. 
Despite decreases in blood and BAL neutrophil counts, PSGL-1 blockade had no detected 
effect on LPS-induced increases in lung neutrophil elastase staining, a measure of all neutro-
phil elastase in the intravascular and extravascular spaces of the lung tissue sampled. A 
potential explanation for this observation is that PSGL-1 blockade does not decrease the 
initial recruitment of neutrophils to the pulmonary circulation but prevents successful neu-
trophil transendothelial and/or transepithelial migration, and perhaps also signalling to in-
crease neutrophil production or release to maintain blood neutrophil counts. The increase in 
lung neutrophil elastase with P-selectin blockade may have been related to the increased 
blood neutrophil content. 
The findings that the quantity of NETs in BAL was not affected by PSGL-1 blockade 
despite anti-PSGL-1 antibody treatment-induced decreases in BAL neutrophil content seem 
conflicting and do not support published in vitro data showing P-selectin and PSGL-1 block-
ade preventing NETosis (Etulain et al., 2015). It is possible that the neutrophils present in 
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the bronchoalveolar space of LPS-challenged mice receiving PSGL-1 blocking antibody may 
have been sufficient to produce a full NET release response in this model. 
As platelet P-selectin did not appear to be an important mediator for LPS-induced lung 
platelet recruitment, experiments were designed to investigate the effects of platelet inhibition 
on lung platelet and neutrophil recruitment responses following LPS inhalation.  
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4.3 Effects of treatment with anti-platelet drugs 
4.3.1 Background – treatment with P2Y antagonists or aspirin 
Anti-platelet pharmacological interventions were identified which are of interest in the 
context of LPS-induced lung inflammation and lung platelet recruitment. In previous studies, 
treatment with antagonists targeting the P2Y1 receptor, as well as treatment with aspirin to 
inhibit COX activity and promote aspirin-triggered lipoxin formation, have been found to 
have effects on lung inflammation following allergen or LPS exposure in mice (Ortiz-Muñoz 
et al., 2014; Tilgner et al., 2016; Amison et al., 2015; 2017), whilst P2Y12 antagonism displayed 
no effect on lung inflammation following either allergen challenge or LPS inhalation (Amison 
et al., 2015; 2017). Treatment with antagonists of P2Y1 or P2Y12, as well as aspirin treatment, 
all have established anti-thrombotic action (Erlinge and Burnstock, 2008; Fuster and Sweeny, 
2011), but the effects of treatment with these drugs on lung platelet recruitment in inflam-
mation is unknown.  
The effect of P2Y antagonists and aspirin treatment relative to vehicle controls was there-
fore investigated in the mouse LPS inhalation model. The selection of drugs and dosing reg-
imen was based on those used in previously reported studies, using the P2Y antagonists used 
by Amison et al., (2015, 2017) (the P2Y1 antagonist MRS2500 and the P2Y12 antagonist AR-
C66096, both at 3 mg/kg i.v.), and the aspirin treatment used by Ortiz-Munoz et al., (2014) 
and Tilgner et al., (2016) (100 mg/kg i.p.). 
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4.3.2 Results – treatment with P2Y antagonists or aspirin 
Effects of anti-platelet drugs on LPS-induced lung CD42b+ platelet recruitment 
LPS inhalation caused an increase in CD42b+ platelets detected in lung sections at 48 
hours after challenge (PBS+vehicle vs. LPS+vehicle: 342±74 vs. 719±51 CD42b+ platelets 
per mm2 of lung fields, P<0.001). There was no detected effect of P2Y1 antagonist treatment 
(932±76 CD42b+ platelets per mm2 of lung fields, P=0.322 vs. LPS+vehicle), P2Y12 antag-
onist treatment (855±91 CD42b+ platelets per mm2 of lung fields, P=0.756 vs. LPS+vehicle), 
or aspirin treatment (838±105 CD42b+ platelets per mm2 of lung fields, P=0.903 vs. 
LPS+vehicle) (Figure 4.16). 
 




Figure 4.16: Effects of anti-platelet drugs on LPS-induced lung CD42b+ platelet recruitment.  
P2Y1 antagonist (MRS2500, 3 mg/kg i.v.), P2Y12 antagonist (AR-C 66096, 3 mg/kg i.v.) or aspirin 
(100 mg/kg i.p) treatment, or vehicle controls given at -1 hour and +24 hours relative to intranasal 
LPS challenge The presence  of CD42b+ platelets detected in immunostained frozen lung sections 
was then measured after lungs were collected at +48 hours. Means ± standard error, PBS group: 
n=4, LPS groups: n=8, one-way ANOVA with Dunnett’s test for difference vs. LPS+vehicle group, 
***=P<0.001. 
 
Effects of anti-platelet drugs on LPS-induced increases in lung neutrophil elastase content 
LPS inhalation caused an increase in neutrophil elastase detected in lung sections at 48 
hours after challenge (PBS+vehicle vs. LPS+vehicle: 0.07±0.01 vs. 1.00±0.18 % of lung field 
neutrophil elastase+, P<0.001). There was no detected effect of P2Y1 antagonist treatment 
(1.31±0.22 % of lung field neutrophil elastase+, P=0.700 vs. LPS+vehicle), P2Y12 antagonist 
treatment (1.41±0.31 % of lung field neutrophil elastase+, P=0.688 vs. LPS+vehicle), or 
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aspirin treatment (1.05±0.20 % of lung field neutrophil elastase+, P=0.999 vs. LPS+vehicle) 
(Figure 4.17). 
 
Figure 4.17: Effects of anti-platelet drugs on LPS-induced increases in lung neutrophil elas-
tase content. P2Y1 antagonist (MRS2500, 3 mg/kg i.v.), P2Y12 antagonist (AR-C 66096, 3 mg/kg 
i.v.) or aspirin (100 mg/kg i.p) treatment, or vehicle controls given at -1 hour and +24 hours 
relative to intranasal LPS challenge The presence  of neutrophil elastase detected in im-
munostained frozen lung sections was then measured after lungs were collected at +48 
hours.Means ± standard error, PBS group: n=4, LPS groups: n=8, one-way ANOVA with Dun-
nett’s test for difference vs. LPS+vehicle group, ***=P<0.001. 
 
 
Effects of anti-platelet drugs on LPS-induced increases in BAL neutrophil content 
LPS inhalation caused an increase in BAL neutrophil counts at 48 hours after challenge 
(PBS+vehicle vs. LPS+vehicle: 0.00±0.00 vs. 1.68±0.23 ×106 neutrophils per ml of BAL, 
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P<0.001). There was no detected effect of P2Y1 antagonist treatment (1.68±0.37 ×106 neu-
trophils per ml of BAL, P=0.999 vs. LPS+vehicle), P2Y12 antagonist treatment (1.62±0.28 
×106 neutrophils per ml of BAL, P=0.999 vs. LPS+vehicle), or aspirin treatment (1.69±0.25 
×106 neutrophils per ml of BAL, P=0.999 vs. LPS+vehicle) (Figure 4.18). 
 
Figure 4.18: Effects of anti-platelet drugs on LPS-induced increases in BAL neutrophil con-
tent. P2Y1 antagonist (MRS2500, 3 mg/kg i.v.), P2Y12 antagonist (AR-C 66096, 3 mg/kg i.v.) or 
aspirin (100 mg/kg i.p) treatment, or vehicle controls given at -1 hour and +24 hours relative to 
intranasal LPS challenge. BAL was collected at +48h and BAL neutrophils were quantified.  
Means ± standard error, PBS group: n=4, LPS groups: n=8 (n=7 in LPS+P2Y12 inhibitor group 
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Effects of anti-platelet drugs on LPS-induced increases in quantity of NETs in BAL 
NETs were measured by CitH3-DNA complex ELISA in BAL supernatant samples in 
order to determine the effect of anti-platelet drug treatment on LPS-induced NET formation 
in lung airspaces. LPS inhalation increased quantity of NETs detected in BAL (PBS+vehicle 
vs. LPS+vehicle: 0.16±0.06 vs. 1.14±0.08 NET units per ml of BAL  but there was no de-
tected effect on this response of P2Y1 antagonist treatment (LPS+P2Y1 antagonist: 1.09±0.06 
NET units per ml of BAL, P=0.999 vs. LPS+vehicle), P2Y12 antagonist treatment 
(LPS+P2Y12 antagonist: 1.15±0.10 NET units per ml of BAL, P=0.999 vs. LPS+vehicle), or 
aspirin treatment (LPS+aspirin: 0.94±0.12 NET units per ml of BAL, P=0.775 vs. LPS+ve-
hicle)  
 




Figure 4.19: Effects of anti-platelet drugs on LPS-induced increases in BAL NETs.  P2Y1 
antagonist (MRS2500, 3 mg/kg i.v.), P2Y12 antagonist (AR-C 66096, 3 mg/kg i.v.) or aspirin (100 
mg/kg i.p) treatment, or vehicle controls given at -1 hour and +24 hours relative to intranasal 
LPS challenge. BAL was collected at +48h and extracellular CitH3-DNA complexes (NETs) were 
quantified by ELISA. Means ± standard error, PBS group: n=4, LPS groups: n=8 (n=7 in 
LPS+P2Y12 inhibitor group due to 1 death), one-way ANOVA with Dunnett’s test for difference 
vs. LPS+vehicle group, ***=P<0.001. 
 
Effects of anti-platelet drugs on LPS-induced body weight loss 
Body weight was monitored over the course of experiments as an index of general health 
status of mice. LPS inhalation caused a decrease in body weight relative to pre-challenge 
baseline detected at 48 hours after challenge (PBS+vehicle vs. LPS+vehicle: -1.4±0.5 vs. -
10.4±0.4 % change in body weight, P<0.001). At 24 hours after intranasal challenge there 
was no detected effect of P2Y1 antagonist treatment (-11.2±0.5 % change in body weight, 
P=0.999 vs. LPS+vehicle), P2Y12 antagonist treatment (-10.6±0.5 % change in body weight, 
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P=0.999 vs. LPS+vehicle), or aspirin treatment (-10.3±0.3 % change in body weight, 
P=0.999 vs. LPS+vehicle) (Figure 4.20). 
An effect of LPS inhalation on body weight was also detected at 48 hours after challenge 
(PBS+vehicle vs. LPS+vehicle: -0.8±0.7 vs. -13.8±0.8 % change in body weight, P<0.001). 
At 48 hours after intranasal challenge there was no detected effect of P2Y1 antagonsit treat-
ment (-13.6±0.7 % change in body weight, P=0.999 vs. LPS+vehicle), P2Y12 antagonist 
treatment (-13.8±0.7 % change in body weight, P=0.999 vs. LPS+vehicle), or aspirin treat-
ment (-12.6±0.7 % change in body weight, P=0.474 vs. LPS+vehicle) (Figure 4.20). 
 
Figure 4.20: Effects of anti-platelet drugs on LPS-induced body weight loss.  P2Y1 antagonist 
(MRS2500, 3 mg/kg i.v.), P2Y12 antagonist (AR-C 66096, 3 mg/kg i.v.) or aspirin (100 mg/kg 
i.p) treatment, or vehicle controls were given at -1 hour and +24 hours relative to intranasal 
challenge with PBS or LPS. Mice were weighed at +24h and +48h . Means ± standard error, PBS 
group: n=8, LPS groups: n=16 (n=15 in LPS+P2Y12 inhibitor group due to 1 death), two-way 
ANCOVA with baseline weights fit as covariates and Holm’s test for difference vs. LPS+vehicle 
group, ***=P<0.001. 
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4.3.3 Summary – treatment with P2Y antagonists or aspirin 
In summary, no effect on LPS-induced lung platelet recruitment was seen with treatment 
with the P2Y1 antagonist MRS2500, the P2Y12 antagonist AR-C 66096, or the irreversible 
COX antagonist aspirin when drugs were administered at doses that reduced lung neutrophil 
recruitment (MRS2500 and aspirin) or increased bleeding time (AR-C 66096) in previously 
published mouse experiments (Ortiz-Muñoz et al., 2014; Amison et al., 2017). Also, none of 
the anti-platelet drugs tested affected LPS-induced increases in lung neutrophil elastase con-
tent, BAL neutrophil recruitment, BAL NET release or body weight loss. 
As these pharmacological antagonists with anti-platelet activity showed no detectable 
effects on inflammatory responses, the effect of complete abrogation of platelet function using 
platelet-depleting antibody treatments was therefore investigated. 
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4.4 Effects of treatment with platelet-depleting antibodies 
4.4.1 Background – platelet depletion 
Previous experiments using busulphan-mediated platelet depletion (Kornerup et al., 
2010), antibody-mediated platelet depletion (Grommes et al., 2012), and busulphan-mediated 
platelet depletion with platelet reconstitution (Pan et al., 2015), as well as studies using anti-
platelet drugs (Ortiz-Muñoz et al., 2014; Amison et al., 2017), were strongly suggestive that 
in mice, neutrophil recruitment following LPS inhalation depends on platelets.  
However, the results from the effects of anti-platelet drug treatment in the present study 
were not consistent with previous results in similar LPS inhalation models, and the effects of 
preventing LPS-induced lung platelet recruitment have not yet been explored in the model 
used in this report. The platelet dependence of inflammatory responses in the mouse LPS 
inhalation model were therefore investigated by comparing control platelet replete mice with 
mice depleted of platelets with anti-GPIbα antibody treatment. 
4.4.2 Results – effects of platelet depletion 
Effect of anti-GPIbα treatment on blood platelet counts 
Anti-GP1bα antibody treatment decreased blood platelet counts made from cardiac blood 
samples by ~85% at 48 hours after intranasal challenge in both PBS control mice (PBS+con-
trol IgG vs. PBS+anti-GPIbα: 8.75±0.53 vs. 1.36±0.28 ×108 platelets per ml of blood, 
P<0.001) and mice challenged with LPS-treated mice (LPS+control IgG vs. LPS+anti-
GPIbα: 8.08±0.56 vs. 1.21±0.17 ×108 platelets per ml of blood, P<0.001). There was no 
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effect of LPS inhalation on blood platelet counts between control IgG-treated groups 
(P=0.533), or between platelet-depleted groups (P=0.809) (Figure 4.21). Platelet quantifica-
tion from CD42b immunostaining was not carried out using lungs from the platelet depletion 
experiment as the anti-GP1bα (CD42b) rat antibodies used for depletion interfere with 
CD42b rabbit antibodies resulting in false negative staining. Lungs were however collected 
from mice used in these experiments permitting immunostaining of platelets in these samples 
using alternative methods in future. 
 
Figure 4.21: Effect of anti-GPIb α treatment on blood platelet counts.  Mice were treated with 
anti-GPIbα antibody or control IgG (at 1 mg/kg i.v. at -1h and +24h relative to intranasal 
challenge) and challenged intranasally with PBS or LPS. Blood platelet counts were made from 
cardiac blood collected at 48 hours after intranasal challenge. Means ± standard error, n=8 (n=7 
in LPS+anti-GPIbα group due to 1 death), 2-way ANOVA with Holm’s test for effects of LPS 
and anti-GPIbα treatment, ***=P<0.001.  
 
Effects of platelet depletion on LPS-induced BAL neutrophil recruitment 
LPS inhalation increased BAL neutrophil counts in both control mice (PBS+anti-GPIbα 
vs. LPS+anti-GPIbα: 0.00±0.00 vs. 2.11±0.28 ×106 neutrophils per ml of BAL, P<0.001), 
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and platelet-depleted mice (PBS+anti-GPIbα vs. LPS+anti-GPIbα: 0.00±0.00 vs. 2.07±0.24 
×106 neutrophils per ml of BAL, P<0.001), and there were no detected effects of antibody-
mediated platelet depletion between PBS control groups (P=0.999) or between LPS-chal-
lenged groups (P=0.999) (Figure 4.22). 
 
 
Figure 4.22: Effects of platelet depletion on LPS-induced BAL neutrophil recruitment.  Mice 
were treated with anti-GPIbα antibody or control IgG (at 1 mg/kg i.v. at -1h and +24h relative 
to intranasal challenge) and challenged intranasally with PBS or LPS. BAL neutrophil counts 
were made from BAL collected at 48 hours after intranasal challenge. Means ± standard error, 
n=8 (n=7 in LPS+anti-GPIbα group due to 1 death), 2-way ANOVA with Holm’s test for effects 
of LPS and anti-GPIbα treatment, ***=P<0.001.  
 
Effect of platelet depletion and LPS inhalation on quantity of red blood cells in BAL 
Because previous experiments had observed bleeding into lungs when LPS-induced lung 
inflammation was combined with thrombocytopenia (Goerge et al., 2008; Gros et al., 2015; 
Deppermann et al., 2017), and endothelial disruption and bleeding into airspaces might affect 
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measurements of neutrophil migration into airspaces, bleeding into the bronchoalveolar air-
spaces was quantified by measuring the index of optical density at 405 nm of a red cell-lysed 
and pelleted sample of BAL. 
LPS inhalation had no detected effect on BAL red blood cells index in control mice 
(Optical density of sample in PBS+control IgG vs. LPS+control IgG: 0.05±0.01 vs. 0.10±0.03 
optical density units, P=0.3115), but in platelet-depleted mice LPS inhalation caused a sig-
nificant increase in the BAL red blood cell index (Optical density of sample in PBS+anti-
Ly6-G 0.10±0.03 vs. 0.51±0.19, P<0.001), which was also significantly higher than in platelet 
replete mice challenged with intranasal LPS (P<0.001). No effect of platelet depletion was 
detected in PBS control mice (P=0.3115) (Figure 4.23). Bleeding into BAL was not detected 
in any previous experiments (Figure 4.30). 
 
Figure 4.23: Effect of platelet depletion and LPS inhalation on quantity of red blood cells in 
BAL. Mice were treated with anti-GPIbα antibody or control IgG (at 1 mg/kg i.v. at -1h and 
+24h relative to intranasal challenge) and challenged intranasally with PBS or LPS. Bleeding into 
airspaces was assessed by measuring optical density at 405 nm of washed, lysed BAL cell pellet 
supernatant samples (100 µl). Means ± standard error, n=8 (n=7 in LPS+anti-GPIbα group due 
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to 1 death), 2-way ANOVA with Holm’s test for effects of LPS and anti-GPIbα treatment, 
***=P<0.001.  
 
Effect of platelet depletion on quantity of NETs in BAL 
NETs (extracellular complexes of citrullinated histone H3 with DNA) were quantified in 
BAL supernatant. Platelet depletion with anti-GPIbα antibody treatment reduced quantity 
of NETs in BAL (LPS+control IgG vs. LPS+anti- GPIbα: 1.06±0.06 vs. 0.57±0.11 NET 
units per ml of BAL, P<0.001), with no detected effect of platelet depletion on NETs in PBS 
control challenged mice (PBS+control IgG vs. PBS+anti- GPIbα: 0.20±0.04 vs. 0.10±0.04 
NET units per ml of BAL, P=0.150). Although the quantity of NETs was reduced by ~53% 
with platelet depletion, LPS inhalation significantly increased BAL NET content in both 
platelet depleted (P<0.001), and control IgG-treated mice (P<0.001). 




Figure 4.24: Effect of platelet depletion and LPS inhalation on quantity of NETs in BAL.  
Mice were treated with anti-GPIbα antibody or control IgG (at 1 mg/kg i.v. at -1h and +24h 
relative to intranasal challenge) and challenged intranasally with PBS or LPS. NETs (extracellular 
CitH3-DNA complexes) were measured in BAL supernatant samples collected at 48 hours after 
intranasal challenge using an ELISA method. Units are relative to a serial dilution of pooled BAL 
supernatant sample from 12 separate mice (1.0 NET unit). Means ± standard error, n=8 (n=7 in 
LPS+anti-GPIbα group due to 1 death), 2-way ANOVA with Holm’s test for effects of LPS and 
anti-GPIbα treatment, ***=P<0.001. 
 
Effect of platelet depletion and LPS inhalation on body weight 
Body weight was monitored as an index of general health status of mice. LPS inhalation 
caused body weight loss in both control IgG-treated control mice (PBS+control IgG vs. 
LPS+control IgG: -0.8±0.5 vs. -10.6±0.4 % change in body weight, P<0.001), and platelet 
depleted mice (PBS+anti-GPIbα vs. LPS+ anti-GPIbα: -1.0±0.7 vs. -9.6±0.7 % change in 
body weight, P<0.001) detectable at 24 hours after intranasal challenge. There was no de-
tected effect of platelet depletion between PBS control mice (P=0.999) or LPS-challenged 
mice (P=0.999) at 24 hours after intranasal challenge. 
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At 48 hours after intranasal challenge a significant decrease both control IgG-treated 
control mice (PBS+control IgG vs. LPS+control IgG: -0.2±0.6 vs. -14.2±0.9 % change in 
body weight, P<0.001), and platelet depleted mice (PBS+anti-GPIbα vs. LPS+ anti-GPIbα: 
-0.7±0.9 vs. -11.7±1.7 % change in body weight, P<0.001), with no detected effect of platelet 
depletion in PBS controls (P=0.999) or mice exposed to LPS (P=0.086) at 48 hours after 
intranasal challenge (Figure 4.25). 
 
Figure 4.25: Effect of platelet depletion on the effect of LPS inhalation on body weight.  Anti-
GPIbα antibody treatment-induced platelet depletion had no detected effect on LPS-induced body 
weight loss. Means ± standard error, n=8 (n=7 in LPS+anti-GPIbα group due to 1 death), 3-
way ANCOVA with repeated measures and baseline values fit as covariates, Holm’s test for effects 
of LPS and anti-GPIbα treatment, ***=P<0.001. 
 
4.4.3 Summary – effects of platelet depletion 
In summary, platelets were successfully depleted with administration of anti-GPIbα anti-
bodies to ~85% of control levels, but neutrophil recruitment to BAL following LPS inhalation 
Chapter 4. Results II  186 
 
 
was not affected by platelet depletion. This observation is suggestive that a full lung neutro-
phil recruitment response in this model at this time point is not entirely dependent on blood 
platelets, which would also explain the absence of detected effects of anti-platelet drugs on 
LPS-induced lung neutrophil recruitement responses.  
However, inflammatory bleeding into airspaces in LPS-challenged, platelet depleted mice 
may have confounded specific measurement of neutrophil migration into airspaces, and its is 
possible that remaining platelets may have been sufficient to mediate lung neutrophil recruit-
ment as previous studies have found that platelet depletion levels of greater than 85% are 
required for inhibition of eosinophil recruitment to BAL following allergen challenge 
(Pitchford et al., 2005).  
In spite of the lack of the effect of platelet depletion on neutrophil recruitment to BAL, 
release of NETs in BAL was reduced by ~53%, suggestive that the presence of platelets is 
important for release of NETs within lung airspaces. This is an interesting observation as 
platelets have been previously associated with formation of NETs following inflammation 
originating from intravascular inflammatory insult (Caudrillier et al., 2012), but not in the 
extravascular formation of NETs in the lung following inhaled LPS challenge. 
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4.5 Summary – Investigations into mechanisms of LPS-induced lung platelet re-
cruitment 
In summary, the major effects of neutrophil depletion, blocking antibody treatment, treat-
ment with anti-platelet drugs and platelet depletion that were detected on platelet and neu-
trophil responses following LPS inhalation in the present body of work are summarised below 
(Table 4.1). 
Table 4.1: Summary of effects of tested interventions on LPS-induced lung platelet recruit-
ment and lung neutrophil inflammatory responses. ↓: Intervention decreased response measured, 
↑: intervention increased response measured, no detected effect: response measured but no effect 
of intervention detected, blank cell: intervention effect not measured on response.  
 
 Measurement 










No detected  
effect 
↓ ↓  
P-selectin  
blockade 
No detected  
effect 
No detected  
effect 
↑ 




No detected  
effect 
↓ 
No detected  
effect 




No detected  
effect 
No detected  
effect 
No detected  
effect 




No detected  
effect 
No detected  
effect 
No detected  
effect 




No detected  
effect 
No detected  
effect 
No detected  
effect 




 No detected  
effect 




Taken together, these data are suggestive that LPS-induced lung platelet recruitment in 
the mouse model used at the time point tested occurs independently of neutrophils, adhesion 
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and signalling mediated through either PSGL-1 or  P-selectin, signalling involving the P2Y1 
and P2Y12 receptors, and is insensitive to aspirin treatment.  
Neutrophil recruitment to the extravascular space in this model, in contrast to platelet 
recruitment to lungs, was reduced by PSGL-1 blocking antibody treatment, with effects on 
reducing the extent of LPS-induced body weight loss suggestive that PSGL-1 blockade 
inmproves general health status following LPS inhalation in this model. 
The lack of detected effects of platelet depletion on recruitment of neutrophils to BAL 
suggests that the mouse model used might not be an ideal one for measuring platelet-depend-
ent inflammatory responses, as neutrophil recruitment to lung airspaces did not show evidence 
of platelet dependence at the time point investigated. It is therefore still a pertinent question 
as to whether platelets are recruited to lungs in inflammatory scenarios where inflammation 
is highly dependent on platelets, and whether and through what mechanisms the platelet 
recruitment underlies platelet-dependence of inflammatory responses.  
The effect of platelet depletion on reducing LPS-induced NET release in the lung in the 
model used in these studies, whilst no effects of platelet depletion were detected on the total 
number of neutrophils recruited to the bronchoalveolar space following LPS inhalation, also 
warrants further investigation. 
  





Figure 4.26: Effects of LPS inhalation on blood total leukocyte and mononuclear cell counts.  
Mice were administered either intranasal PBS or LPS, and tail blood samples were collected at 4 
hours and 48 hours after intransal challenges. Total leukocyte counts (A) and total blood mono-
nuclear leukocyte counts (B) were made from blood samples. Mean ± standard error, PBS groups: 
n=4, LPS groups: n=8, 2-way ANOVA with Holm’s test for LPS effects within time points, 
**=P<0.01, ***=P<0.001. 
 




Figure 4.27: Effects of anti-Ly6-G antibody treatment and LPS inhalation on blood total 
leukocyte and mononuclear cell counts.  Mice were administered either control IgG or anti-Ly6-
G antibody at -24h, -1h, and +24h in relation to intranasal administration of PBS or LPS, and 
serial tail blood microsamples were used to quantify blood total leukocyte counts (A) and blood 
mononuclear cell counts (B). Mean ± standard error, n=12, 3-way ANOVA with repeated 
measures and Holm’s test for LPS and anti-Ly6-G treatment effects, *=P<0.05, **=P<0.01, 
***=P<0.001. 
 




Figure 4.28: Effects of anti-Ly6-G antibody treatment and LPS inhalation on the quantity 
of total leukocytes and monocytes/macrophages in BAL.  Mice were administered either control 
IgG or anti-Ly6-G antibody at -24h, -1h, and +24h in relation to intranasal administration of 
PBS or LPS, and BAL was collected at 48 hours after intranasal chellenges. Total leukocyte counts 
(A) and monocytes/macrophage counts (B) were made from BAL samples. Mean ± standard 
error, n=6, 2-way ANOVA with Holm’s test for LPS and anti-Ly6-G treatment effects, 
***=P<0.001. 
 




Figure 4.29: Effects of interventions on LPS-induced increases in BAL supernant protein 
content. Mice were challenged with PBS or LPS intranasally, treated with the various interven-
tions tested in the present body of work, and BAL collected 48 hours later. Total protein was 
quantified in BAL supernatant as an index of plasma extravasation. (A) Effects of neutrophil 
depletion, (B) Effects of anti-P-selectin or anti-PSGL-1 blocking antibody treatment, (C) effects 
of treatment with the P2Y1 antagonist MRS2500, the P2Y12 antagonist AR-C 66096 or aspirin, 
(D) effects of platelet depletion. The increase in BAL protein with neutrophil depletion and LPS 
inhalation correlated with relatively high measurements of red cells in samples with high protein 
content and so may have been the result of bleeding into BAL. Mean ± standard error, n=4-8, 
one or two-way ANOVA with Holm’s or Dunnett’s test, *=P<0.05, **=P<0.01, ***=P<0.001.  
 




Figure 4.30: Effects of LPS inhalations and interventions on red cells in BAL.  Mice were 
challenged with PBS or LPS intranasally, treated with the various interventions tested in the 
present body of work, and BAL collected 48 hours later. The optical density at 405 nm of spun, 
lysed and spun BAL cell samples was quantified as an index of bleeding into BAL. (A) Effects of 
neutrophil depletion, (B) Effects of anti-P-selectin or anti-PSGL-1 blocking antibody treatment, 
(C) effects of treatment with the P2Y1 antagonist MRS2500, the P2Y12 antagonist AR-C 66096 or 
aspirin, (D) effects of platelet depletion. Graphs are scaled to match (D) where significant bleeding 
was detected. Mean ± standard error, n=4-8, one or two-way ANOVA with Holm’s or Dunnett’s 
test, ***=P<0.001. 
Chapter 5. Discussion and conclusions  194 
 
 
5 Discussion and conclusions 
5.1 General discussion and future research 
5.1.1 Methods for measuring platelet recruitment in inflammation 
Immunohistochemistry 
The immunohistochemistry methods reported here constitute a range of imaging methods 
allowing for imaging and relatively rapid quantification of platelets in mouse lungs, and proof-
of-concept experiments showed that these methods have potential for use on human tissue 
samples. To be able to identify and quanitify distinct platelets in situ is a advance on meth-
odologies that rely upon the detection of platelet activation markers which may become spa-
tially disconnected from platelets (Shibazaki et al., 1996), western blots of platelet proteins 
which are limited by protein extraction methods (Ortiz-Muñoz et al., 2014), more qualitita-
tive observations of the extent of lung platelet staining (Looney et al., 2009; Ortiz-Muñoz et 
al., 2014), and the detection of platelets in tissue samples using flow cytometry which requires 
tissue disruption and digestion steps which may alter platelet activation status (Rafii et al., 
2015). 
Immunofluorescence staining also allowed for study of the spatial relationship of platelets 
with neutrophils in lungs, and for the counting of markers of lung thrombopoiesis. Although 
these studies were limited in measurements of colocalisation by the constraints of 2-dimen-
sional epi-fluorescence microscopy (Dunn et al., 2011), these methods could be adapted to 
used with 3-dimensional confocal microscopy image stacks. Such 3-dimensional images could 
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then be used for measuring the spatial patterns of platelet activation using antibodies tar-
geted against the high-affinity conformation of the αIIbβ3 integrin or membrane P-selectin in 
a similar fashion to flow cytometry assays of platelet activation, and to investigate whether 
platelets, or activated platelets, colocalise with neutrophils or other cells more or less than 
anticipated based on random models of platelet distribution across the pulmonary circulation, 
in order to provide further insights into which interactions do or do not mediate platelet 
recruitment to lungs. 
However, it is acknowledged that these methods have the disadvantages of requiring ter-
minaton of, or invasive sampling from the experimental subject, and of potential introduction 
of artifacts during sample collection and processing. Carrying out these studies in either 
formalin-fixed, paraffin embedded tissue or fresh, whole mount preparations made from tissue 
of reporter mice would minimise artifacts which are unavoidably introduced during freezing 
and cryosectioning of lung tissue. Quality of data could be increased and variation between 
groups potentially decreased by sampling from an increased number of sections from a greater 
number of regions across the lung, although doing so would decrease the throughput of this 
method. 
Radiolabelled platelet tracking methods 
The radiolabelled platelet studies developed for this project enabled the quantification of 
platelet clearance from blood and recruitment to whole livers, spleens and lungs, and platelet 
migration into airspaces following LPS inhalation, as well as non-invasive measurements of 
pulmonary thromboembolism following intravenous administration of the platelet agonist 
ADP. However, the non-invasive radiolabelled platelet tracking methods used in this thesis 
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were not sensitive enough to detect lung platelet recruitment following LPS inhalation, but 
the combination of blood microsampling and  more advanced 3-dimensional radioimaging 
techniques such as single photon emission computed tomography may still enable non-invasive 
recordings of radiolabelled platelet recruitment to lungs following LPS inhalation (Khalil et 
al., 2011). 
The chief disadvantages of tracking platelets through radiolabelling are the requirement 
of platelet manipulation ex vivo for radiolabelling which may alter platelet function, the 
partially labelled platelet pool in recipient mice with supraphysiological blood platelet counts, 
and the potential for changes in perfusion or blood pooling which could be mistaken for 
platelet recruitment. 
Both immunohistochemistry, and the use of reporter mice with genetically labelled plate-
lets for intravital microscopy, overcame the problem of only partial platelet population label-
ling as they allowed for imaging of more complete population of platelets, although micros-
copy favours larger platelets and slower platelets with the frame-rates currently possible using 
multiphoton intravital microscopy. A potential way to enable whole-body non-invasive imag-
ing of platelets without requiring labelling ex vivo would be to use recently generated mice 
expressing infrared-fluorescing reporter proteins (Tran et al., 2014), for the breeding of mice 
with infrared reporters restricted to the megakaryocyte-platelet lineage which could be used 
in whole body fluorescence imaging systems to track all platelets across the body. Adapting 
antibody reporters developed for non-invasive imaging of conformational changes in platelet 
integrins associated with platelet activation, previously employed for measuring platelet ac-
tivation in the brain in a murine cerebral malaria model might also allow for the first whole-
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lung imaging studies of platelet activation following lung inflammation (von zur Muhlen et 
al., 2008). Co-administration of red cells or another perfusion control labelled with a different 
radionuclide allowing for spectral unmixing, as previously reported (Bureau et al., 1989), 
would improve radiolabelled platelet tracking studies through enabling better understanding 
of the contributions of variations in perfusion or blood retention to regional increases or 
decreases in radiolabelled platelet content. 
Intravital microscopy 
Intravital microscopy using PF4-cre × mTmG mice allowed for quantification of platelet 
adhesion within the living pulmonary circulation with the entire population of platelets la-
belled. Experiments comparing lungs of LPS-challenged mice with those of controls showed 
that LPS inhalation increased the quantity of platelet adhesion events in the circulation of 
living lungs, and that this adhesion did not appear to progress to aggregation, lending further 
support to conclusions made from measurements of LPS-induced lung platelet recruitment 
from immunohistochemistry and radiolabelled platelet distribution experiments which used 
post mortem tissue samples. Platelet recruitment in this manner has previously been observed 
in inflamed systemic venules of the mesentery, skin, and cremaster muscle (Frenette et al., 
1998; Gros et al., 2015; Zuchtriegel et al., 2016), but to our knowledge this is the first auto-
mated measurement of individually counted inflammatory platelet recruitment events occur-
ring in the pulmonary circulation. 
These studies could be advanced to investigate the labelling of leukocytes in order to 
better detect platelet-leukocyte interactions which were not clearly visible in videos produced 
in this thesis, as has been previously achieved in lungs (Ortiz-Muñoz et al., 2014), and with 
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the simultaneous measurement of blood perfusion and oxygen saturation mapping possible in 
intravital preparations in order to relate platelet and cell recruitment events with deteriora-
tion in lung function over time (Tabuchi et al., 2013). Furthermore, the full time course of 
increases and decreases in platelet and leukocyte adhesion responses would be illuminating 
with respect to the primacy of platelet versus leukocyte recruitment. Another limitation of 
intravital multiphoton microscopy was difficulty in determining whether GFP+ events were 
single platelets, aggregates, or proplatelet/megakaryocyte processes. The breeding of a ‘con-
fetti’ reporter mouse (Schepers et al., 2012), with a platelet lineage reporter would allow the 
labelling of platelets stochastically with four different fluorophores depending on their 
megakaryocyte of origin, and could better permit discrimination of the number of platelets 
incorporated into adhesion events and their motility. 
Outside of the living context, the study of lungs removed from PF4-Cre × mTmG mice 
using confocal, multiphoton, or light-sheet microscopy might also allow for imaging of a larger 
area of tissue in the absence of sectioning artifacts or motion artifacts from breathing or the 
heartbeat, potentially allowing for clearer observation of platelets in the bronchoalveolar 
space. 
Platelet recruitment to the liver and spleen following LPS inhalation 
The increased clearance of radiolabelled platelets from the blood into the liver and spleen 
following LPS inhalation highlights the need for tracking cells in in vivo preparations with an 
intact systemic circulation and functioning mononuclear phagocyte system. The detection of 
the increased hepatic and splenic recruitment, following LPS-induced lung inflammation, but 
preceding lung platelet recruitment raises several questions for future research: 
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1. Does the liver and spleen recruitment following LPS inhalation involve perma-
nent clearance of platelets from the bloodstream, or increased temporary seques-
tration through increased frequency or duration of platelet adhesion events, as 
previously reported following intravenous exposure to whole bacteria (Wong et 
al., 2013)? 
2. Are the platelets recruited to lungs following LPS inhalation those that are se-
questered in the liver or spleen? 
Studies involving whole body radioimaging, intravital microscopy for platelet tracking in 
the microvasculature of the liver and spleen, and experimental mononuclear phagocyte deple-
tion or splenectomy may provide answers to these questions. Importantly, the finding that 
the early thrombocytopenia shows little temporal connection to lung platelet recruitment 
highlights the importance of directly imaging platelets when measuring platelet recruitment 
to organs, as decreases in blood platelet counts have been previously used as indices of the 
extent of thromboembolism (Smith, 1981), and inflammatory lung platelet recruitment 
(Shibazaki et al., 1996). 
Alterations in platelet production and clearance following LPS inhalation 
Although an early decrease in blood platelet counts was detected, from 24 hours after 
LPS challenge blood platelet counts were returned to levels not significantly different from 
PBS control mice, despite evidence of platelet recruitment to lungs, liver and spleen. Megakar-
yocte and proplatelet events, although a minority of total CD41+ events observed in the lung, 
were increased with LPS inhalation suggesting that pulmonary thrombopoiesis, or pulmonary 
retention of megakaryocytes released into the bloodstream, might be increased in the context 
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of lung inflammation. Particularly with regards to previous observations that exposure to 
LPS one week prior to measurements alters platelet function in mice in a TLR4-independent 
manner (Jayachandran et al., 2007). 
A more thorough analysis of the effect of LPS inhalation on the quantity of megakaryocyte 
release and duration of megakaryocyte-proplatelet-platelet transit time across the lungs, as 
well as measurements of platelet volume, reticulated ‘young’ platelet fraction and platelet 
lifespan may help to shed more light on how blood platelet counts are maintained in the 
context of lung inflammation. 
5.1.2 Characterising mechanisms of LPS-induced lung platelet recruitment 
Mechanistic insights into how platelets are recruited to lungs following LPS inhalation 
The studies discussed above showed that LPS inhalation resulted in lung platelet recruit-
ment involving increased platelet adhesion in the pulmonary circulation which did not appear 
to progress on to platelet aggregation.  
Using the immunohistochemistry method to quantify lung platelet recruitment as well as 
other inflammation readouts, interventional studies enabled the identification of contrasts 
between the mechanisms through which neutrophils are recruited to lungs with those under-
lying platelet recruitment to lungs following LPS inhalation. PSGL-1 blocking antibody ad-
ministration, which reduced lung neutrophil recruitement, as well as depletion of blood neu-
trophils to reduce lung neutrophil recruitment even further, had no detected effect on lung 
platlet recruitment following LPS inhalation, suggesting that platelet recruitment requires 
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different mechanisms to neutrophil recruitment and that neutrophils are not essential for a 
the optimal recruitment of platelets into the lung.  
Interventional experiments also showed that both platelet and neutrophil recruitment to 
lungs in this model appeared to progress to similar amounts with P-selectin blocking anti-
body, P2Y1 antagonist, P2Y12 antagonist, or aspirin treatment, indicating that these treat-
ments, all of which have demonstrated anti-inflammatory or anti-platelet activity in other 
contexts, were not active in reducing platelet or neutrophil recruitment to inflamed lungs 
following inhalation of LPS in the model used in this thesis. 
What are the key mediators of platelet recruitment to inflamed lungs? 
Experiments reported in this thesis suggest that, in the context of lung inflammation in 
mice following inhalation of LPS, the recruitment of platelets from the blood to the lungs 
does not require a full neutrophil recruitment response. Furthermore, LPS-induced lung plate-
let recruitment in the model used showed no significant alteration with blockade of either 
PSGL-1, P-selectin or with antagonists targeting P2Y1, P2Y12 or COX enzymes, suggestive 
that platelets did not require the function of these adhesion molecules, receptors or enzymes 
in order to become recruited to inflamed lungs. 
However, these experiments have not identified which mediators are responsible for lung 
platelet recruitment following LPS inhalation. There are a number of possible experiments 
which may prove enlightening as to the mechanisms through which platelet recruitment to 
lungs in inflammation occurs. 
Chapter 5. Discussion and conclusions  202 
 
 
Firstly, it would be interesting to further investigate the contribution of platelet adhesion 
molecules in addition to P-selectin and PSGL-1 using drug treatment, non-depleting blocking 
antibody interventions or knockout mouse studies. Potential platelet adhesion molecules of 
interest would include GP1b, αIIbβ3, GPVI, CLEC-2, ICAM-2, PECAM-1, which are all ca-
pable of mediating platelet adhesion and can all influence inflammatory progression to greater 
or lesser extents in different contexts (Diacovo et al., 1994; Woodfin et al., 2007; Varga-Szabo 
et al., 2008). 
The importance of platelet CD40L and platelet serotonin production remains unstudied 
in inflammatory lung platelet recruitment whilst both mediators are important in lung in-
flammation responses (Dürk et al., 2013; Tian et al., 2014). Furthermore, platelet P-Rex1 
and Vav1 or Vav3 GEFs, which integrate GPCR and ITAM-mediated signalling, are im-
portant for both lung neutrophil recruitment and decreases in blood platelet counts in re-
sponse to LPS challenge (Pan et al., 2015), but it is unknown whether the absence of these 
signalling mediators alters lung platelet recruitment following LPS inhalation. Experiments 
in mice which have defects in platelet granule release would also be interesting to investigate 
whether platelet degranulation is necessary for lung platelet recruitment in inflammation 
(Deppermann et al., 2017). 
To add to results from neutrophil depletion studies, experiments using clodronate-loaded 
liposomes to deplete alveolar macrophages, or blood monocytes and intravascular-facing mac-
rophages could be used to explore whether these cell types, important for both the induction 
and resolution of LPS-induced inflammation (Ley et al., 2016), are important for platelet 
recruitment in inflammation. It would also be interesting to study the conjugation of platelets 
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with neutrophils, monocytes and macrophages in BAL and to investigate whether monocyte 
or macrophage depletion reduces platelet migration into lung airspaces. 
Lastly, it is possible that inflammatory platelet recruitment may also be initiated by 
activation of the coagulation or complement cascades following LPS inhalation, and interven-
tions possible in mice allow the investigation into the contributions of these systems to LPS-
induced lung platelet recruitment (Shibazaki et al., 1999; Davis et al., 2016). However, it is 
notable that decreases in blood platelet counts were relatively small (<30%), and in a similar 
LPS model, bleeding times and platelet aggregation responses to ADP were not altered 
(Amison et al., 2017), suggestive that LPS inhalation models do not provoke a coagulation 
response similar to that seen in patients with disseminated intravascular coagulation. Perti-
nent to intravascular activation of coagulation or complement, future studies could also assess 
the extent to which LPS crosses into the bloodstream following LPS, and such studies may 
benefit from the use of human blood and the production of a humanised fibrinogen mouse, 
as at least in the context of human blood and O111:B4 LPS, recent studies have shown that 
LPS can initiate coagulation with altered fibrin mesh structure at substoichiometric concen-
trations, similar to mechanisms of diseases caused by prion proteins (Pretorius et al., 2016). 
Differences between LPS inhalation models and detected effects of treatments 
In the present body of research, the previous finding that treatment with PSGL-1 blocking 
antibody could reduce LPS-induced lung inflammation was reproduced (Kornerup et al., 
2010). However, decreases in LPS-induced lung neutrophil recruitment were not detected with 
treatment with the P2Y1 antagonist MRS2500, with aspirin, or with experimental depletion 
of blood platelets, results that contrast with the conclusions of previously published studies 
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in other models of LPS inhalation in mice (Kornerup et al., 2010; Grommes et al., 2012; 
Ortiz-Muñoz et al., 2014; Pan et al., 2015; Tilgner et al., 2016), although it should be noted 
that the models used in this study and previous studies differ in several aspects, so the 
experiments reported in this thesis were not designed to be replication studies. Differences 
between models used in published studies and that used in this reported which may have lead 
to different resuts from studies investigating the effects of antiplatelet drug treatment or 
platelet depletion on LPS inhalation responses are summarised below (Table 5.1). 
 
Table 5.1: Differences between methods used in published studies of effects of platelet deple-
tion or anti-platelet drugs on lung inflammation response and those used in the present 














Time point Reference 
C57Bl/6 ♂ Non-barrier E. coli O55:B5 1 mg/kg i.n. +24 hours 
(Kornerup et al., 
2010) 




(Grommes et al., 
2012) 
C57Bl/6 ♂ Non-barrier E. coli O55:B5 0.2 mg/kg i.n. +4 hours 
(Pan et al., 
2015) 
Balb/c ♂ Barrier E. coli O55:B5 5 mg/kg i.t. +48 hours 
(Ortiz-Muñoz et 
al., 2014) 




(Tilgner et al., 
2016) 
Balb/c ♀ Non-barrier E. coli O55:B5 1.25 mg/kg i.n. +4 hours 
(Amison et al., 
2017) 
Balb/c ♀ Non-barrier E. coli O55:B5 5 mg/kg i.n. +48 hours Present study 
 
A potentially key difference between studies is the time point at which samples were 
collected. In the present report samples were collected at 48 hours after LPS inhalation, 
whereas in the majority of other studies investigating the effects of platelet depletion or anti-
platelet drugs, samples were collected earlier at 4 hours (Grommes et al., 2012; Pan et al., 
2015; Tilgner et al., 2016; Amison et al., 2017), or 24 hours after LPS inhalation (Kornerup 
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et al., 2010). It is also notable with regards to time point of sample collection that most of 
the previously reported studies have involved a lesser degree of bronchoaveolar neutrophil 
recruitment, ~105 neutrophils or less, versus more than 106 neutrophils per ml of BAL in the 
present study (Kornerup et al., 2010; Grommes et al., 2012; Pan et al., 2015; Tilgner et al., 
2016; Amison et al., 2017). These differences could be crucial if, over time, the inflammatory 
response develops such that the minority of neutrophils that are initially recruited that are 
independent of platelets occur sufficiently to produce a more substantial inflammatory re-
ponse that enables a subsequent neutrophil recruitment response independently of platelets 
at 48 hours. Pharmacokinetics of the  drugs used in the present study might provide inade-
quate levels of receptor antagonism over the duration of exposure despite repeated dosing, as 
although the same dosing strategy reduced eosinophil recruitment over four days of allergen 
challenge responses (Amison et al., 2015), receptor occupancy or drug efficacy may have been 
insufficient to prevent the more pronounced neutrophil recruitment response to LPS. In the 
context of platelet depletion, if haemorrhage develops over time leading to additional neutro-
phils entering airspaces from bleeding, as well as those that have entered the bronchoalveolar 
space through transendothelial migration, a later sampling time point may also show a smaller 
decrease in neutrophils recovered in BAL with platelet depletion.  
In contrast to other published studies, Ortiz-Muñoz et al., (2014), used the same dose of 
LPS in the same strain of mice to cause similar levels of neutrophil recruitment (>106 neu-
trophils), and in contrast to results in the present report, found significant effects of aspirin 
treatment on lung inflammation (~50% reduction in BAL neutrophil recruitment), and so 
differences in time point and extent of inflammation are unlikely to explain the differences 
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the between observed effects of aspirin. A few differences between methods used in the present 
study and those used by Ortiz Muñoz et al., (2014) can be postulated to explain differences 
between reults of experiments, and may be important to investigate further. 
In contrast to the model used in the present report, Ortiz Muñoz et al., (2014) used:  
1. a higher quantity of DMSO in drug vehicle (15% vs 2% in the present study), 
which may have altered the pharmacokinetics, or may have had an additional 
anti-inflammatory effect as DMSO has shown anti-inflammatory properties in 
LPS reponses (Kelly et al., 1994; Elisia et al., 2016). 
2. male mice rather than female mice, which have a number of differences in physi-
ology including in responses to LPS (Card et al., 2006; Karp et al., 2017). 
3. barrier-housed mice, which may have altered immune responses compared to more 
immunologically experienced non-barrier housed mice (Looney et al., 2009). 
4. intratracheal rather than intranasal instillation. Intratracheal dosing may have 
caused a more even and consistent dispersal of LPS through the lungs than with 
intransasal dosing, which interventions may be more effective at targeting. 
The study of all of these factors could potentially produce interesting results, as clinical 
investigation would be warranted if either aspirin pharmacokinetics, sex, immune experience, 
or distribution of inflammation could be shown to significantly alter responsiveness to aspirin 
in the context of lung inflammation in mice. Improving understanding the importance of 
these factors in animal models and in the clinic is important as effects of aspirin in reducing 
inflammation in models used to study ARDS (Zarbock et al., 2006; Looney et al., 2009; Ortiz-
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Muñoz et al., 2014; Tilgner et al., 2016; Hamid et al., 2017), have so far not translated into 
efficacy in reduction of ARDS in clinical trials (Kor et al., 2016a). 
Overcoming limitations of neutrophil depletion 
Treatment of mice with intraperitoneal doses of anti-Ly6-G antibody depleted neutrophils 
from blood and consequently reduced lung neutrophil recruitment, with LPS-induced lung 
platelet recruitment not significantly altered, suggestive that the platelet recruitment re-
sponse did not depend on neutrophils. However, neutrophil-depleted mice still had a degree 
of lung neutrophil recruitment, and so it remains possible that some platelet recruitment is 
neutrophil-dependent and the number of neutrophils present in depleted mice was sufficient 
to support lung platelet recruitment. A potential reason for lung neutrophil recruitment re-
maining in neutrophil-depleted mice might be that neutrophils were released from bone mar-
row and recruited to lungs before antibody and monocyte/macrophage-mediated clearance 
could occur (Bruhn et al., 2016). Further experiments using genetically modified mice with 
neutrophil deficiencies (Weber et al., 2015), and cytotoxic drugs which cause a relatively high 
degree of neutrophil depletion (Zuluaga et al., 2006), may be helpful to support results from 
anti-Ly6-G antibody-mediated neutrophil depletion experiments, as would targeting neutro-
phil function through either CCL2 inhibition, decreasing NETosis with PAD4 knockout or 
decreasing the quantity of NETs with DNAse treatment. 
Decreases in body weight and blood platelet counts with administration of anti-Ly6-G 
antibody in both PBS control and LPS-challenged mice suggested that this highly-neutrophil 
selective depletion method also had some undesired adverse effects on general health status 
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of mice, and possibly on the production of platelets. However, all mice survived the experi-
ment, and these adverse effects were less severe than the anaphylaxis with thrombocytopenia 
and increased lung neutrophil aggregate trapping reported with the intravenous administra-
tion of LPS and anti-Ly6-G antibody (Tanaka et al., 2011). In contrast, administration of 
anti-Ly6-G intraperitoneally reduced lung neutrophil recruitment, suggestive that intraperi-
toneal administration of anti-Ly6-G is a sensible method for experiments investigating the 
importance of neutrophils in inflammatory responses. 
Reduced NETs in BAL from platelet-depleted mice without reductions in neutrophil counts 
Even though the number of neutrophils recruited to the LPS-inflamed bronchoalveolar 
space was unaltered with platelet depletion, the finding that platelet depletion reduced the 
quantitiy of NETs detected in BAL was suggestive of some dependence of LPS-induced lung 
inflammation responses on platelets. 
It is possible that this effect of platelet depletion was due to decreased interactions of 
neutrophils with platelets in the blood or potentially in the airspaces, and as previous in vitro 
experiments identified platelet promotion of NET release as dependent upon P-selectin func-
tion (Caudrillier et al., 2012; Etulain et al., 2015), it is of note that P-selectin blockade had 
no detectable effect on BAL NET content. Bleeding into lungs in platelet-depleted mice may 
also have led to the counting of blood neutrophils, as well as transmigrated neutrophils, in 
BAL, with the former possibly less disposed towards NET release, and may also have inter-
fered with signalling that promotes NETosis.  
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In order to shed more light on these findings, the effects of platelet depletion at more 
time points over the course of the inflammatory response could be studied in order to inves-
tigate the full time course of neutrophil recruitment and NETosis in the presence and absence 
of platelets, and the activation status of neutrophils recruited to lung airspaces could be 
assessed in platlet replete and depleted mice using immunohistochemistry or flow assays. As 
NETs are potential mediators of pathophysiology, it would be interesting to investigate the 
effects of platelet depletion on changes in lung function in this model. 
The observation that BAL neutrophil counts were reduced with PSGL-1 blocking anti-
body treatment, but the quantity of NETs detected in BAL was unaltered, seems paradoxical 
as the level of bronchoalveolar NETosis would be expected to be highly dependent on the 
number of neutrophils migrated into the bronchoalveolar space, although it is possible that 
the neutrophils recruited to the bronchoalveolar space in anti-PSGL-1-treated mice following 
LPS inhalation were sufficient in number to mount a full NET release reponse by 48 hours 
after challenge. The time course of lung neutrophil recruitment and NETosis, with or without 
PSGL-1 blockade, would also be interesting to study, as would levels of systemic cytokines, 
particularly KC given that PSGL-1 blockade decreased blood neutrophil counts, in order to 
guide investigations into how PSGL-1 blockade improves general health status of mice after 
LPS inhalation as indicated by reduced body weight loss. 
P-selectin, PSGL-1 and inflammatory neutrophil homeostasis 
The finding that P-selectin blockade increases, whilst PSGL-1 blockade decreases, blood 
neutrophil counts in the context of LPS inhalation suggests a role for both P-selectin and 
Chapter 5. Discussion and conclusions  210 
 
 
PSGL-1 in maintaining blood neutrophil homeostasis in inflammation. Interestingly, P-selec-
tin knockout mice have been shown to have increased blood neutrophil counts (Mayadas et 
al., 1993) and increased blood neutrophil lifespan (Johnson et al., 1995), whilst in contrast 
to blocking antibody effects reported here in the context of inflammation, PSGL-1 knockout 
mice displayed elevated leukocyte counts at baseline (Xia et al., 2002). 
Exploring the mechanisms through which PSGL-1 blockade reduces blood neutrophil con-
tent in inflammation may reveal more about the mechanisms of the anti-inflammatory action 
through inhibition of PSGL-1 function and the mechanisms of inflammatory neutrophil ho-
meostasis, both of which are incompletely understood (Basu et al., 2000; Carlow et al., 2009; 
Summers et al., 2010). Investigations into whether the blockade of P-selectin or PSGL-1 alter 
inflammatory cytokine release, neutrophil production, or neutrophil release from the bone 
marrow, and whether the shedding of these molecules from cells and platelets, or their medi-
ation of cell adhesion or signalling are important in neutrophil homeostasis may therefore 
produce interesting results. 
P-selectin or PSGL-1 blockade-induced alterations in neutrophil homeostasis in inflam-
mation warrant further investigation as both increased neutrophil counts or neutropenia could 
potentially be dangerous side effects for new drugs, especially as interventions targeting P-
selectin and PSGL-1 are in development and in the case of P-selectin blockade in sickle cell 
disease, are entering clinical usage (Kanabar et al., 2016; Ataga et al., 2017). 
  




Experiments reported in this thesis showed that inhalation of LPS caused recruitment of 
platelets to the pulmonary microcirculation and the bronchoalveolar airspace, and demon-
strate methods for quantifying these responses in mice, with immunohistochemistry and ra-
diolabelling techniques also having potential utitility for translation into experiments in the 
human setting.  
Interventional studies revealed that lung platelet recruitment in the mouse model ap-
peared to occur independently of neutrophils and through different mechanisms to lung neu-
trophil recruitment as, in contrast to lung neutrophil recruitment, lung platelet recruitment 
was insensitive to treatment with an anti-PSGL-1 blocking antibody. The mouse LPS inha-
lation model characterised here offers a platform for the identification of which mediators are 
essential for lung platelet recruitment, and research into whether this response is protective 
or harmful. 
Experiments reported here are also suggestive of alterations in platelet clearance, platelet 
recruitment to liver and spleen, and platelet production in the context of inflammation, and 
showed that P-selectin blockade increased, while PSGL-1 blockade decreased, blood neutro-
phil counts following LPS inhalation. These observations open up new avenues for investiga-
tion into platelet and neutrophil dynamics in the context of lung inflammation. 
Hopefully, the application and further development of methods described in this report 
will be useful for further exploration of platelet functions in inflammation, and will aid in the 
development of safer and more effective drugs for use in inflammatory diseases.
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